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ABSTRACT

Identification and engineering of nonribosomal peptide biosynthetic systems
by

Fuchao Xu, Doctor of Philosophy
Utah State University, 2018
Major Professors: Jixun Zhan
Department: Biological Engineering

Nonribosomal peptides represent an important family of natural products, including
antimicrobials, anticancer agents, immunosuppressants, siderophores, herbicides,
antifungals, insecticides, and anthelminthics. They are biosynthesized by giant modular
enzymes called nonribosomal peptide synthetases (NRPSs).
In my doctoral dissertation research, I identified a new indigoidine biosynthetic gene
cluster and reconstituted this indigoidine biosynthetic pathway in two different
heterologous hosts, Streptomyces coelicolor CH999 and Escherichia coli BAP1. The blue
pigment indigoidine is synthesized by condensation of two units of L-glutamine by an
activated NRPS. Under the optimal fermentation conditions, the titer of indigoidine
reached 2.78 g/l in E. coli BAP1. To further improve the production of indigoidine, a
metabolic engineering technique was used to directly enhance the in situ supply of its
precursor, L-glutamine. Engineering of a glutamine synthetase (GS) into the E. coli host
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followed by the addition of the ammonium salt (NH4)2HPO4 at 2.5 mM led to the
production of indigoidine at 7.08 g/l.
Cyclooligomer depsipeptides (CODs) are a particular group of nonribosomal
peptides often found in fungi as mycotoxins, such as beauvercins, bassianolide and
enniatins. We examined the heterologous reconsititution of fungal CODSs in Sacchomyces
cerevisiae and production of the corresponding anticancer CODs. The activities of two
fungal NRPSs, BbBEAS and BbBSLS, were reconstituted efficiently in S. cerevisiae
BJ5464-NpgA. The titers of the anticancer natural products, beauvericins and bassianolide,
are comparable to those in the native producer. I also dissected the two modular NRPSs
into modules and reconstituted the biosynthetic pathways by co-expressing the fragments
in S. cerevisiae. The C3 domain was found to play a central role in product length control.
A domain swapping approach was established to reprogram fungal iterative NRPSs for
peptides with altered lengths. In vitro reaction of C2 and C3 with monomer/dimer/trimerN-acetylcysteamines demonstrated that C2 forms the amide bond and C3 catalyzes the
synthesis of the ester bond. We also successfully reconstituted the total biosynthesis of
beauvericin in vitro by reacting C2 and C3 with two SNAC-linked precursors. These
findings revealed that fungal iterative NRPSs use a strategy for product length control that
is different than their counterparts in bacteria.
(207 pages)
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PUBLIC ABSTRACT

Identification and engineering of nonribosomal peptide biosynthetic systems
by

Fuchao Xu, Doctor of Philosophy
Utah State University, 2018
Major Professors: Jixun Zhan
Department: Biological Engineering

This research focuses on the understanding and engineering of nonribosomal peptide
biosynthetic pathways in Streptomyces coelicolor CH999, Escherichia coli BAP1 and
Saccharomyces cerevisiae BJ5464-NpgA. The biosynthetic systems of indigoidine from
bacteria and beauvericin/bassianolide from fungi were studied in this research. The
production of these valuble products was significantly increased by enhancing their
synthetic pathway with metabolic engineering approaches.
Indigoidine is a bacterial natural product with antioxidant and antimicrobial activities.
Its bright blue color resembles the industrial dye indigo, thus representing a new natural
blue dye that may find uses in industry. Indigo is a dark blue crystalline powder and has
been known for more than 4,000 years. It is commonly used to dye cotton yarn for the
production of denim cloth to make blue jeans but the chemical synthesis of indigo requires
harsh conditions and use of a strong base. Indigoidine is a new natural blue dye that is
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assembled from two molecules of L-glutamine under the catalysis of indigoidine synthetase.
We identified a novel indigoidine synthetic gene from the genome of Streptomyces
chromofuscus ATCC 49982. The successful heterologous expression of Sc-indC in E. coli
BAP1 give us a pretty good yield of indigoidine under the optimized conditions. The
production of this blue dye was then further improved by introducing two additional genes,
sc-indB and glnA, into the biosynthetic pathway.
Beauvericins and bassianolide are anticancer natural products from fungi and are
assembled by corresponding iterative nonribosomal peptide synthetases. The beauvericin
(BbBEAS) and bassianolide (BbBSLS) synthetases were successfully reconstituted in S.
cerevisiae BJ5464-NpgA, leading to the production of beauvericins and bassianolide,
respectively. The production of beauvericins was significantly improved by co-expression
of BbBEAS and ketoisovalerate reductase (KIVR). To better understand the synthetic
strategy of fungal iterative NRPs, the module/domain of BbBSLS and BbBEAS were
dissected and reconstituted in S. cerevisiae. The result shows the intermodular linker is
essential for the reconstitution of the separate modules and the domain swapping results
indicated the fungal iterative NRPSs use a liner biosynthetic route which is different than
bacterial iterative NRPs. The in vitro reactions of C2 and C3 with monomer/dimer/trimerN-acetylcysteamines demonstrated that C2 forms the amide bond and C3 catalyses the
synthesis of the ester bond. Beauvericin could be reconstituted in vitro through co-reaction
of C2(BbBEAS) and C3(BbBEAS) with D-Hiv-SNAC and N-Me-L-Phe- SNAC. This work also
provides an unprecedented tool for engineering fungal iterative NRPSs to yield ‘unnatural’
cyclooligomer depsipeptides with varied chain lengths.
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CHAPTER 1
INTRODUCTION
1.1

Background
Nonribosomal peptide synthetases (NRPSs) are large multifunctional enzymes used

by bacteria and fungi to produce peptides of broad structural and biological properties. Not
only could the antibiotics produced by these enzymes be artificially modified, but the
combinatorial approaches also represent a promising basis for the development of
substances with novel activities [1]. Nonribosomal peptides (NRPs) are biosynthesized by
NRPSs and represent an important family of natural products, including antimicrobials,
anticancer agents,

antifungals,

insecticides,

and

anthelminthics,

such

as

the

immunosuppressant cyclosporine A, the antibiotic daptomycin, and the anticancer
molecule bleomycin A2. Vancomycin (Fig. 1a), a bacterial NRP, is widely used as an
antibiotic to treat a number of bacterial infections [2]. The vancomycin-based Oritavancin
was also approved by the FDA in 2014 for treatment of drug resistant skin infections [3].
NRPSs are classified into three categories, linear (Type A), iterative (Type B) and
nonlinear (Type C) based on their biosynthetic mechanisms. In the linear strategy (Type A)
the number and sequence of the modules in the enzymes matches the number and order of
amino acids in the peptides (Fig. 1a). In type B, the modules or domains of the synthetases
are used more than once to synthesize the peptides, which consist of repeated moieties (Fig.
1b). Lastly, nonlinear NRPSs generate peptides in which the sequence of amino acids does
not correlate to the arrangement of modules of the enzymes (Fig. 1c).
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Figure 1. Representative natural products synthesized by three different types of NRPS.
The thiolation (T) (or peptidyl carrier protein, PCP), adenylation (A) and
condensation (C) domains constitute the three core domains that define a typical NRPS
module. The A domain recognizes and activates the amino acid building block by
formation of an amino acyl adenylate intermediate through the consumption of ATP [4]. A
domains are generally referred to as the “gate keepers” of NRPSs because they select the
amino acid to be activated and incorporated into the nonribosomal peptide and are therefore
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the first level of substrate selectivity in the enzyme system. T domains belong to the same
superfamily of proteins as acyl carrier proteins (ACP) involved in fatty acid and polyketide
biosynthesis. Like ACPs, T domains must be post-translationally modified with a 4′-Ppant
group [5]. T domains pass amino acids or peptidyl substrates from one catalytic center to
the next and play a central role in the function of NRPSs as they must interact not only
with A domains in the context of aminoacyl thioester formation but also with other catalytic
domains involved in peptide bond formation, peptide modification, or peptide release from
the NRPS. C domains are most commonly located at the beginning of each NRPS module,
precisely positioned for catalyzing peptide bond formation between two substrates tethered
to the adjacent modules. The C-terminus of the final NRPS module typically contains a TE
domain. This domain catalyzes either the hydrolysis of the nonribosomal peptide from the
NRPS or the intramolecular cyclization and release of the peptide from the NRPS [6].
Aside from those enzymatic units required to build up a peptide, the nonribosomal
machinery can fall back on a much bigger repository of additional enzymes compared with
those in the ribosomal system. A number of NRPSs contain methyltransferases (MTs) that
are responsible for the N- or C-methylation of amino acid residues, thus making the peptide
less susceptible to proteolytic breakdown. Both N- and C-MT domains use S-adenosyl
methionine (SAM) as the methyl donor. Epimerization domain (E) could epimerize Lamino acids into D-amino acids. The oxidation (Ox) domain oxidizes the thiazoline ring to
the thiazole in the presence of the cofactor flavin mononucleotide (FMN). The reduction
(R) domain reduces the thiazoline ring to the thiazolidine in the presence of NADPH [4].
The water-insoluble blue pigment indigoidine was isolated from phytopathogenic
Erwinia [7] and other bacteria [8]. It is synthesized by condensation of two units of L-
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glutamine by a PPTase-activated NRPS, such as IndC from Erwinia chrysanthemi and
Streptomyces aureofaciens CCM 3239 and BpsA from Streptomyces lavendulae [9-11].
Because of the presence in its structure of carbon–carbon double bonds conjugated with a
carbonyl group, indigoidine is a powerful radical scavenger that enables phytopathogens
to tolerate oxidative stress, organic peroxides, and super oxides during the plant defense
response (Fig. 2). Recent studies have also shown that this blue pigment has antimicrobial
activity. The redox activity and bright blue color make indigoidine a possible redox state
sensor or industrial dye [12].

Figure 2. Structure of indigoidine
Fungi are also known to produce a diversity of NRPs. Cyclooligomer depsipeptides
(CODs) are a particular group of NRPs often found in fungi as mycotoxins, such as
beauvercins (1-4, Fig. 3), bassianolide (5, Fig. 3) and enniatins (6-8, Fig. 3). 1 is produced
by a number of fungal strains such as Fusarium species, Beauveria bassiana, Paecilomyces
fumoso-roseus (renamed Isaria fumosorosea), and P. tenuipes (renamed I. tenuipes). Its
congeners, beauvericins A–C (2–4), were also observed as minor products in many
producing strains. 5 was isolated from B. bassiana. 1 has displayed potent anticancer
activity against various cell lines by increasing cytoplasmic Ca2+ concentration, triggering
ATP depletion, and activating calcium-sensitive cell apoptosis [13-15]. Recently, we have
found that 1 can also inhibit migration of the metastatic prostate cancer (PC-3M) and breast
cancer (MDA-MB-231) cells, and has antiangiogenic activity in HUVEC-2 cells at
sublethal concentrations [16].
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Figure 3. Structure of beauvericins (1-4), bassianolide (5) and enniatins (6-8). The
monomer unit is green shaded.
Fungal CODs are assembled by COD synthetases (CODSs), a subclass of Type B
NRPSs which use their modules iteratively for the biosynthesis of several copies of
identical or nearly identical peptide/peptidol monomer units that remain covalently bound
on the enzyme. The monomer units of CODs undergo recursive head-to-tail condensation,
or oligomerization, followed by macrocyclization [17]. Typically, the monomers are
formed from one unit of 2-hydroxycarboxylic acid and one molecule of amino acid. Both
the biosynthetic gene clusters of 1 and 5 have recently been characterized from B. bassiana
ATCC 7159 [18]. Analysis of the gene clusters revealed that the beauvericin synthetase
(BbBEAS) and the bassianolide synthetase (BbBSLS) have the same domain organization
of C1-A1-T1-C2-A2-MT-T2a-T2b-C3 (Fig. 4). In addition to the CODS gene, a kivr gene is
found in the beauvericin biosynthetic gene cluster, which encodes a putative NADPHdependent ketoisovalerate reductase (KIVR) involved in the biosynthesis of D-Hiv. The
detailed mechanism of these CODSs is not fully understood and requires more studies to
demonstrate.
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Figure 4. Domain organization of BbBEAS and BbBSLS. C: condensation domain; A:
adenylation domain; T: thiolation domain; MT: methyltransferase domain. Different colors
(red for BbBEAS and blue for BbBSLS) are used to differentiate these two similar CODSs
1.2

Objectives
The main goal of my doctoral dissertation research is to identify and engineer

microbial NRPS biosynthetic systems for novel or industrially important molecules.
Specifically, I will work on a bacterial NRP biosynthetic pathway that synthesizes the
natural blue dye indigoidine and two fungal NRPSs that assemble the anticancer molecules
beauvericin and bassianolide.
Five specific objectives of my dissertation include:
1. Functionally identify and reconstitute a new indigoidine biosynthetic gene
cluster in heterologous hosts
2. Optimize the production of indigoidine in Escherichia coli
3. Engineer the production of fungal anticancer cyclooligomer depsipeptides
beauvericin and bassianolide in Saccharomyces cerevisiae
4. Dissect and reconstitute the beauvericin and bassianolide synthetases in the
yeast
5. Decode and reprogram the product length control in fungal iterative
nonribosomal peptide synthetases
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1.3

A guide to the dissertation
This dissertation includes six chapters. Chapter 1 is a background literature review.

Chapter 2 focuses on the discovery of a putative indigoidine biosynthetic gene cluster from
Streptomyces chromofuscus ATCC 49982. The Sc-indB gene was identified to be a helper
during indigoidine biosynthesis. Chapter 3 describes an efficient way for the production of
indigoidine in E. coli. The indigoidine biosynthetic pathway was enhanced by introducing
two additional genes, sc-indB and glnA. Chapter 4 talked about the engineered production
of fungal anticancer cyclooligomer depsipeptides in Saccharomyces cerevisiae. Two
fungal cyclooligomer depsipeptide synthetases (CODSs), BbBEAS (352 kDa) and
BbBSLS (348 kDa) from Beauveria bassiana ATCC 7159, were reconstituted in
Saccharomyces cerevisiae BJ5464-NpgA, leading to the production of the corresponding
anticancer natural products, beauvericins and bassianolide, respectively. In Chapter 5, the
BbBSLS and BbBEAS were dissected and reconstituted in Saccharomyces cerevisiae. The
intermodular linker was confirmed to be essential for the reconstitution of the separate
modules. Chapter 6 describes the work about elucidating fungal iterative NRPSs’ chain
elongation and length control strategy and provides an unprecedented tool for engineering
fungal iterative NRPSs to yield ‘unnatural’ cyclooligomer depsipeptides with varied chain
lengths. Chapter 7 is a summary of this dissertation and engineering value.
A number of research techniques are used in these studies, including molecular
cloning, genetic engineering, metabolic engineering, microbial fermentation, protein
expression, protein purification, in vitro reaction, natural products purification,
spectroscopic analyses for structure determination, DNA sequence analysis, aseptic
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techniques, laboratory skills, and others. A detailed explanation of each chapter is shown
in following chapters.
1.4
1.
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CHAPTER 2
AN INDIGOIDINE BIOSYNTHETIC GENE CLUSTER FROM STREPTOMYCES
CHROMOFUSCUS ATCC 49982 *
2.1 Abstract
A putative indigoidine biosynthetic gene cluster was located in the genome of
Streptomyces chromofuscus ATCC 49982. The silent 9.4-kb gene cluster consists of five
open reading frames, named orf1, Sc-indC, Sc-indA, Sc-indB, and orf2, respectively. ScIndC was functionally characterized as an indigoidine synthase through heterologous
expression of the enzyme in both Streptomyces coelicolor CH999 and Escherichia coli
BAP1. The yield of indigoidine in E. coli BAP1 reached 2.78 g/l under the optimized
conditions. The predicted protein product of Sc-indB is unusual and much larger than any
other reported IndB-like protein. The N-terminal portion of this enzyme resembles IdgB
and the C-terminal portion is a hypothetical protein. Sc-IndA and/or Sc-IndB were coexpressed with Sc-IndC in E. coli BAP1, which demonstrated the involvement of Sc-IndB,
but not Sc-IndA, in the biosynthetic pathway of indigoidine. The yield of indigoidine was
dramatically increased by 41.4 % (3.93 g/l) when Sc-IndB was co-expressed with Sc-IndC
in E. coli BAP1. Indigoidine is more stable at low temperatures
2.2 Introduction
Streptomyces is well known to produce structurally diverse natural products,
including many industrially important bioactive molecules, such as oxytetracycline,

This chapter has been published as Yu, D.,# Xu, F.,# Valiente, J., Wang, S., Zhan, J.* (2013): An
indigoidine biosynthetic gene cluster from Streptomyces chromofuscus ATCC 49982 contains an unusual
IndB homologue. Journal of Industrial Microbiology and Biotechnology 40(1), 159–168. (# : equal
contribution)
*
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chloramphenicol, and bleomycin. Most of these bacterial secondary metabolites are
produced by complex biosynthetic pathways encoded by physically clustered genes [2].
Among the reported biosynthetic enzymes, polyketide synthases (PKSs) and nonribosomal peptide synthetases (NRPSs) are the ones most commonly observed. The waterinsoluble

blue

pigment

indigoidine

[5,5´-diamino-4,4´-dihydroxy-3,3´-

diazadiphenoguinone-(2,2´)] was isolated from phytopathogenic Erwinia [21] and other
bacteria [12]. It is synthesized by condensation of two units of L-glutamine by a 4´phosphopantetheinyl transferase (PPTase)-activated NRPS, such as IndC from Erwinia
chrysanthemi and Streptomyces aureofaciens CCM 3239 and BpsA from Streptomyces
lavendulae [15, 19, 22]. Because of the presence in its structure of carbon–carbon double
bonds conjugated with a carbonyl group, indigoidine is a powerful radical scavenger that
enables phytopathogens to tolerate oxidative stress, organic peroxides, and superoxides
during the plant defense response [11, 19]. Recently, indigoidine has also been found to
possess antimicrobial activity [5].
Streptomyces chromofuscus ATCC 49982 was isolated from soil collected from a
stand of mixed woods from the Stepping Stone Falls Beach Pond State Park, Rhode Island,
USA [13]. It is the producer of the anti-cholesterol polyketide natural product herboxidiene,
which was found to up-regulate the gene expression of the low density lipoprotein receptor
(LDLR) in Chinese hamster ovary cells transfected by a LDLR promoter-luciferase gene
construct. It showed stronger luciferase increasing activity than the well-known
cholesterol-lowering agent lovastatin. Herboxidiene also increased the specific binding of
125

I-LDL to the LDLR by 31% at 10-9 M in human hepatoma HepG2 cells, whereas

lovastatin only increased the binding by 17 % at a much higher concentration, 10-6 M. Thus,
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herboxidiene is a potent compound that activates the synthesis of the LDLR and represents
a novel template to generate promising LDLR up-regulators [10]. To better understand this
pharmaceutically important strain, we have recently sequenced the genome of S.
chromofuscus ATCC 49982. We identified a non-iterative type I polyketide biosynthetic
gene cluster that is responsible for the biosynthesis of herboxidiene [20]. Further looking
into other potential PKS and NRPS gene clusters in the genome of S. chromofuscus ATCC
49982 led to the discovery of a 9.4-kb biosynthetic gene cluster that contains five open
reading frames (ORFs), including a putative indigoidine synthase gene, designated Sc-indC.
We cloned the Sc-indC gene and two other genes from the same gene cluster, Sc-indA and
Sc-indB, whose homologous proteins were reported to be associated with the biosynthesis
of indigoidine in E. chrysanthemi [19]. Heterologous expression of Sc-indC in
Streptomyces coelicolor CH999 and Escherichia coli BAP1 demonstrated that Sc-IndC is
responsible for the synthesis of the blue pigment indigoidine. The fermentation conditions
for indigoidine production in E. coli BAP1were studied and optimized. Furthermore, the
roles of Sc-IndA and Sc-IndB in the indigoidine biosynthetic pathway were investigated
by co-expression of these proteins with Sc-IndC.
2.3

Materials and methods

2.3.1 Bacterial strains, vectors, and culture conditions
S. chromofuscus ATCC 49982 was obtained from the American Type Culture
Collection (ATCC). It was grown at 30 ℃ in YEME medium [8] for the extraction of
genomic DNA. S. coelicolor CH999 and E. coli BAP1 were gifts from Dr. Chaitan Khosla
at Stanford University. S. coelicolor CH999 was routinely grown in R5 medium at 30 ℃
[6]. The pRM5-derived plasmid pJX28 carrying the thiostrepton-resistance gene was used
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as an E. coli/Streptomyces shuttle vector to express Sc-IndC in S. coelicolor CH999. For
the blue pigment synthesis, the engineered strain of S. coelicolor CH999 was cultured at
30 ℃ in R5 medium supplemented with 50 μg/ml thiostrepton.
E. coli XL1-Blue (Agilent) and pJET1.2 (Fermentas) were used for DNA cloning and
sequencing. E. coli BAP1 and pET28a (Novagen) were used for protein expression and
pACYCDuet-1 (Novagen) was used for the co-expression experiments. E. coli cells were
grown in Luria–Bertani (LB) medium. When necessary, appropriate antibiotics were added
at the following concentrations: ampicillin, 50 μg/ml; kanamycin, 50 μg/ml; and
chloramphenicol, 25 μg/ml. For protein expression and product synthesis, 200 μM of
isopropyl β-D-1-thiogalactopyranoside (IPTG) was added into the E. coli BAP1 cultures
for induction.
2.3.2 DNA manipulations
The genomic DNA of S. chromofuscus was isolated following a standard protocol
[8]. Plasmids in E. coli were extracted using a Gene JETTM Plasmid Miniprep Kit
(Fermentas).
2.3.3 Genome sequencing and homology analysis of the predicted proteins
The genomic DNA of S. chromofuscus ATCC 49982 was sequenced using a 454
next-generation sequencing system and annotated with RAST (Rapid Annotation using
Subsystem Technology) [1]. The 9,457-kb indigoidine biosynthetic gene cluster was
further analyzed through FramePlot [7] and BLAST, and was deposited in GenBank under
accession number JX499187.
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2.3.4 Expression of Sc-indC in S. coelicolor CH999
The Sc-indC gene (4,134 bp) was amplified by the polymerase chain reaction (PCR)
(Fig. B1) from the genome of S. chromofuscus ATCC 49982 with Phusion Hot Start HighFidelity DNA Polymerase (New England Biolabs) using a pair of primers, 5´aaTTAATTAAGGAGGAGCCCATatgagcgtagagaccatccc-3´ (the PacI and NdeI sites are
underlined) and 5´-aaGCTAGCAAGCTTtcagtagttgggcgtcttgc-3´ (the NheI and HindIII
sites are underlined). These primers were designed by us based on the sequence of Sc-indC
and synthesized by Sigma-Aldrich. The amplified Sc-indC was ligated into the cloning
vector pJET1.2 to yield pJV3 (Table 1).
The Sc-indC insert was excised from pJV3 with PacI and NheI and ligated into pJX28
between the same sites to generate pDY49 (Table 1). The plasmid was introduced into S.
coelicolor CH999 by protoplast transformation, and correct transformants were selected
on R5 agar containing 50 μg/ml thiostrepton after 5–7 days of incubation at 30 ℃. The
correct transformant was grown in 50 ml of R5 medium supplemented with 50 μg/ml
thiostrepton, which was maintained at 30 ℃ with shaking at 250 rpm for 5–7 days to
produce indigoidine.
Table 1. Plasmids constructed in chapter II
Plasmid
pJV1
pJV2
pJV3
pJV6
pDY49
pDY52
pDY53
pDY54

Description
Sc-indA in pJET1.2
Sc-indB in pJET1.2
Sc-indC in pJET1.2
Sc-indC in pET28a
Sc-indC in pJX28
Sc-indA in pACYCDuet-1
Sc-indB in pACYCDuet-1
Sc-indA and Sc-indB in pACYCDuet-1
under two separated T7 promoters
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2.3.5 Expression of Sc-indC in E. coli BAP1
The Sc-indC gene was excised from pJV3 by digestion with NdeI and HindIII and
inserted into the same sites of pET28a to generate pJV6 (Table 1). The plasmid was
transformed into E. coli BAP1 and correct transformants were selected on LB agar
supplemented with 50 μg/ml kanamycin. To reconstitute the biosynthesis of indigoidine,
the correct transformant was grown in LB broth supplemented with 50 μg/ml kanamycin
at 37 ℃ and 250 rpm. When the OD600 reached 0.4–1.0, 200 μM of IPTG was added to
induce the expression of Sc-IndC at a lower temperature (18 or 25 ℃).
2.3.6 Co-expression of Sc-indC with Sc-indA and/or Sc-indB in E. coli BAP1
To clone Sc-indA and Sc-indB, we designed specific primers based on their gene
sequences. The Sc-indA gene (954 bp) was amplified by PCR (Fig. S1) from the S.
chromofuscus genome using 5´-aaCATatggacgatccccgccccccg-3´ (the NdeI site is
underlined) and 5´- aatcactggtcttcctcgtc-3´. The amplified Sc-indA gene was ligated with
the pJET1.2 vector to yield pJV1 (Table 1). The Sc-indA gene was excised from pJV1 by
digestion with NdeI and XhoI (on pJET1.2) and inserted into MCS2 of the pACYCDuet-1
vector between the same sites to yield pDY52 (Table 1). The Sc-indB gene (1,845 bp) was
amplified by PCR (Fig. B1) from the S. chromofuscus genome using 5´aaGGATCCatgttcgacctggacggaac-3´

(the

BamHI

site

is

underlined)

and

5´-

aaAAGCTTtcagtcgaccgggggctgct-3´ (the HindIII site is underlined). The amplified ScindB gene was ligated with the pJET1.2 vector to yield pJV2 (Table 1). After gene
sequencing, Sc-indB was excised from pJV2 by digestion with BamHI and HindIII and
inserted into MCS1 of the pACYCDuet-1 vector between the same sites to yield pDY53
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(Table 1). The Sc-indA gene was excised from pJV1 using NdeI and BglII (on pJET1.2)
and ligated into MCS2 of pDY53 between the same sites to afford pDY54 (Table 1). Each
of these pACYCDuet-1 derived plasmids (pDY52, pDY53 and pDY54) was cotransformed with pJV6 into E. coli BAP1. Co-expression experiments of Sc-indC with ScindA and/or Sc-indB in E. coli BAP1 were performed at 18 ℃.
2.3.7 Extraction and analysis of indigoidine
To extract the blue pigment, 1 ml of dark blue fermentation broth was taken into a
1.5-ml microcentrifuge tube, which was centrifuged at 21,000×g for 10 min. The
supernatant was discarded and the pellet was washed with 1 ml of methanol three times
with gentle vortexing to remove other metabolites from the cells. By centrifugation at
21,000×g for 10 min, the crude blue pigment was collected, dried in vacuo, and dissolved
in 1 ml of dimethyl sulfoxide (DMSO) by sonication. The DMSO-insoluble components
and cell debris were removed by centrifugation (850×g, 5 min). The solution of indigoidine
in DMSO was analyzed on an Agilent 1200 HPLC and 6130 Single Quad LC/MS (C18, 5
μm, 4.6 × 150 mm column), eluted with a linear gradient of 10–90 % aqueous methanol
over 25 min at a flow rate of 1 ml/min.
2.3.8 Preparation of a standard curve for indigoidine to measure the yields
To obtain pure indigoidine for a standard curve, the fermentation broth was
centrifuged at 850×g for 5 min. At this speed, the cells were pelleted while indigoidine still
remained in the supernatant. After removal of the cells, the supernatant was further
centrifuged at a much higher speed (21,000×g) for 10 min to allow indigoidine to settle.
This blue pigment was then successively washed twice with water, methanol, ethyl acetate,
and hexanes to remove impurities, which yielded pure indigoidine.
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One milligram of purified indigoidine was dissolved in 1 ml of DMSO. This solution
was then serially diluted into six different concentrations (0.01, 0.025, 0.05, 0.10, 0.20, and
0.25 mg/ml). Each solution was measured for OD600 values on a Thermo Scientific
GENESYS 20 Visible Spectrophotometer. The standard curve was established by the linear
relationship between the absorbance and concentration.
2.3.9 SDS-PAGE analysis of protein expression
The engineered E. coli BAP1 strains were grown in 100 ml of LB medium
supplemented with appropriate antibiotics and induced with 200 μM IPTG at 18 ℃ for 12
h. The cells were collected by centrifugation at 2,700×g for 5 min and resuspended in 3 ml
of lysis buffer (20 mM Tris–Cl, 500 mM NaCl, pH 7.9). After 10 min of ultrasonication
(18 W, 30-s interval), the resultant lysates were centrifuged at 21,000×g for 10 min.
Insoluble proteins were dissolved in 8 M urea. Both soluble and insoluble fractions were
analyzed by 12 % SDS-PAGE.

Figure 5. The indigoidine biosynthetic gene cluster in S. chromofuscus ATCC 49982. The
structural organization of Sc-IndC and Sc-IndB is shown. A adenylation, Ox oxidation, T
thiolation, TE thioesterase
2.4

Results

2.4.1 Analysis of a putative indigoidine biosynthetic gene cluster
A 9.4-kb putative indigoidine biosynthetic gene cluster was found in the genome of
S. chromofuscus ATCC 49982 (Fig. 5; Table 2). It contains five ORFs. The first ORF was
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named orf1, which encodes a putative transmembrane transporter. The second ORF ScindC encodes an indigoidine synthase that is homologous to IndC from E. chrysanthemi.
IndC is a NRPS that synthesizes indigoidine in E. chrysanthemi. Further analysis of ScIndC showed that this protein contains an adenylation (A) domain, a thiolation (T) domain,
a thioesterase (TE) domain, and an oxidation (Ox) domain that is embedded in the A
domain. This structural organization is the same as other homologues such as BpsA from
S. lavendulae ATCC 11924 [22]. Two conserved core motifs, DDFFELGGNSL (963–973)
and GYSFG (1,099–1,103), were found in the T and TE domains, respectively. The A
domain has the signature sequence DAWQFGLINK for recognition of L-glutamine, which
is the precursor for indigoidine biosynthesis. This further suggested that Sc-IndC is an
indigoidine synthase. The predicted protein product of the third ORF Sc-indA is similar to
IndA that was previously found in the indigoidine biosynthetic pathway in E. chrysanthemi,
although the function of IndA in indigoidine biosynthesis is still unclear. The fourth ORF
Sc-indB in this gene cluster encodes a 614-aa protein. Interestingly, the N-terminal portion
(1–221 aa) of this unusual protein is a homologue of IdgB from E. chrysanthemi, while the
C-terminal part (217–614) resembles SclaA2_37635 of Streptomyces clavuligerus, which
is a hypothetical protein without a known function. IndB and IdgB have been previously
reported in the indigoidine biosynthetic pathway in different strains of E. chrysanthemi. In
this studied gene cluster, Sc-IndB is a fusion protein of two proteins and it is unknown
what role it plays in indigoidine biosynthesis in S. chromofuscus ATCC 49982. The last
ORF is named orf2, which encodes a phosphoribosyl transferase and is homologous to
SanR of Streptomyces ansochromogenes (Table 2).
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Table 2. Deduced functions of ORFs in the indigoidine biosynthetic gene cluster
Gene

No.
of Protein homologue
amino acids (accession no.)

Identity/
similarity (%)

orf1

421

Transmembrane
transporter of
Streptomyces
hygroscopicus
ATCC 53653
(EFL27184)

55/68

Transmembrane
transporter

Sc-indC

1,377

IndC of Erwinia
chrysanthemi
(CAB87990)

54/71

Indigoidine
synthase

Sc-indA

317

IndA of
E. chrysanthemi
(CAB87988)

65/80

Hypothetical
protein

Sc-indB

614

1–221
IdgB of
E. chrysanthemi
(AAF74780)

51/62

Predicted
phosphatase

orf2

238

SanR of
Streptomyces
ansochromogenes
(AAG48136)

76/84

Phosphoribosyl
transferasetype
type I domain

Proposed function

2.4.2 Reconstitution of Sc-indC in S. coelicolor CH999
Although we located a putative indigoidine biosynthetic gene cluster in the genome
of S. chromofuscus ATCC 49982, no blue pigments were detected from the extract of this
bacterium, which indicated that this gene cluster is silent in S. chromofuscus ATCC 49982
under laboratory conditions. In order to identify the function of Sc-indC, this gene was
ligated into an E. coli/Streptomyces shuttle vector to yield pDY49 (Table 1). This plasmid
was introduced through protoplast transformation into S. coelicolor CH999, which is a host
widely used for synthesizing natural products from Streptomyces. The engineered strain of
S. coelicolor CH999/pDY49 was grown in R5 medium supplemented with 50 μg/ml
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thiostrepton at 30 ℃ and was found to produce a blue pigment (Fig. 6a). The pigment was
extracted as described in the Methods and materials section and re-dissolved in DMSO,
which showed a bright blue color (Fig. 6b). LC–MS analysis of the extracted pigment at
600 nm showed a major peak at 9.64 min (Fig. 6c) that has a maximum UV absorption at
602 nm (Fig. 6d), which is consistent with that of indigoidine. ESI–MS spectrum of this
compound showed a [M+H]+ peak at m/z 249, further confirming that this product is
indigoidine [22]. Thus, heterologous expression of Sc-indC confers the ability to synthesize
indigoidine in S. coelicolor CH999. Accordingly, the function of Sc-IndC was
characterized as an indigoidine synthase. A standard curve using purified indigoidine was
established based on the absorbance at 600 nm and used to quantify the production of this
pigment. In S. coelicolor CH999, the maximum yield of indigoidine achieved was 593.5
mg/l after 6 days of cultivation.

Figure 6. Reconstitution of indigoidine biosynthesis in S. coelicolor. a Production of the
blue pigment by S. coelicolor CH999/pDY49. The engineered strain was grown in a R5
medium supplemented with 50 μg/ml thiostrepton at 30 ℃ for 6 days. S. coelicolor CH999
harboring the blank shuttle vector was used as the vector control. All experiments were
performed in triplicate, and a representative result was shown. b Indigoidine extracted from
S. coelicolor CH999/pDY49 and redissolved in DMSO. c HPLC analysis of the extracted
blue pigment at 600 nm. d UV spectrum ofindigoidine
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2.4.3 Reconstitution of Sc-IndC in E. coli BAP1
Compared with Streptomyces, E. coli possesses some advantages such as fast growth
rate and high expression level for many heterologous proteins. E. coli has been used for
heterologous expression of numerous enzymes including NRPSs and synthesis of their
products previously [3, 22]. Because Sc-IndC is a NRPS, its T domain needs to be activated
from apo to holo form to be functional. Accordingly, a dedicated PPTase is required to
transfer the phosphopantetheinyl group from coenzyme A to a conserved serine residue in
the T-domain of Sc-IndC [14, 17, 23]. E. coli BAP1 is an engineered strain of E. coli
BL21(DE3) and harbors a sfp gene encoding a PPTase from Bacillus subtilis in the genome
[18]. We thus used it as a host to functionally reconstitute Sc-IndC. The Sc-indC gene was
ligated into pET28a to yield pJV6 (Table 1), which was transformed into E. coli BAP1 for
protein expression. As expected, the E. coli BAP1 cells transformed with pJV6 produced
indigoidine (Fig. 7a). Compared to S. coelicolor CH999, the synthesis of this blue pigment
in E. coli BAP1 was much faster. The blue color could be easily observed in the E. coli
culture 30 min after IPTG induction.
2.4.4 Optimization of the production of indigoidine in E. coli BAP1
To optimize the production of indigoidine in E. coli BAP1, the fermentation
conditions including the optimal OD600 value for IPTG induction, production temperature,
and fermentation time were investigated. E. coli BAP1/pJV6 was grown in four flasks
containing 50 ml of LB medium supplemented with 50 μg/ml kanamycin at 37 ℃. The
cultures were induced with 200 μM IPTG when the OD600 reached 0.4, 0.6, 0.8, and 1.0,
respectively. The induced broths were maintained at 25 ℃ and 250 rpm for 13 h, and then
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the yields of indigoidine were determined. As shown in Fig. 7b, induction of the
fermentation broth at OD600 0.6 gave the best yield of the blue pigment.

Figure 7. Reconstitution of indigoidine biosynthesis in E. coli BAP1. a Production of
indigoidine by E. coli BAP1/pJV6. The strain was grown in LB medium supplemented
with 50 μg/ml kanamycin at 37 °C and induced with 200 μM IPTG at 25 °C for 13 h. E.
coli BAP1/pET28a was used as the vector control. b Effect of the OD600 values with
IPTG induction on the yield of indigoidine. c Time-course analysis of indigoidine
production at 18 and 25 °C. d Effect of temperature on the stability of indigoidine. The
pigment was stored at room temperature (left) and 4 °C (right) in cell-free LB medium
for 2 days. Experiments were performed in triplicate and presented as mean±SD (n = 3)
To understand the effects of the fermentation temperature on the production of
indigoidine, we tested four different fermentation temperatures including 18, 25, 30, and
37 ℃. Almost no indigoidine synthesis was detected at 30 and 37 ℃, which might be
attributed to the thermal instability and oxidability of indigoidine [19]. Time course
analysis was conducted to monitor the production of indigoidine at 18 and 25 ℃. As shown
in Fig. 7c, the yield of indigoidine reached the highest (1.73 g/l) after 13 h of IPTG
induction at 25 ℃, while at 18 ℃ the best yield (2.78 g/l) was achieved at 28 h. The yield
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of indigoidine dropped after the maximal point, suggesting that long fermentation or
storage time may result in the degradation of this blue pigment.
2.4.5 Investigation of the stability of indigoidine
Some antioxidants, such as ascorbic acid, were previously supplemented to stabilize
indigoidine [14]. It was reported that the pigment was very stable in tetrahydrofuran and
did not fade for over 1 month [9], but indigoidine was hardly dissolved in this solvent in
our experiments. Instead, we found that DMSO was a good solvent to dissolve the pigment.
However, even in DMSO, the blue color of indigoidine can fade at room temperature over
months. Degradation of indigoidine is much faster in the fermentation broth, as seen in the
time course of indigoidine production at 25 ℃ (Fig. 7c). We also tested the stability of
indigoidine in LB medium at room temperature and 4 ℃. As shown in Fig. 3d, indigoidine
in cell-free LB medium was more stable at 4 ℃, while the color of the pigment at room
temperature faded significantly after 2 days.
2.4.6 Involvement of the unusual Sc-IndB in indigoidine biosynthesis
The Sc-indA and Sc-indB genes are present with Sc-indC in the same gene cluster in
S. chromofuscus ATCC 49982. Similar proteins were also found in other bacteria such as
E. chrysanthemi [19], although their functions remain unclear. To find out whether the ScindA and Sc-indB genes participate in indigoidine biosynthesis in S. chromofuscus ATCC
49982, we constructed three plasmids using the pACYCDuet-1 vector, named pDY52,
pDY53 and pDY54, which contain Sc-indA, Sc-indB, and Sc-indA and Sc-indB,
respectively (Table 1). The plasmids were co-transformed into E. coli BAP1 with pJV6,
separately. Both soluble and insoluble proteins of these strains were analyzed. SDS-PAGE
analysis showed that Sc-IndA (33 kDa) and Sc-IndB (67 kDa) were co-expressed with Sc-
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IndC (150 kDa) in E. coli BAP1 cells at 18 ℃ (Fig. 8a). A comparison of the yield of
indigoidine revealed that the presence of Sc-IndB dramatically increased the production of
indigoidine.
As shown in Fig. 4b, E. coli BAP1/pJV6+pDY53 that expressed both Sc-IndC and
Sc-IndB gave the highest yield of 3.93 g/l at 18 ℃ after 28 h. Co-expression of Sc-IndA
with Sc-IndC did not show any improvement in the production of the pigment. Instead, a
slight decrease in the yield was observed. This is likely due to the high-level expression of
Sc-IndA, which might have influenced the expression of other proteins in the cells.
Similarly, a slightly lower yield of indigoidine than that in E. coli BAP1/pJV6 +pDY53
was observed when Sc-IndC was co-expressed with both Sc-IndB and Sc-IndA (Fig. 8b).
Thus, our experiments clearly revealed that Sc-IndB, but not Sc-IndA, is involved in the
indigoidine biosynthetic pathway in S. chromofuscus ATCC 49982.

Figure 8. Co-expression of Sc-IndC with Sc-IndA and/or Sc-IndB in E. coli BAP1. a SDSPAGE analysis of co-expression of Sc-IndA and/or Sc-IndB with Sc-IndC in E.
coli BAP1 at 18 °C. b The yield of indigoidine in E. coli BAP1 with or without coexpression of Sc-IndA and/or Sc-IndB. Experiments were performed in triplicate and
presented as mean±SD (n = 3). ABC: Sc-IndA, Sc-IndB and Sc-IndC, AC: Sc-IndA and
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Sc-IndC, BC: Sc-IndB and Sc-IndC, C: Sc-IndC, M: protein ladder, S: soluble fraction, I:
insoluble fraction
2.5

Discussion
Indigoidine is a blue pigment that has been found in several different bacteria such

as S. aureofaciens and E. chrysanthemi. It is a powerful radical scavenger for the producing
strains. This pigment can be easily extracted and quantified. More and more useful
properties of indigoidine have been discovered and utilized in recent years. In addition to
the antimicrobial activity, the bright blue color of this natural product makes it a useful and
sensitive indicator in biochemical studies. For instance, indigoidine has recently been
developed into a versatile and universal reporter for bacteria and mammalian cells [14].
The indigoidine synthase BpsA has also been used as a reporter for rapid and flexible
measurement of PPTase activity. This system can be used for discovery and
characterization of PPTase inhibitors [17]. The present study identified a new indigoidine
biosynthetic gene cluster from the pharmaceutically important strain S. chromofuscus
ATCC 49982 which produces the anti-cholesterol compound herboxidiene, further
expanding the spectrum of indigoidine-producing strains. This gene cluster is silent under
laboratory conditions as no pigment formation was observed in the host. We were able to
reconstitute this indigoidine biosynthetic pathway in two different heterologous hosts, S.
coelicolor CH999 and E. coli BAP1. Sc-IndC is a single module NRPS that contains four
domains (A, Ox, T, and TE). It was proposed that the A domain selects and activates the
substrate L-glutamine and transfers the precursor to the PPTase-activated T domain. The
TE domain hydrolyzes the amino acid from the enzyme and catalyzes the cyclization to
form 5-aminopiperidine-2,6-dione, which can be further oxidized and dimerized by the Ox
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domain to yield indigoidine [19]. Thus, activation of Sc-IndC is critical to the biosynthesis
of the pigment. Although no heterologous PPTase was introduced into S. coelicolor CH999,
the strain was found to be an effective host for indigoidine biosynthesis. An endogenous
PPTase may contribute to the activation of the T domain of Sc-IndC. The yield difference
between S. coelicolor CH999 and E. coli BAP1 is likely due to the efficiency of the PPTase
and expression level of Sc-IndC.
A number of factors can affect the yield of indigoidine, such as fermentation time
and temperature. We found that 18 ℃ is the best temperature among the four tested. Low
temperatures may attribute to the stability of the modular indigoidine synthase Sc-IndC
and the product indigoidine. The yield of indigoidine drops after the maximum point, when
the degradation rate is larger than the biosynthesis rate. This was revealed by the time
course analysis at both 18 and 25 ℃. No pigment formation was observed at 30 and 37 ℃,
suggesting that the production process prefers a lower temperature. In this work, we also
for the first time found that OD600 values at which expression of Sc-IndC was induced with
IPTG can also influence the yield of indigoidine. We induced at four different OD600 values
and 0.6 was found to be the best. Under the optimal fermentation conditions, the yield of
indigoidine reached 2.78 g/l in E. coli BAP1.
Indigoidine is water-insoluble. The pigment precipitates during the fermentation,
which provides a convenient way to harvest it by centrifugation. This compound is also not
soluble in most organic solvents, but DMSO is a suitable solvent for this pigment.
Degradation of indigoidine is fast and it can be stored longer at lower temperatures.
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Genes encoding IndA- and IndB-like proteins are often found in the indigoidine
biosynthetic pathways from different strains. However, the functions of these two proteins
are still unknown. While IndA (or IdgA) is a hypothetical protein, IndB (or IdgB) is a
putative phosphatase. A previous study has shown that an idgA mutant of E. chrysanthemi
RA3B was deficient in the pigment production, while the idgB mutant produced only low
level of indigoidine, suggesting that both IdgA and IdgB are involved in indigoidine
biosynthesis in E. chrysanthemi RA3B [4]. IndA- and IndB-like enzymes were also found
in some other natural product biosynthetic pathways. For instance, AlnA and AlnB, which
are homologous to IdgA and IdgB, respectively, have been found to be involved in the
formation and attachment of the dioxan moiety in alnumycin biosynthesis in Streptomyces
sp. CM020 through a gene disruption approach [16]. In this study, we used a heterologous
expression approach to investigate the functions of Sc-IndA and Sc-IndB. Our results
showed that the presence of Sc-IndA had no obvious effects on the production of the blue
pigment, while co-expression of Sc-IndB with Sc-IndC increased the yield of indigoidine
by 41.4 %. Thus, Sc-IndB plays a role of helper in indigoidine biosynthesis. Sc-IndB is a
unique fusion protein found in an indigoidine biosynthetic pathway. Its N-terminal portion
is similar to IdgB and other homologues, which is a putative phosphatase belonging to the
family of haloacid dehalogenase-like hydrolases. However, Sc-IndB is nearly three times
the size of IdgB, as it has a large C-terminal domain without a known function. Although
the exact function of Sc-IndB is still unknown, it is clear from this work that this unusual
enzyme is involved in the biosynthesis of the blue pigment. Co-expression of this protein
with Sc-IndC provides an effective way to significantly improve the production of
indigoidine.
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CHAPTER 3
EFFICIENT PRODUCTION OF INDIGOIDINE IN ESCHERICHIA COLI †
3.1

Abstract
Indigoidine is a bacterial natural product with antioxidant and antimicrobial activities.

Its bright blue color resembles the industrial dye indigo, thus representing a new natural
blue dye that may find uses in industry. In our previous study, an indigoidine synthetase
Sc-IndC and an associated helper protein Sc-IndB were identified from Streptomyces
chromofuscus ATCC 49982 and successfully expressed in Escherichia coli BAP1 to
produce the blue pigment at 3.93 g/l. To further improve the production of indigoidine, in
this work, the direct biosynthetic precursor L-glutamine was fed into the fermentation broth
of the engineered E. coli strain harboring Sc-indC and Sc-indB. The highest titer of
indigoidine reached 8.81±0.21 g/l at 1.46 g/l L-glutamine. Given the relatively high price
of L-glutamine, a metabolic engineering technique was used to directly enhance the in situ
supply of this precursor. A glutamine synthetase gene (glnA) was amplified from E. coli
and co-expressed with Sc-indC and Sc-indB in E. coli BAP1, leading to the production of
indigoidine at 5.75±0.09 g/l. Because a nitrogen source is required for amino acid
biosynthesis, we then tested the effect of different nitrogen-containing salts on the supply
of L-glutamine and subsequent indigoidine production. Among the four tested salts
including (NH4)2SO4, NH4Cl, (NH4)2HPO4 and KNO3, (NH4)2HPO4 showed the best effect
on improving the titer of indigoidine. Different concentrations of (NH4)2HPO4 were added
to the fermentation broths of E. coli BAP1/Sc-IndC+Sc-IndB+GlnA, and the titer reached

This chapter has been published as Xu, F., Gage, D., Zhan, J.* (2015): Efficient production of
indigoidine in Escherichia coli. Journal of Industrial Microbiology & Biotechnology 42(8), 1149–1155.
†

51
the highest (7.08±0.11 g/l) at 2.5 mM (NH4)2HPO4. This work provides two efficient
methods for the production of this promising blue pigment in E. coli.
3.2

Introduction
Nature provides a variety of molecules that have particular functions. Some

compounds have significant health benefiting properties such as antimicrobial, anticancer
and anti-cholesterol activities. Many promising natural products have been developed into
therapeutics for different diseases, such as vancomycin (antibacterial), paclitaxel
(anticancer), artemisinin (anti-malarial) and lovastatin (anti-cholesterol). In addition to
these therapeutic compounds, some other naturally occurring compounds have useful
properties that may find uses in industry, such as natural pigments. Dyes are applicable in
many fields and closely linked to our daily life. They are commonly used in the textile and
food industries for desired colors. Dyes can be divided into two categories, natural dyes
and synthetic dyes. The majority of natural dyes are from plants, fungi and lichens [12].
Indigo is a dark blue crystalline powder and one of the oldest blue dyes that has been known
for more than 4,000 years. It can be obtained from a variety of plant sources such as
Indigofera tinctoria (Africa, Asia, East India, South America), Polygonum tinctorium
(China, Korea) and Isatistinctoria (Europe) [15]. It is commonly used to dye cotton yarn
for the production of denim cloth to make blue jeans [5, 18]. The precursor to indigo is
indicant which is a colorless natural product from plant leaves [20]. After extraction from
plants, indican is hydrolyzed toyield glucose and indoxyl. The latter is then converted to
indigo through several steps. Also, the extraction needs a strong base such as lye and other
substances that are harmful to the environment [15, 19]. Since the natural source for indigo
is limited, chemical synthesis becomes a more economic method to produce this dye.
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However, chemical synthesis requires harsh conditions and use of a strong base [8].
Indigoidine, 5,5´-diamino-4,4´-dihydroxy-3,3´-diazadiphenoquinone-(2,2´), is a natural
blue pigment from bacteria that was first isolated from Erwinia [16]. Because of the
carbon–carbon double bonds conjugated with a carbonyl group in its structure, indigoidine
is a powerful radical scavenger that enables phytopathogens to tolerate oxidative stress [13],
thus representing a strong antioxidant agent. Recent studies have also shown that this blue
pigment has antimicrobial activity. The redox activity and bright blue color make
indigoidine a possible redox state sensor or industrial dye [3].

Figure 9. Biosynthetic pathway of indigoidine. GS: glutamine synthetase; Sc-IndC:
indigoidine synthetase from S. chromofuscus ATCC 49982; ATP: adenosine triphosphate;
ADP: adenosine diphosphate; NH3: ammonia; Pi: inorganic phosphate
Indigoidine is synthesized through the condensation of two molecules of L-glutamine
under the catalysis of indigoidine synthetase (Fig. 9). Several indigoidine biosynthetic gene
clusters have been reported from different bacterial strains such as Erwinia [13],
Streptomyces [10, 17, 21] and Photorhabdus [2]. We have recently discovered an
interesting indigoidine biosynthetic gene cluster from Streptomyces chromofuscus ATCC
49982 consisting of ScindA, Sc-indB and Sc-indC. Sc-IndC was identified as the
indigoidine synthetase and it was successfully expressed in both Escherichia coli BAP1
and Streptomyces coelicolor CH999 to reconstitute indigoidine biosynthesis. The titer of
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indigoidine reached 2.78 g/l under the optimized fermentation conditions [21]. While the
exact function of Sc-IndB is unclear, it is found that co-expression of this protein with ScIndC significantly increased the titer of indigoidine by 41.4 % in E. coli BAP1, suggesting
that it acts as a helper in indigoidine biosynthesis [21]. Sc-IndA is a hypothetical protein.
Its function is unknown and co-expression of this protein with Sc-IndC did not improve
the production of indigoidine in E. coli [21]. In this work, we report the optimization of
indigoidine production in E. coli by improving the availability of the biosynthetic precursor
L-glutamine. Two approaches were used, including direct supplementation of L-glutamine
in the fermentation broth and enhanced self-supply of L-glutamine by engineering a
glutamine synthase (GS) into E. coli and adding extra nitrogen-containing salt. While the
first approach allows the engineered E. coli strain to produce the blue pigment at 8.81 g/l,
the second approach provides a more economical method to produce indigoidine and the
titer reached 7.08 g/l.
3.3

Materials and methods

3.3.1 Vectors, strains and culture conditions
E. coli XL1-Blue (Agilent) and the pJET1.2 vector (Fermentas) were used for DNA
cloning and sequencing. The expression vectors pET28a (Novagen) and pACYCDuet-1
(Novagen) were used to construct the expression plasmids. E. coli BAP1 was used as the
host for protein expression. All E. coli strains were grown at 37 ℃ in liquid Luria-Bertani
(LB) medium or LB agar supplemented with appropriate antibiotics at the following
concentrations: ampicillin, 50 μg/ml; kanamycin, 50 μg/ml; and chloramphenicol, 25
μg/ml. 200 μM isopropyl-1-thio-β-D-galactopyranoside (IPTG) was used to induce gene
expression.
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3.3.2 Construction of plasmids
The plasmids pJV6 (pET28a-Sc-indC) and pDY53 (pACYCDuet-1-Sc-indB) were
from our previous work [21]. The glnA gene (1284 bp) was amplified by the polymerase
chain reaction (PCR) from the genome of E. coli BL21(DE3) with Phusion Hot Start HighFidelity DNA Polymerase (New England Biolabs) using a pair of primers, 5´aaCATATGTCCGCTGAACACGTACTGAC-3´ (the NdeI site are underlined) and 5´aaCTCGAGTTAGACGCTGTAGTACAGCTC-3´ (the XhoI site are underlined). These
primers were designed based on the reported glnA sequence [1] and synthesized by SigmaAldrich. The amplified glnA gene was ligated into the cloning vector pJET1.2 to yield
pFC5 (Table 1).
Table 3. Plasmids used in chapter III
Plasmid

Description

References

pJV6

Sc-indC in pET28a

[21]

pDY53

Sc-indB in pACYCDuet-1

[21]

pFC5

glnA in pJET1.2

This work

pFC6

glnA in pACYCDuet-1

This work

pFC7

glnA and Sc-indB in pACYCDuet-1
under two separate T7 promoters

This work

After gene sequencing, the glnA gene was excised from pFC5 with NdeI and XhoI
and ligated into pACYCDuet-1 or pDY53 between the same sites to generate pFC6 or
pFC7, respectively (Table 1). E. coli BAP1 was co-transformed with pJV6 and each of
these pACYCDuet-1-derived plasmids (pDY53, pFC6 and pFC7) for indigoidine
production.
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3.3.3 Indigoidine production by engineered E. coli BAP1 with supplementation of
L‑glutamine
pJV6 was transferred into E. coli BAP1 and the correct transformant was grown in
250-ml Erlenmeyer flasks containing 50 ml of LB broth supplemented with 50 μg/ ml
kanamycin at 37 ℃ with shaking at 250 rpm. When the OD600 value reached 0.6, 200 μM
IPTG was added to induce the expression of Sc-indC. After the induction, the fermentation
broths were cultured at 18 ℃ and 250 rpm for 30 min and then L-glutamine powder was
added at different concentrations (0, 0.73, 1.46, 4.38 and 11.68 g/l). The broths were
maintained under the same conditions for an additional 28 h. The cultures were then
harvested and the titers of indigoidine were determined according to the method described
previously [21]. Briefly, 1 ml of fermentation broth was centrifuged at 21,000×g for 10
min. The supernatant was discarded and the pellet was successively washed with 1 ml of
water and methanol and then dissolved in 1 ml of dimethyl sulfoxide (DMSO) by
sonication. The DMSO-insoluble components and cell debris were removed by
centrifugation (8509×g, 5 min). The absorption value of the DMSO solution at 600 nm was
measured on a Thermo Scientific GENESYS 20 Visible Spectrophotometer. The titer of
indigoidine was then calculated according to a standard curve of pure indigoidine.
Similarly, pJV6 and pDY53 were co-transferred into E. coli BAP1 and the same procedure
described above was applied to the resulting engineered E. coli strain except that two
antibiotics were supplied in the cultures (kanamycin and chloramphenicol). The
experiments were conducted in triplicate and the titers are shown as mean±SD.
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3.3.4 Co‑expression of glnA with Sc‑indC and/or Sc‑indB in E. coli BAP1
Each of the pACYCDute-1 derived plasmids (pFC6 and pFC7) was co-transferred
with pJV6 into E. coli BAP1. The resulting E. coli strains were grown in 250-ml
Erlenmeyer flasks containing 50 ml of LB broth supplemented with 50 μg/ml kanamycin
and 25 μg/ml chloramphenicol at 37 °C and 250 rpm. When the OD600 reached 0.6, 200
μM IPTG was added to induce gene expression and the induced broths were cultured at
18 °C with shaking at 250 rpm for an additional 28 h. The titers of indigoidine from each
engineered strain were calculated and compared. The experiments were conducted in
triplicate and the titers are shown as mean±SD.
3.3.4 Supply of different nitrogen‑containing salts for L‑glutamine synthesis
The engineered E. coli strain (pJV6 + pFC7) expressing Sc-IndC, GlnA and Sc-IndB
was cultured in 1L Erlenmeyer flasks containing 250 ml of LB medium supplemented with
50 μg/ml kanamycin and 25 μg/ml chloramphenicol at 37 °C with shaking at 250 rpm.
When the OD600 reached 0.6, 200 μM IPTG was added to induce the expression of Sc-indC,
glnA and Sc-indB. After the induction, the fermentation broth was cultured at 18 °C and
250 rpm for 30 min and then evenly divided into 5 flasks. Four nitrogen- containing salts
including (NH4)2HPO4 (10 mM), (NH4)2SO4 (10 mM), NH4Cl (20 mM) and KNO3 (20
mM) were separately added into one of the flasks, with the extra one (without any
exogenous salts) as control. The cultures were maintained under the same conditions for
an additional 28 h. The experiments were conducted in triplicate and the titers are shown
as mean±SD.
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3.3.5 Indigoidine production with the supplementation of different concentrations of
(NH4)2HPO4
The engineered E. coli strain expressing Sc-IndC, GlnA and Sc-IndB was cultured in
1-L Erlenmeyer flasks containing 300 ml of LB broth supplemented with 50 μg/ml
kanamycin and 25 μg/ml chloramphenicol at 37 °C with shaking at 250 rpm. When the
OD600 value reached 0.6, 200 μM IPTG was added to induce the expression of the enzymes.
After the induction, the fermentation broth was evenly distributed into 6 flasks, which were
cultured at 18 °C and 250 rpm for 30 min. (NH4)2HPO4 was then added to the induced
broths at different concentrations ranging from 0 to 20 mM. The cultures were maintained
under the same conditions for an additional 28 h. The experiments were conducted in
triplicate and the titers are shown as mean±SD.
3.4

Results

3.4.1 Improved production of indigoidine by feeding L‑glutamine
L-Glutamine is the direct biosynthetic precursor of indigoidine. It is a key amino acid
in primary metabolism and thus naturally exists in E. coli. Expression of Sc-IndC in E. coli
led to the production of indigoidine in our previous study [21]. We hypothesize that supply
of exogenous L-glutamine can improve the production of indigoidine in E. coli. To test the
hypothesis, different concentrations of L-glutamine were fed into the induced culture of E.
coli BAP1/Sc-IndC or E. coli BAP1/Sc-IndC+Sc-IndB. As shown in Fig. 10,
supplementation of L-glutamine at the four test concentrations (0.73, 1.46, 4.38 and 11.68
g/l) increased the titer of indigoidine significantly. The titer reached 7.22±0.31 g/l when
1.46 g/l L-glutamine was supplied into the fermentation broth of E. coli BAP1-Sc-IndC.
Further increase in the L-glutamine concentrations (4.38 and 11.68 g/l) led to the reduced
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production of the blue pigment (Fig. 10). The same pattern was observed for E. coli
BAP1/Sc-IndC+Sc-IndB. 1.46 g/l L-Glutamine was found to be the best among the four
test concentrations, at which the titer of indigoidine reached 8.81±0.21 g/l. This represents
a 124 % increase compared to the culture without supplementing L-glutamine.

Figure 10. Effect of L-glutamine concentrations on indigoidine production in E. coli.
3.4.2 Engineering of a glutamine synthetase into E. coli
While supplementation of L-glutamine significantly increased the titer of indigoidine,
its relatively high price will increase the production costs of the blue pigment. An
alternative approach is to enhance the ability of E. coli to generate L-glutamine in situ using
metabolic engineering techniques. Glutamine synthetase (GS) synthesizes L-glutamine
from L-glutamate (Fig. 9). The GS in E. coli is GlnA. We thus amplified the corresponding
gene from E. coli BL21(DE3) and co-expressed it with the indigoidine biosynthetic genes.
As shown in Fig. 11, the titer of indigoidine in E. coli BAP1/Sc-IndC+GlnA was 4.80±0.15
g/l, which is 76% higher than E. coli BAP1/Sc-IndC. Similarly, E. coli BAP1/Sc-IndC+ScIndB+GlnA produced the blue compound at 5.75±0.09 g/l, representing a 46.3 % increase
compared to E. coli BAP1/Sc-IndC+Sc-IndB. Thus, it is apparent that overexpression of
GlnA in E. coli BAP1 can greatly increase the production of indigoidine. This provides
another approach to improve the production of the blue pigment in E. coli. blue compound
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at 5.75±0.09 g/l, representing a 46.3% increase compared to E. coli BAP1/Sc-IndC+ScIndB. Thus, it is apparent that overexpression of GlnA in E. coli BAP1 can greatly increase
the production of indigoidine. This provides another approach to improve the production
of the blue pigment in E. coli.

Figure 11. Improved production of indigoidine in E. coli through the overexpression of a
glutamine synthetase.
3.4.3 Effect of different nitrogen‑containing salts on indigoidine production
GS plays a key role in the amino acid metabolism through the synthesis of Lglutamine from L-glutamate and ammonia. We next tested the effect of different nitrogencontaining salts on L-glutamine biosynthesis and subsequent indigoidine production. Four
salts were used, including (NH4)2SO4, NH4Cl, (NH4)2HPO4 and KNO3. (NH4)2SO4 and
(NH4)2HPO4 were supplemented into the induced broth of E. coli BAP1/Sc-IndC+ScIndB+GlnA at 10 mM, while NH4Cl and KNO3 were supplied at 20 mM so that equivalent
amounts of nitrogen were provided for the strain. As shown in Fig. 12a, all the three
ammonium salts were found to increase the titer of indigoidine to certain extent, among
which (NH4)2HPO4 has the best effect on increasing indigoidine production (Fig. 12a), with
a titer of 6.27±0.10 g/l. By contrast, when the nitrate salt KNO3 was supplied, the
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production of indigoidine was decreased and the titer was only 5.08±0.09 g/l (Fig. 12a).
The pH values of the cultures were measured right after the addition of the salts and at the
end of the fermentation. As shown in Table 4, the pH values of the fermentation broths
supplied with NH4Cl, (NH4)2SO4, and KNO3 were similar to those of the control in which
no salt was added, suggesting that the supply of NH4Cl and (NH4)2SO4 increased the
production of indigoidine without causing pH changes. In contrast, the pH values of the
cultures with (NH4)2HPO4 were 7.22±0.02 (0 h) and 7.37±0.06 (28 h), which are slightly
basic and higher than those supplemented with other salts. At higher pH values, more
ammonia will be generated from the ammonium ion for L-glutamine biosynthesis. This
may explain why the titer of indigoidine with the supply of (NH4)2HPO4 was higher than
those with NH4Cl and (NH4)2SO4 even though equivalent amounts of ammonium were
present in the cultures.

Figure 12. Improved production of indigoidine in E. coli through the supplementation of
nitrogen-containing salts. a Effect of different nitrogen-containing salts on indigoidine
biosynthesis in E. coli BAP1/Sc-IndC+Sc-IndB+GlnA. b Effect of the concentrations of
(NH4)2HPO4 on indigoidine biosynthesis in E. coli BAP1/Sc-IndC+Sc-IndB+GlnA
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3.4.4 Effect of the concentrations of (NH4)2HPO4 on indigoidine production
To determine the optimal concentration of (NH4)2HPO4 for indigoidine production,
this salt was added to the IPTG induced broths of E. coli BAP1/Sc-IndC+Sc-IndB+GlnA at
1, 2.5, 5, 10 and 20 mM, respectively. As shown in Fig. 12b, compared to the control in
which no exogenous salt was added, all the samples with (NH4)2HPO4 showed higher titers,
further confirming that supplementation of this ammonium salt has a positive impact on
the production of the blue pigment. When (NH4)2HPO4 was fed at 1 mM, the titer of
indigoidine was 6.06±0.05 g/l. When the salt concentration was increased to 2.5 mM, the
titer of the target product reached 7.08 g/l. Higher concentrations of the salt did not yield
more indigoidine. Instead, the titers of this pigment slightly decreased. The blue compound
was produced at 6.54±0.06, 6.27±0.10, and 6.20±0.09 g/l at 5, 10 and 20 mM (NH4)2HPO4,
respectively. Thus, 2.5 mM was found to be the best for indigoidine production among the
five test concentrations.
Table 4. The pH values of the fermentation broths of E. coli BAP1/Sc-IndC+ScIndB+GlnA in the presence of different nitrogen-containing salts
Time (h)

pH
Control

(NH4)2HPO4

NH4Cl

(NH4)2SO4

KNO3

0

6.76±0.01

7.22±0.02

6.74±0.01

6.78±0.02

6.75±0.01

28

6.92±0.16

7.37±0.06

6.88±0.06

7.01±0.03

6.91±0.01

3.5

Discussion
Natural pigments represent promising colorants for foods and drinks. Blue

compounds have been found from various sources including plants, animals and
microorganisms. Several major types of blue pigments have been identified, such as
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azulenes, flavonoids, quinones and quinoids, linear tetrapyrrole alkaloids, phenazine
alkaloids, indole alkaloids, pyridine alkaloids, as well as organometallics and
metalloproteins [9]. Development of a new colorant requires several important factors,
such as color intensity, stability and efficient method to produce in large scale. Indigoidine
belongs to the family of nonribosomal peptide natural products. It is synthesized by a
modular nonribosomal peptide synthetase (NRPS) which condenses two units of Lglutamine to form the blue pigment. We have previously identified a gene cluster from S.
chromofuscus that is involved in indigoidine biosynthesis [21]. By co-expressing the
indigoidine synthetase Sc-IndC and the helper protein Sc-IndB, indigoidine biosynthesis
can be reconstituted in E. coli BAP1 that contains a chromosomal copy of the
phosphopantetheinyl transferase Sfp to activate the thiolation domain of Sc-IndC [11].
Biosynthesis of natural products in a heterologous host can be limited by the availability
of the precursors. L-Glutamine is one of the 20 proteinogenic amino acids. It also acts as
an energy source and plays a central role in cell metabolism and function. The heterologous
Sc-IndC can pull L-glutamine from the natural metabolic pathways in E. coli to generate
indigoidine. However, the availability of this indigoidine biosynthetic precursor relies on
the ability of the host to synthesize this amino acid, and the best titer achieved in E. coli
BAP1 was 3.93 g/l [21]. In this work, we demonstrated that supplementation of Lglutamine into the fermentation broth can effectively increase the production of indigoidine.
Feeding of exogenous L-glutamine provides extra substrate for Sc-IndC to synthesize
indigoidine, leading to a titer of 8.81 g/l, which represents an efficient production process
for this pigment.
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E. coli can recruit free amino acids including L-glutamine from tryptone and yeast
extract in the LB medium using its oligopeptide permeases and peptidases. However, the
amount of L-glutamine from the medium is limited. A previous study showed that the
concentration of L-glutamine in LB medium after acidic hydrolysis was 0.6 mM (0.088 g/l)
[14]. To get sufficient L-glutamine for primary and secondary metabolism, E. coli uses its
own biosynthetic machinery to generate this key amino acid. GS is an enzyme that plays
an essential role in catalyzing the condensation of glutamate and ammonia to form
glutamine [7]. When performing its reaction, the active site of GS binds to glutamate,
ammonia, and ATP that powers the reaction [4]. This enzyme is a central control point in
nitrogen metabolism. L-Glutamine acts as a storage form of ammonia and the amino group
donor in the biosynthesis of many metabolites. Although E. coli contains the GS gene glnA,
overexpression of the same gene can increase the titer of indigoidine from 3.93 to 5.75 g/l,
indicating that the elevated expression of this enzyme enhanced the in situ supply of Lglutamine in the cells for the biosynthesis of this blue compound. This provides an
alternative approach to improving the production of indigoidine. L-Glutamate and
ammonia are the two substrates for L-glutamine biosynthesis. Supplementation of
ammonium salts into the culture of the engineered E. coli strain increased the production
of indigoidine, suggesting that these exogenous salts provided more ammonia for the
formation of L-glutamine. At 2.5 mM (NH4)2HPO4, indigoidine was produced at 7.08 g/l
by E. coli BAP1/Sc-IndC+Sc-IndB+GlnA. Although the titer from this approach is slightly
lower than direct feeding of L-glutamine, this process can avoid using L-glutamine that is
more costly than common ammonium salts. Additionally, previous studies have reported
various metabolic engineering approaches for overproduction of L-glutamine in E. coli.
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For example, a novel mechanism for L-glutamine overproduction was found in an E. coli
K-12-derived strain by random mutagenesis and genome-wide mutation analysis.
Reduction of chromosomal DNA supercoils in the mutant caused an increase in Lglutamine accumulation in the cells. L-Glutamine was produced at 500 mM using DNA
gyrase mutations in E. coli [6]. These studies provide useful approaches for further
improvement of indigoidine production in E. coli.
In summary, this work demonstrates two different approaches for efficient production
of indigoidine in E. coli. Direct supply of exogenous L-glutamine at 1.46 g/l in the
fermentation broth leads to the production of this blue pigment at 8.81 g/l. Engineering of
a GS into the E. coli host followed by the addition of the ammonium salt (NH4)2HPO4 at
2.5 mM led to the production of indigoidine at 7.08 g/l.
3.6
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CHAPTER 4
ENGINEERED PRODUCTION OF FUNGAL PRODUCTION OF FUNGAL
ANTICANCER CYCLOOLIGOMER DEPSIPEPTIDES IN SACCHAROMYCES
CEREVISIAE ‡
4.1

Abstract
Two fungal cyclooligomer depsipeptide synthetases (CODSs), BbBEAS (352 kDa)

and BbBSLS (348 kDa) from Beauveria bassiana ATCC 7159, were reconstituted in
Saccharomyces cerevisiae BJ5464-NpgA, leading to the production of the corresponding
anticancer natural products, beauvericins and bassianolide, respectively. The titers of
beauvericins (33.8±1.4 mg/l) and bassianolide (21.7±0.1 mg/l) in the engineered S.
cerevisiae BJ5464-NpgA strains were comparable to those in the native producer B.
bassiana. Feeding D-hydroxyisovaleric acid (D-Hiv) and the corresponding L-amino acid
precursors improved the production of beauvericins and bassianolide. However, the high
price of D-Hiv limits its application in large-scale production of these cyclooligomer
depsipeptides. Alternatively, we engineered another enzyme, ketoisovalerate reductase
(KIVR) from B. bassiana, into S. cerevisiae BJ5464-NpgA for enhanced in situ synthesis
of this expensive substrate. Co-expression of BbBEAS and KIVR in the yeast led to
significant improvement of the production of beauvericins. The total titer of beauvericin
and its congeners (beauvericins A–C) was increased to 61.7±3.0 mg/l and reached 2.6-fold
of that in the native producer B. bassiana ATCC 7159. Supplement of L-Val at 10 mM
improved the supply of ketoisovalerate, the substrate of KIVR, which consequently further

This chapter has been published as Yu, D.,# Xu, F.,# Zi, J., Wang, S., Gage, D., Zeng, J., Zhan, J.*
(2013): Engineered production of fungal anticancer cyclooligomer depsipeptides in Saccharomyces
cerevisiae.Metabolic Engineering 18, 60–68. (# : equal contribution)
‡
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increased the total titer of beauvericins to 105.8±2.1 mg/l. Using this yeast system, we
functionally characterized an unknown CODS from Fusarium venenatum NRRL 26139 as
a beauvericin synthetase, which was named as FvBEAS. Our work thus provides a useful
approach for functional reconstitution and engineering of fungal CODSs for efficient
production of this family of anticancer molecules.
4.2

Introduction
Nonribosomal peptides represent an important family of natural products, including

antimicrobials, anticancer agents, immunosuppressants, siderophores, herbicides,
antifungals, insecticides, and anthelminthics. They are biosynthesized by giant modular
enzymes called nonribosomal peptide synthetases (NRPSs) [1, 2]. The assembly of the
peptides is well programmed and controlled by the dedicated enzymes. Cyclooligomer
depsipeptides (CODs) are a particular group of nonribosomal peptides often found in fungi
as mycotoxins, such as beauvercins (1 -4, Fig. 3), bassianolide (5, Fig. 3) and enniatins. 1
is produced by a number of fungal strains such as Fusarium species, Beauveria bassiana,
Paecilomyces fumoso-roseus (renamed Isaria fumosorosea), and P. tenuipes (renamed I.
tenuipes)[3] . It is a cyclic trimer of a dipeptidol monomer synthesized from N-methyl-Lphenylalanine and D-hydroxyisovaleric acid (D-Hiv). Its congeners, beauvericins A–C (2–
4), were also observed as minor products in many producing strains. 5 was isolated from
B. bassiana [4], Lecanicillium sp. [3], and the wood-decaying Xylaria sp. BCC1067 [5]. It
is an octadepsipeptide that is assembled as the cyclic tetrameric ester of the dipeptidol
monomer D-Hiv-N-Methyl-L-leucine. Fungal CODs have displayed a wide variety of
bioactivities, including antibiotic, insecticidal, anthelminthic, herbicidal, antiretroviral,
cytotoxic, anti-haptotactic, anti-cholesterol, and chemosensitizer activities, as well as
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repression of amyloid plaque formation in Alzheimer's disease [6]. In addition, recent
studies have shown that some fungal CODs are novel anticancer agents[7, 8]. 1 has
displayed potent anticancer activity against various cell lines by increasing cytoplasmic
Ca2+ concentration, triggering ATP depletion, and activating calcium-sensitive cell
apoptosis [9-11]. Recently, we have found that 1 can also inhibit migration of the metastatic
prostate cancer (PC-3M) and breast cancer (MDA-MB-231) cells, and has antiangiogenic
activity in HUVEC-2 cells at sublethal concentrations [12]. Inhibition of angiogenesis is
an effective cancer chemotherapy strategy, and thus 1 may be a useful anticancer agent that
restrains new tumor formation or increases successful containment of solid tumors. 5 was
also shown to have moderate cytotoxic activity against different cancer cell lines[5].
Therefore, these fungal natural products represent promising anticancer drug leads.
Fungal CODs are assembled by COD synthetases (CODSs), a subclass of Type B
NRPSs which use their modules iteratively for the biosynthesis of several copies of
identical or nearly identical peptide/peptidol monomer units that remain covalently bound
on the enzyme. The monomer units of CODs undergo recursive head to tail condensation,
or oligomerization, followed by macrocyclization[13]. Typically, the monomers are
formed from one unit of 2-hydroxycarboxylic acid and one molecule of amino acid. Two
building blocks of 1 are D-Hiv and L-phenylalanine (L-Phe), while 5 is biosynthesized
from D-Hiv and L-leucine (L-Leu). We have previously used a precursor-directed
biosynthesis approach to generate a series of new beauvericin analogs by feeding 2hydroxycarboxylic acids and amino acids into the fermentation broth of B. bassiana. The
fluorine-containing products showed increased cytotoxicity while maintaining comparable
antihaptotactic activity [14]. These results suggested that the dedicated CODS has relaxed
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substrate specificity and may represent an interesting target for engineered biosynthesis of
new molecules.
Both the biosynthetic gene clusters of 1 and 5 have recently been characterized from
B. bassiana ATCC 7159 [4, 15]. Analysis of the gene clusters revealed that the beauvericin
synthetase (BbBEAS) and the bassianolide synthetase (BbBSLS) have the same domain
organization of C1-A1-T1-C2-A2-MT-T2a-T2b-C3 (Fig. 4). In addition to the CODS gene, a
kivr gene is found in the beauvericin biosynthetic gene cluster, which encodes a putative
NADPH-dependent ketoisovalerate reductase (KIVR) involved in the biosynthesis of DHiv [4]. The detailed mechanism of these CODSs is not fully understood and requires more
studies to demonstrate.
Heterologous expression of CODSs in strains that are easier to manipulate genetically
than the native fungal producers will facilitate enzymatic characterization of CODSs and
their engineered variants, enable efficient production of these anticancer agents, and
promote combinatorial biosynthesis of novel CODs. BbBEAS has been functionally
expressed in Escherichia coli, but the best beauvericin titer was achieved at only 8 mg/l in
E. coli when D-Hiv and L-Phe were supplemented [4] . This represents less than 40% of
the titer of the native producer B. bassiana, suggesting that E. coli is not an efficient host
for the expression and functional reconstitution of the giant CODS. On the other hand,
Saccharomyces cerevisiae is a fungus and may represent a better system for engineering
of fungal CODSs. S. cerevisiae BJ5464-NpgA is an engineered yeast strain containing a
chromosomal copy of the 4´-phosphopantetheinyl transferase (PPTase) gene npgA from
Aspergillus nidulans [16]. PPTases catalyze the 4´-phosphopantetheinylation of serine
residues within T domains using coenzyme A as the 4´-phosphopantetheine donor to
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activate NRPSs[16, 17]. Thus, it is essential to have a PPTase such as NpgA for functional
expression of NRPSs in the yeast. S. cerevisiae BJ5464-NpgA has been used for functional
reconstitution of giant enzymes such as the lovastatin nonaketide synthase, a highly
reducing iterative polyketide synthase (PKS) [18]. In the present study, we successfully
engineered BbBEAS and BbBSLS into S. cerevisiae BJ5464-NpgA to reconstitute the
production of 1–5. Supplement of the direct biosynthetic precursors (D-Hiv and L-Phe/LLeu) improved the production of these CODs in the yeast. Furthermore, engineering of
KIVR into the strain further enhanced the production of beauvericins, and improved supply
of the substrate of KIVR by feeding L-Val led to an unprecedented high titer of
beauvericins. Using this expression system, we also characterized a new beauvericin
synthetase, named FvBEAS, from Fusarium venenatum NRRL 26139.
4.3

Materials and methods

4.3.1 Strains, plasmids, and culture conditions
B. bassiana ATCC 7159 was obtained from the American Type Culture Collection
(ATCC), maintained on potato dextrose agar (PDA), and fermented in potato dextrose
broth (PDB) for the production of 1 and 5. Fermentation of B. bassiana ATCC 7159 was
carried out in 250-ml flasks containing 100 ml of PDB on a rotary shaker at 250 rpm and
30 ℃ for 4 days. F. venenatum NRRL 26139 was obtained from the Agricultural Research
Service Culture Collection (NRRL), and fermented in DPY medium (20 g/l dextrin, 10 g/l
multipeptone, 5 g/l yeast extract, 5 g/l monopotassium phosphate, 0.5 g/l magnesium
sulfate) at 30 ℃ for 6–8 days to produce 1. E. coli XL1-Blue (Agilent) was used for routine
cloning and pJET1.2 (Fermentas) was used as the cloning vector. E. coli cells were grown
in Luria-Bertani (LB) medium. When necessary, 50 μg/ml of ampicillin was added. S.
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cerevisiae BJ5464-NpgA (MATα ura352 his3-Δ200 leu2-Δ1 trp1 pep4::HIS3 prb1 Δ1.6R
can1 GAL) was obtained from Dr. Nancy Da Silva at the University of California, Irvine.
The plasmids pXW55 and pXW06 were gifts from Dr. Yi Tang at the University of
California, Los Angeles. S. cerevisiae BJ5464-NpgA was maintained on yeast
extract/peptone/dextrose (YPD) agar plates. The plasmid pXW55 carries the ampicillin
resistance gene and URA3 as the selection markers and was used as an E. coli/S. cerevisiae
shuttle vector to express BbBEAS, BbBSLS and FvBEAS. The plasmid pXW06 carries
the ampicillin-resistance gene and TRP1 as the selection markers and was used as an E.
coli/ S. cerevisiae shuttle vector to express KIVR.
4.3.2 DNA manipulations
Genomic DNAs were extracted from B. bassiana ATCC 7159 and F. venenatum
NRRL 26139 and used as the templates for gene amplification. Plasmids were isolated
from E. coli using a Gene-JET™ Plasmid Miniprep Kit (Fermentas). Gene ligations were
performed with T4 DNA ligase (New England Biolabs).
4.3.3 PCR amplification and plasmid construction
The total size of bbBeas is 9570 bp (GenBank accession number EU886196), and
bbBsls contains 9441 bp (GenBank accession number FJ439897). The gene fragments
bbBeas-a (7.3 kb), bbBeas-b (2.3 kb), bbBsls-a (6.9 kb), bbBsls-b (2.6 kb), and bbkivr
(1389 bp, GenBank accession number EU886196) were amplified by PCR from the
genome of B. bassiana ATCC 7159 with Phusions High-Fidelity DNA Polymerase (New
England Biolabs) using specific primers (Table 5). The fvBeas gene contains 9390 bp and
was deposited in GenBank under accession number JX975482. Similarly, two fragments
of this gene, fvBeas-a (3.4 kb) and fvBeasb (6.0 kb), were amplified from the F. venenatum
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NRRL 26139 genome. These gene fragments were ligated into the cloning vector pJET1.2
to yield seven plasmids including pJCZ47, pJCZ48, pJCZ49, pJCZ50, pDY47, pDY55 and
pDY56 (Table 6). These plasmids were confirmed by digestion checks and gene
sequencing.
Table 5. Primers used in chapter IV.
Primer

Sequence

Restriction

bbBeas-a-F
bbBeas-a-R

5′-aaGCTAGCatggagccgctcaaaaatgt-3′
5′-tcggcgGCTAGCtgcacaag-3′

NheI
NheI

bbBeas-b-F

5′-ttgtgcaGCTAGCcgccgag-3′

NheI

bbBeas-b-R

5′-aaCACGTGcaaagccgagtttagactct-3′

PmlI

bbBsls-a-F

5′-aaCATATGgagccacccaacaacgc-3′

NdeI

bbBsls-a-R

5′-ttgtgCATATGggatgcttg-3′

NdeI

bbBsls-b-F

5′-aagcatccCATATGcacaag-3′

NdeI

bbBsls-b-R

5′-aaCACGTGtaaagacgcattcaaagcct-3′

PmlI

bbkivr-F

5′-aaCATATGccatctccggagcatcc-3′

NdeI

bbkivr-R

5′-aaGTTTAAACttacaacagccttctcgcca-

PmeI

fvBeas-a-F

5′-aaCATATGgaatatcttactgctgt-3′

NdeI

fvBeas-a-R

5′-tctcacagCATATGgaatca-3′

NdeI

fvBeas-b-F

5′-tctgattcCATATGctgtga-3′

NdeI

fvBeas-b-R

5′-aaCACGTGcaaagaagagttgagaccct-3′

PmlI

Table 6. Plasmids constructed in chapter IV.
Plasmid

Description

Plasmid

Description

pJCZ49

bbBeas-a in pJET1.2

pDY35

bbBeas-b in pXW55

pJCZ48

bbBeas-b in pJET1.2

pDY37

bbBeas-a and bbBeas-b in pXW55

pJCZ50

bbBsls-a in pJET1.2

pDY36

bbBsls-b in pXW55

pJCZ47

bbBsls-b in pJET1.2

pDY42

bbBsls-a and bbBsls-b in pXW55

pDY47

bbkivr in pJET1.2

pDY48

bbkivr in pXW06

pDY55

fvBeas-a in pJET1.2

pDY57

fvBeas-b in pXW55

pDY56

fvBeas-b in pJET1.2

pDY59

fvBeas-a and fvBeas-b in pXW55
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The bbBeas-b insert was excised from pJCZ48 with NheI and PmlI and ligated into
pXW55 between the same sites to generate pDY35, and then bbBeas-a was excised from
pJCZ49 with NheI and inserted into pDY35 at the same site to generate pDY37 (Table 6
and Fig. C1). The bbBsls-b insert was excised from pJCZ47 with NdeI and PmlI and ligated
into pXW55 between the same sites to generate pDY36. The bbBsls-a insert was excised
from pJCZ50 with NdeI and ligated into pDY36 at the same site to yield pDY42 (Table 6).
The fvBeas-b insert was excised from pDY56 with NdeI and PmlI and ligated into pXW55
between the same sites to generate pDY57, and then the fvBeas-a insert was excised from
pDY55 with NdeI and ligated into pDY57 at the same site to generate pDY59 (Table 6).
The bbkivr insert was excised from pDY47 with NdeI and PmeI and ligated into pXW06
between the same sites to generate pDY48 (Table 6 and Fig. C2).
4.3.4 Transformation and fermentation of S. cerevisiae BJ5464-NpgA
Transformation of plasmid pDY37, pDY42 or pDY59 and co-transformation of
pDY37 and pDY48 into S. cerevisiae BJ5464-NpgA competent cells, as well as the
selection of correct transformants were conducted as previously described [19]. The
engineered S. cerevisiae strain carrying pDY37, pDY42 or pDY59 was fermented in a SCUra dropout medium (6.7 g/l yeast nitrogen base; 20 g/l glucose; 0.77 g/l-Ura DO
supplement) at 30 ℃ with shaking at 250 rpm until the OD600 reached 0.6, and then an
equal volume of YP medium (10 g/l yeast extract; 20 g/l peptone) with or without extra
substrates was added. The cultures were maintained under the same conditions for an
additional 72 h to produce the CODs. S. cerevisiae BJ5464-NpgA/pDY37+pDY48 was
fermented in a SC-Ura-Trp dropout medium (6.7 g/l yeast nitrogen base; 20 g/l glucose;
0.72 g/l-Trp/-Ura DO supplement) at 30 ℃ with shaking at 250 rpm until the OD600 reached
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0.6, and then an equal volume of YP medium with or without extra substrates was added.
The fermentation broths were cultured under the same conditions for an additional 72 h to
produce beauvericins. S. cerevisiae BJ5464-NpgA/pDY37+pDY48 was also grown at 20 ℃
to compare the titer with that at 30 ℃.
4.3.5 Extraction, isolation, and analysis of metabolites in the wild type fungal strains and
engineered S. cerevisiae strains
The culture of B. bassiana ATCC 7159 was filtered through Whatman No. 1 filter
paper. The filtrate was extracted three times with the same volume of ethyl acetate. The
mycelium cake from 100 ml of fermentation broth was extracted twice with 50 ml of
methanol. The extracts were concentrated under reduced pressure and dissolved in 500 μl
of methanol for LC–MS analysis. Extraction of the culture of F. venenatum NRRL 26139
was performed using the same method.
To purify 1 and 5 for establishing the standard curves, fermentation of B. bassiana
ATCC 7159 was carried out in a 2 L flask containing 500 ml of PDB on a rotary shaker at
250 rpm and 30 ℃ for 4 days. The fermentation broth was then extracted as described
above. A small portion (10%) of the extract was separated on an Agilent 1200 HPLC using
an Agilent Ecilpse XDB-C18 column (5 μm, 4.6 mm150 mm column), eluted with a
gradient of methanol–water (80–100% over 20 min) at a flow rate of 1 ml/ min. The peaks
at 9.6 min and 12.6 min were collected to yield 1.7 mg of 1 and 1.2 mg of 5. These two
samples were dissolved in 500 μl of methanol, which was serially diluted to obtain different
concentrations. For each concentration, 100 μl of these samples were injected into the
HPLC to obtain the peak areas to establish standard curves for 1 and 5. Compounds 1-4
were purified using the same HPLC method from the fermentation broth of S. cerevisiae
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BJ5464-NpgA/pDY37 for structural characterization. Standard curves based on the linear
relationship between the amounts and the peak areas were established for 2–4 for
quantification of their production in different engineered strains. Similarly, 5 was isolated
from S. cerevisiae BJ5464-NpgA/pDY42 for structural characterization. NMR spectra
were acquired on a JEOL instrument (300 MHz).
To analyze the products in the engineered S. cerevisiae BJ5464-NpgA strains, 100
ml of fermentation broth was centrifuged at 273×g for 5 min to pellet the cells. The
supernatant was extracted three times with the same volume of ethyl acetate, and the cells
were extracted twice with 50 ml of methanol. The extracts were evaporated in vacuo to
remove the solvents. The residues were then dissolved in 500 μl of methanol and analyzed
on an Agilent 6130 Single Quad LC–MS, eluted with a gradient of methanol–water (80–
100% over 20 min) at a flow rate of 1 ml/min and detected at 210 nm.
4.3.6 Extraction and analysis of the production of D-Hiv in S. cerevisiae BJ5464NpgA/pDY37 and S. cerevisiae BJ5464-NpgA/pDY37 +pDY48
S.

cerevisiae

BJ5464-NpgA/pDY37

and

S.

cerevisiae

BJ5464-

NpgA/pDY37+pDY48 were grown and harvested as described above. For each strain, the
concentrations of D-Hiv in the cells and supernatants were measured separately 24 and 48
h after the addition of YP medium. Experiments were conducted in triplicate. The cells
were extracted by 50 ml of methanol twice and the supernatant was extracted with 100 ml
of ethyl acetate for three times. The extracts were dried in vacuo and re-dissolved in 500
μl of methanol for HPLC analysis. The samples were analyzed by HPLC at 210 nm, eluted
with 15% methanol–water containing 0.1% formic acid for 15 min. The retention time of
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D-Hiv is 11.9 min. A standard curve of D-Hiv (VWR) was established to quantify the
concentration of this compound in the cells and supernatants.
4.4

Results

4.4.1 Reconstitution of BbBEAS and BbBSLS in S. cerevisiae BJ5464-NpgA
The expression plasmids pDY37 and pDY42, which carry bbBeas and bbBsls,
respectively, were introduced into S. cerevisiae BJ5464-NpgA and the engineered strains
were fermented to reconstitute the biosynthesis of 1 and 5, respectively. As shown in Fig.
15a, HPLC analysis of S. cerevisiae BJ5464-NpgA/pDY37 indicated that peak 1 at 9.6 min
was produced as a major product. The retention time and UV spectrum of 1 were the same
as those for beauvericin produced by the original producing strain, B. bassiana ATCC 7159.
ESI–MS (Fig. 15b) showed a series of quasimolecular ion peaks, including [M+H]+ at m/z
784.1, [M+NH4]+ at m/z 801.4, [M+Na]+ at m/z 806.3 and [M+K]+ at m/z 822.3, which is
consistent with the molecular weight of beauvericin (Fig. C3a). Three analogs 3–5 were
also produced. ESI–MS analysis of these compounds (Fig. 15d–f) showed that their
molecular weights were 797, 811 and 825, respectively, same as those of beauvericins A–
C produced by the original host B. bassiana (Fig. C3c–e). We purified these four products
from S. cerevisiae BJ5464-NpgA/pDY37 for structural analysis (Fig. C4). The NMR data
of these compounds (Figs. C5 and C6) are in agreement with those reported for beauvericin
[12], beauvericin A, beauvericin B , and beauvericin C, which confirmed the successful
reconstitution of beauvericins in the yeast. Similarly, peak 2 at 12.6 min in trace (iii) of Fig.
13a was found to be a major product in S. cerevisiae BJ5464-NpgA/pDY42. ESI-MS
analysis (Fig. 15c) revealed that it has the same molecular weight as bassianolide produced
by B. bassiana (Fig. C3b). This compound was then purified from S. cerevisiae BJ5464-
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NpgA/pDY42 (Fig. C4) and subjected to NMR analysis. A comparison of the NMR data
of 5 with the literature [5] confirmed that this compound is bassianolide. The titers of these
fungal CODs were determined and are shown in Table 7. The titers of 1 and 5 were close
to those in the native producer B. bassiana, which were 22.3±1.5 and 18.2±0.6 mg/l,
respectively.

Figure 13. LC–MS analysis of the production of 1–5 in B. bassiana ATCC 7159 and
engineered S. cerevisiae strains. (a) HPLC traces of the extracts of B. bassiana ATCC 7159
(i), S. cerevisiae BJ5464-NpgA/pDY37 (ii), and S. cerevisiae BJ5464-NpgA/pDY42 (iii).
(b) ESI-MS spectrum of 1, (c) ESI-MS spectrum of 5, (d) ESI-MS spectrum of 2, (e) ESIMS spectrum of 3, and (f) ESI-MS spectrum of 4. All experiments were performed in
triplicate, and a representative result is shown.
4.4.2 Improvement of the production of fungal CODs in S. cerevisiae by supplement of the
biosynthetic precursors
D-Hiv and L-amino acid are essential substrates for the synthesis of 1–5 [6] . It is
apparent that S. cerevisiae can provide these biosynthetic precursors since we have been
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able to reconstitute the production of 1–5 in this yeast by only expressing the corresponding
CODSs. However, the supply of these precursors may not be sufficient to allow these
heterologous CODSs to work at their full catalytic capacity. Thus, it is possible that
supplement of the direct biosynthetic precursors will improve the titers of these compounds.
To test the effects of addition of DHiv and L-Phe on the production of beauvericins, the
fermentation broth of S. cerevisiae BJ5464-NpgA/pDY37 was fed with these two
precursors at two different final concentrations, 0.8 and 2.0 mM. As shown in Table 3, at
these two concentrations, the titer of 1 was increased to 29.7±1.9 and 36.1±3.4 mg/l,
respectively. In contrast, the production of 2-4 was negatively influenced. While the titer
of 2 was slightly decreased, the biosynthesis of 3 and 4 was completely not detectable at 2
mM of D-Hiv and L-Phe. The overall titer of all these beauvericins was increased from
33.8±1.4 mg/l (without supplemented precursors) to 38.5±0.6 mg/l (0.8 mM precursors)
and 42.3±1.4 mg/l (2.0 mM precursors). Similarly, the fermentation broth of S. cerevisiae
BJ5464-NpgA/pDY42 was fed with D-Hiv and L-Leu at 0.8 and 2.0 mM, which led to the
obvious increase in the production of 5 as shown in Table 7.
4.4.3 Effects of co-expression of KIVR on beauvericin biosynthesis
Although supplement of D-Hiv and L-amino acids apparently increased the titers of
1–5 in the engineered S. cerevisiae strains, the high cost of D-Hiv may hamper its use in
large-scale production of these anticancer compounds. Thus, an improved in situ synthesis
of D-Hiv in the yeast represents an attractive approach for enhanced biosynthesis of fungal
CODs. Fungi biosynthesize D-Hiv by reducing the appropriate free ketocarboxylic acids,
derived from amino acid catabolic and anabolic pathways. The beauvericin biosynthetic
gene cluster in B. bassiana was found to contain a kivr gene encoding a putative reductase
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with a GxGxxGxxxA NADPH binding signature, which is highly similar to COG1893
ketopantoate reductases [15]. No similar gene was clustered with the bbBsls gene in the
same strain. Thus, KIVR was proposed to supply D-Hiv for the biosynthesis of both 1 and
5. This was confirmed by disruption of kivr in the genome of B. bassiana, which abolished
the production of both 1 and 5 in the fungus. Chemical complementation of the mutant by
supplementing the fermentation medium with D-Hiv restored the production of both CODs
[15]. Thus, KIVR is the dedicated enzyme that synthesizes D-Hiv in B. bassiana for COD
biosynthesis.
Table 7. Titers of 1–5 in engineered S. cerevisiae BJ5464-NpgA strains with or without
supplemented biosynthetic precursors (D-Hiv and L-Phe for S. cerevisiae BJ5464NpgA/pDY37; D-Hiv and L-Leu for S. cerevisiae BJ5464-NpgA/pDY42). Data are
presented as means±SD (n=3).
Titer (mg/l)
Precursor

0 mM

0.8 mM

2.0 mM

1

21.9± 0.8

29.7±1.9

36.1±3.4

2

7.1±0.2

6.7±0.1

6.2±0.2

3

3.4±0.3

1.7±0.5

NDa

4

1.4±0.2

0.5±0.2

NDa

Total

33.8±1.4

38.5±0.6

42.2±1.4

21.7±0.1

23.9±2.2

26.7±2.8

pDY37

pDY42
5

ND : not detected.
a

We next examined whether co-expression of KIVR with CODSs in S. cerevisiae
BJ5464-NpgA will increase the titers of these CODs. The kivr gene was cloned into
pXW06, and the resulting plasmid pDY48 was co-expressed in S. cerevisiae BJ5464-NpgA
with pDY37. The engineered strain, S. cerevisiae BJ5464-NpgA/pDY37+pDY48, thus
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contains a two-enzyme system composed of BbBEAS and KIVR. LC–MS analysis of the
products revealed the production of 1 and its congeners 2–4. Compared to S. cerevisiae
BJ5464-NpgA/pDY37, this double transformant produced the same compounds except that
the ratio of the products was different (Fig. C7). While 1 was the major product in S.
cerevisiae BJ5464-NpgA/pDY37, 2 was found to be the most abundant product in S.
cerevisiae BJ5464-NpgA/pDY37+pDY48.
Table 8. Titers of beauvercins in S. cerevisiae BJ5464-NpgA/pDY37+pDY48. Data are
presented as means±SD (n=3).
Titers (mg/l)
1

19.4±1.4

2

21.6±1.3

3

14.7±1.1

4

5.9±0.2

Total beauvericins

61.7±3.0

The titers of 1 and 2–4 in S. cerevisiae BJ5464-NpgA/pDY37 +pDY48 were
measured. As shown in Table 8, although the titer of 1 was slightly lower than that in S.
cerevisiae BJ5464-NpgA/pDY37 (Table 7), co-expression of KIVR and BbBEAS
enhanced the production of 2–4 more than 3-fold. The total titer of beauvericins in S.
cerevisiae BJ5464-NpgA/pDY37+pDY48 reached 61.7±3.0 mg/l, a 2-fold increase
compared to that in S. cerevisiae BJ5464-NpgA/pDY37. We also measured the production
of D-Hiv in the yeast strains with and without KIVR. As shown in Table 9, D-Hiv was
detected in both cells and supernatants and the production of D-Hiv in S. cerevisiae
BJ5464-NpgA/pDY37+pDY48 was higher than in S. cerevisiae BJ5464-NpgA/pDY37,
further confirming that the expression of KIVR has enhanced D-Hiv biosynthesis in the
yeast.
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A previous study on the production of δ-(L-α-aminoadipyl)-Lcysteinyl- D-valine in
S. cerevisiae reported that a 30-fold enhancement of the product titer was achieved by
lowering the cultivation temperature from 30 ℃ to 20 ℃ [20]. To test the effects of
fermentation temperatures on beauvericin biosynthesis, we also cultured S. cerevisiae
BJ5464-NpgA/pDY37+pDY48 at 20 ℃ and measured the titer of beauvericins at 3 and 5
days. We found that the production of these compounds at 20 ℃ were approximately 50%
of that at 30 ℃.
Table 9. Production of D-Hiv in S. cerevisiae BJ5464-NpgA/pDY37 and S. cerevisiae
BJ5464-NpgA/pDY37+pDY48. Data are presented as means±SD (n=3).
pDY37

pDY37+pDY48

24 h
Supernatant

5.2±0.1 mg/l

6.4±0.1 mg/l

Cells

3.0±0.1 mg/l

4.9±0.2 mg/l

Total

8.1±0.2 mg/l

11.3±0.3 mg/l

Supernatant

6.6±0.5 mg/l

8.7±1.0 mg/l

Cells

3.7±0.1 mg/l

6.6±0.1 mg/l

Total

10.3±0.4 mg/l

15.3±1.1 mg/l

48 h

4.4.4 Effects of supplement of L-amino acids on beauvericin biosynthesis
D-Hiv and D-2-hydroxy-3-methylvalerate (D-Hmv) are common biosynthetic
precursors for COD biosynthesis. D-Hiv is used in the biosynthesis of 1 and D-Hmv is a
precursor for the biosynthesis of 4, while the biosynthesis of 2 and 3 requires both
substrates. D-Hiv and D-Hmv can be synthesized from the intermediates of both amino
acid catabolic and anabolic pathways. One of the possible biosynthetic pathways using the
α-keto acids from amino acid catabolism was proposed in Fig. 14. L-Val is converted into

α -ketoisovalerate (Kiv) by a branched-chain amino acid transaminase, which was
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subsequently transformed into D-Hiv by KIVR. Similarly, D-Hmv can be synthesized from
L-Ile catabolism. To examine whether supplement of L-amino acids can improve
beauvericin biosynthesis in the yeast, L-Val or L-Ile was fed to the fermentation broth of
S. cerevisiae BJ5464-NpgA/pDY37+pDY48 at different concentrations. The growth of the
yeast strain was not influenced by addition of these amino acids at the tested concentrations,
as the final OD600 values were approximately 2.0 for all the cultures. It was found that
supplement of L-Val significantly improved the production of 1 in S. cerevisiae. As shown
in trace (i) of Fig. C8, the peak of 1 became predominant and the production of 3 and 4
was almost undetectable. Four different concentrations (3, 10, 30 and 100 mM) of L-Val
were added into the fermentation broth of S. cerevisiae BJ5464-NpgA/pDY37+pDY48 and
the titers of beauvericins were measured. As seen in Fig. 15a, the titer of 1 was increased
to 47.5±0.6, 69.3±1.0, and 74.1±0.3 mg/l, respectively, when 3, 10 and 30 mM L-Val was
supplemented. However, when the concentration of L-Val was increased to 100 mM, the
titer of 1 slightly dropped. The titer of 2 was increased when 3 and 10 mM L-Val was
supplied, while higher concentrations (30 and 100 mM) led to a decrease in the production
of 2. The titers of 3 and 4 were decreased at all four tested concentrations of L-Val. The
overall titer of all beauvericins was increased to 93.1±1.8, 105.8±2.1, 93.0±0.7 and
67.3±1.2 mg/l, respectively, at the four tested concentrations.
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Figure 14. Proposed biosynthesis of D-Hmv and D-Hiv by KIVR in S. cerevisiae. The
substrates of KIVR can be recruited from both amino acid catabolic and anabolic pathways.
This proposed biosynthetic pathway only shows the KIVR substrates from the catabolic
pathways.
Supplement of L-Ile had a different effect on the production of beauvericins. The
ratio of the different beauvericins has changed. As shown in trace (ii) of Fig. C8, when 10
mM L-Ile was supplemented, 4 became the most abundant product, with 1 as a minor
product. The titers of the products are shown in Fig. 15b. The titer of 1 was decreased to
11.5±0.4, 6.9±0.6, 2.2±0.2, and 0.6±0.2 mg/l, respectively, when L-Ile was supplemented
at 1, 3, 10 and 30 mM. Similarly, the titer of 2 was also decreased. The titer of 3 was
increased to 18.1±0.4 and 19.5±1.2 mg/l, respectively, at 1 and 3 mM, but was decreased
to 14.7±0.5 and 4.2±0.4 mg/l when 10 mM and 30 mM L-Ile was supplied. The titer of 4
was increased at the first three concentrations of L-Ile, but dropped when 30 mM of L-Ile
was supplemented. The overall titer of total beauvericins was decreased to 57.9±1.2,
52.7±1.5, 38.8±1.4, and 12.4±1.7 mg/l at the four concentrations.
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Figure 15. Effects of supplement of L-Val and L-Ile on the production of 1 and its
congeners 2–4 in S. cerevisiae BJ5464-NpgA/pDY37+pDY48: (a) titers of beauvericins in
S. cerevisiae BJ5464-NpgA/pDY37+pDY48 when various concentrations of L-Val were
supplemented. (b) Titers of beauvericins in S. cerevisiae BJ5464-NpgA/pDY37+pDY48
when various concentrations of L-Ile were supplemented. Data are presented as means±SD
(n=3).
4.4.5 Functional characterization of a new beauvericin synthetase
To further examine whether the activity of CODSs from other fungi could also be
reconstituted in the yeast using this expression system, a putative CODS gene, fvBeas, was
amplified from the genome of F. venenatum NRRL 26139. This gene contains 9390 bp and
analysis of the deduced amino acid sequence indicated that it is a putative CODS with the
same domain organization as BbBEAS and BbBSLS. BLAST analysis of the deduced
protein revealed that FvBEAS shares 58% identity and 74% similarity with BbBEAS
(GenBank accession number ACI30655), and 57% identity and 73% similarity with
BbBSLS (GenBank accession number ACR78148). Using a similar approach for the
cloning of bbBeas and bbBsls, this gene was ligated into pXW55 to yield the expression
plasmid pDY59, which was subsequently expressed in S. cerevisiae BJ5464-NpgA. Both
the wild type F. venenatum and S. cerevisiae BJ5464-NpgA/pDY59 were fermented for
product analysis. As shown in trace (i) of Fig. C9, the major metabolite in F. venenatum
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NRRL 26139 was confirmed to be 1 by LC–MS analysis, suggesting that fvBeas encodes
a beauvericin synthetase. This was confirmed by detection of 1 in S. cerevisiae BJ5464NpgA/pDY59, as shown in trace (ii) of Fig. C9. Thus, FvBEAS was functionally
reconstituted in S. cerevisiae BJ5464-NpgA and was identified as a beauvericin synthetase.
4.5

Discussion
Fungal CODSs represent an important group of natrally occurring molecules, which

have shown a variety of biological activities. The compounds studied in this work, 1–5,
were found to be promising anticancer molecules. In spite of formidable technical
difficulties, heterologous production of secondary metabolites is increasingly feasible 1.
has been previously produced in E. coli by expressing BbBEAS in E. coli [20]. However,
the titer was low. When the engineered E. coli strainwas fermented at 16 ℃, with
supplement of 15 mM D-Hiv and L-Phe, the final titer of 1 only reached approximately 8
mg/l, which is far less than that in the native producer [4]. Thus, a convenient, fast and
low-cost biosynthetic way to produce these anticancermolecules is desireable. In this work,
we expressed BbBEAS and BbBSLS in S. cerevisiae BJ5464-NpgA. S. cerevisiae BJ5464NpgA is a genetically modified strain that contains a chromosomal copy of the PPTase
NpgA that is necessary for activation of NRPSs. This strain has been previously used for
heterologous expression of several giant modular enzymes such as LovB, a PKS involved
in lovastatin biosynthesis [18]. Unlike the native producer B. bassiana ATCC 7159, which
produces 1 and 5 as the major products, expression of BbBEAS in S. cerevisiae BJ5464NpgA led to the production of a series of beauvericins, including 14. Production of these
different beauvericins indicated that S. cerevisiae can supply two different 2hydroxycarboxylate precursors for beauvericin biosynthesis. This also revealed that
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BbBEAS, or more specifically the A1 domain of BbBEAS, has relatively relaxed substrate
specificity. In addition to the natural substrate D-Hiv, the A1 domain can select and load
D-Hmv as an alternative substrate onto the CODS to yield 2–4. BbBEAS takes three units
of D-Hiv and L-Phe as the biosynthetic precursors to synthesize 1. When one unit of DHmv is taken, 2 will be synthesized by BbBEAS. Incorporation of two units of D-Hmv led
to the production of 3. When the three units of D-Hiv are completely replaced by D-Hmv,
4 will be produced. The production of 2–4 in relatively larger amounts is likely due tomore
abundant supply of D-Hmv in the yeast than B. bassiana. Reconstitution of BbBSLS
further confirmed that fungal CODSs can be reconstituted in S. cerevisiae. Although
expression of catalytic fragments of the enniatin synthetase has been done[21],
reconstitution of entire fungal CODSs in S. cerevisiae has not previously been achieved.
This work thus represents the first example of functional reconstitution of fungal CODSs
in S. cerevisiae. Unlike E. coli which requires exogenous supply of D-Hiv for the
production of 1, S. cerevisiae can directly supply the biosynthetic precursors D-Hiv and DHmv for the production of CODs.
Supplementation of D-Hiv and L-Phe into the fermentation broth of S. cerevisiae
BJ5464-NpgA/pDY37 led to an increase in the production of 1, while decreased the
production of 2–4. This may be attributed to the increased supply of the direct precursors
of 1. The supplemented D-Hiv, together with the synthesized D-Hiv by the host, might
have dominated the binding site of BbBEAS. This makes it more difficult for D-Hmv to
be incorporated into the products. Thus, the product type is dominated by the relative
amount of the available substrates. The overall titer of total beauvericins was increased due
to the addition of D-Hiv and L-Phe. The titer of 5 was also increased when D-Hiv and L-
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Leu were supplied, confirming that substrate feeding is useful in improving the
biosynthesis of CODs in S. cerevisiae, which also indicated that the supply of these
precursors in the yeast is relatively insufficient for the catalytic capacity of the expressed
enzymes.
KIVR has been previously reported to supply D-Hiv for the biosynthesis of both 1
and 5 in B. bassiana ATCC 7159, as disruption of kivr in this fungus abolished the
biosynthesis of these compounds [15]. Because the high cost of D-Hiv makes it an
expensive material for large-scale production of these anticancer CODs, we further
engineered KIVR from B. bassiana into S. cerevisiae BJ5464-NpgA. We found that
expression of KIVR in S. cerevisiae BJ5464-NpgA increased the concentration of D-Hiv
in the cells and fermentation broth. While measurements of the concentration of D-Hiv
provide a snapshot of the dynamic synthesis process of this precursor, the increased
metabolic flux was reflected in the significantly increased titer of total beauvericins in S.
cerevisiae BJ5464-NpgA/pDY37+pDY48. It was expected that the expression of KIVR
will lead to better supply of D-Hiv and higher titer of 1. However, it is interesting that the
titers of 2–4 were increased, while the production of 1 was slightly decreased. This result
suggested that KIVR is not strictly substrate specific and can synthesize both D-Hiv and
D-Hmv in the yeast. This is similar to a KIVR recently characterized from Fusarium
proliferatum LF061, which takes 2-ketovalerate, pyruvate, 2-ketocapronate, 2ketoglutarate and 2-ketobutyrate in addition to Kiv, although the enzymatic activity
towards these unnatural substrates was low [22]. In this work, we found that KIVR can
efficiently synthesize D-Hmv, resulting in a significant increase in the formation of 2–4.
This enzyme utilizes Kiv to synthesize D-Hiv, and reduces α-keto-β-methylvalerate (Kmv)
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into D-Hmv (Fig. 14). Kiv is an important metabolite from both L-Val catabolic and
anabolic pathways. In S. cerevisiae, a bidirectional reaction between L-Val and Kiv is
catalyzed by the branched-chain aminoacid aminotransferases Bat1 and Bat2, which are
present in the mitochondrial matrix and the cytosol, respectively [23, 24]. Similarly, Kmv
can be obtained from both L-Ile catabolism and anabolism. The structural compositions,
the decreased titer of 1 and the increased titers of 2–4 suggested that much more D-Hmv
was synthesized by the heterologous KIVR than D-Hiv in the yeast. This might be due to
the different supply of Kmv and Kiv in the host or a substrate preference of KIVR to Kmv.
In contrast, 1 was found to be the predominant product in B. bassiana, while 2–4 were only
produced in small amounts. It is likely that the supply of Kiv, and consequently D-Hiv,
was dominant in B. bassiana. This indicated that production of the substrates for KIVR in
the native host and the yeast was different, which led to different production profiles of
beauvericins in these strains. One of the major sources of 2-hydroxycarboxylate precursors
is the catabolism of L-amino acids, as proposed in Fig. 14. Supplement of L-Val
significantly increased the titer of beauvericins. More specifically, the ratio of the products
has changed and 1 became the predominant metabolite in S. cerevisiae BJ5464NpgA/pDY37+pDY48. Because the only 2-hydroxycarboxylate precursor for 1 is D-Hiv,
improved biosynthesis of D-Hiv from the supplemented L-Val directly facilitated the
biosynthesis of 1. In contrast, the production of 2 and 3 was limited by the supply of the
second precursor D-Hmv. The presence of large amount of D-Hiv reduced or even
abolished the production of 4, likely due to the substrate competition between D-Hiv and
D-Hmv. Our work enabled the production of beauvericins at an unprecedented high level
of 105.8±2.1 mg/l in S. cerevisiae when 10 mM L-Val was supplemented. This titer is

91
approximately 4-fold of that in the native producer, which was 24.5±1.5 mg/l in the
presence of the same concentration of L-Val. Thus, this work provides an efficient
production process for these anticancer natural products. Higher concentrations decreased
the production of beauvericins, likely due to the over occupation of the active site of
BbBEAS by excess D-Hiv, which may lower the efficiency of this giant modular enzyme.
Supplement of L-Ile was supposed to improve the supply of D-Hmv, which was
confirmed by the predominant production of 4 (Fig. C8). However, it was unexpected that
the overall titer of beauvericins was decreased. Since the growth of the yeast cells was not
affected, supplemented L-Ile might have interfered with the expression or function of
BbBEAS in S. cerevisiae. Overall, our feeding experiments confirmed that supplement of
L-Val is an effective approach to enhancing the in situ supply of D-Hiv and the production
of beauvericins.
Overexpression of the pathway-specific regulator has been previously shown to
significantly improve the titer of cytochalasin E from 25 to 175 mg/l in Aspergillus clavatus
NRRL 1, suggesting that this is a useful approach to enhancing natural product biosynthesis.
Similarly, overexpression of the dedicated ABC transporter AvtAB improved avermectin
production about two-fold in Streptomyces avermitilis [25]. Thus, further improvement of
the titer of beauvericins may be achieved by overexpression of the related regulator and
transporter in the beauvericin biosynthetic pathway. No transporter gene exists in the
reported beauvericin biosynthetic gene cluster, while a gene orf1 encoding a putative Gal4like transcriptional regulator with a Zn2Cys6 binuclear cluster DNA-binding domain was
located in the flanking region of bbBeas on the genome of B. bassiana ATCC 7159.
Although it is unclear whether this regulator is associated with beauvericin biosynthesis,
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this regulator represents a potential target for further improvement of beauvericins. Other
KIVR analogs, such as the one recently identified in F. proliferatum LF061 that has broad
substrate specificity, can also be engineered into the system to generate novel beauvericins.
Additionally, further understanding of the catalytic properties of BbBEAS and KIVR will
also provide useful information for future engineering of these enzymes for improved
efficiency.
4.6

Conclusions
In this work, we examined the heterologous reconsititution of fungal CODSs in S.

cerevisiae and production of the corresponding anticancer CODs. The activities of two
fungal CODSs, BbBEAS and BbBSLS from B. bassiana ATCC 7159, were reconstituted
efficiently in S. cerevisiae BJ5464-NpgA. The titers of the anticancer natural products,
beauvericins and bassianolide, are comparable to those in the native producer. Supplement
of the biosynthetic precursors, D-Hiv and L-amino acids (L-Phe or L-Leu) can significantly
increase the production of these CODs in the yeast. Alternatively, we co-expressed
BbBEAS and KIVR in S. cerevisiae BJ5464-NpgA, leading to a nearly 100% increase in
the total titer of beauvericins (from 33.8 to 61.7 mg/l). Furthermore, we fed L-Val and LIle into the engineered strain S. cerevisiae BJ5464-NpgA/pDY37+pDY48 to test the effects
of these amino acids on the production of beauvericins at different concentrations. The titer
of beauvercins reached 105.8±2.1 mg/l when 10 mM L-Val was supplemented. The best
titer of 1 was achieved at 74.1±0.3 mg/l when 30 mM LVal was supplemented. With this
efficient expression system, we also functionally characterized a CODS from F. venenatum
NRRL 26139 as a new beauvericin synthetase, which was named as FvBEAS. This work
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provides a useful platform for functional reconstitution of fungal CODSs and efficient
production of the corresponding natural products.
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CHAPTER 5
FUNCTIONAL DISSECTION AND MODULE SWAPPING OF FUNGAL
CYCLOOLIGOMER DEPSIPEPTIDE SYNTHETASES §
5.1

Abstract
BbBSLS and BbBEAS were dissected and reconstituted in Saccharomyces cerevisiae.

The intermodular linker is essential for the reconstitution of the separate modules. Module
1 can be swapped between BbBEAS and BbBSLS, while modules 2 and 3 control the
product profiles. BbBSLS is a flexible enzyme that also synthesizes beauvericins.
5.2

Introduction
Beauvericin, beauvericins A–C and bassianolide (Fig. 3) are a group of promising

anticancer cyclooligomer depsipeptides (CODs) derived from several fungal species [1-3].
The genes encoding the synthetases for these compounds have been reported [4-6].
Beauvericin synthetase (BbBEAS, 352 kDa) and bassianolide synthetase (BbBSLS, 348
kDa) from Beauveria bassiana ATCC 7159 have the same domain organization of C1–A1–
T1–C2–A2–MT–T2a–T2b–C3 (Fig. 4) and share 66% identity and 79% similarity overall (Fig.
16). Most reported fungal COD synthetases (CODSs) have the same structural organization
except a bassianolide synthetase from Xylaria sp. BCC1067, which has an additional Cterminal reductase (R) domain.
The assembly of fungal CODs has been previously proposed. CODSs use a unit of
D-hydroxycarboxylic acid and L-amino acid to form the corresponding dipeptidols. These

This chapter has been published as Yu, D.,# Xu, F.,# Gage, D., Zhan, J.* (2013): Functional
dissection and module swapping of fungal cyclooligomer depsipeptide synthetases. Chemical
Communications 49, 6176–6178. (# : equal contribution)
§
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intermediates will then undergo catalytic cyclooligomerization to form the final CODs.
BbBEAS synthesizes cyclohexadepsipeptides including beauvericin and its congeners
beauvericins A–C, while BbBSLS uses D-hydroxyisovaleric acid (D-Hiv) and L-leucine
(L-Leu) to generate the cyclohexadepsipeptide bassianolide. We have recently successfully
reconstituted BbBEAS and BbBSLS in the intact form in Saccharomyces cerevisiae
BJ5464-NpgA and achieved high-titer production of beauvericins and bassianolide [7]. In
this communication, we report the functional dissection and reconstitution of these modular
enzymes in S. cerevisiae, characterization of BbBSLS as a flexible enzyme that synthesizes
both bassianolide and beauvericins, module swapping between BbBEAS and BbBSLS, and
construction of hybrid CODSs.

Figure 16. Partial alignment of the amino acid sequences of BbBEAS and BbBSLS. The
M1–M2 linker is boxed.

5.3

Materials and methods

5.3.1 Strains, plasmids, and culture conditions
Escherichia coli XL1-Blue (Agilent) was used for routine cloning and pJET1.2
(Fermentas) was used as the cloning vector. E. coli cells were grown in Luria-Bertani (LB)
medium at 250 rpm and 37 ℃. When necessary, 50 μg mL-1 ampicillin was added. S.
cerevisiae BJ5464-NpgA (MATα ura3-52 his3-Δ200 leu2- Δ1 trp1 pep4::HIS3 prb1 Δ1.6R
can1 GAL) was obtained from Dr. Nancy Da Silva at the University of California, Irvine.
The strain was maintained on YPD (yeast extract/peptone/dextrose) agar plates at 30 ℃.
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The E. coli/S. cerevisiae shuttle vectors pXW55 and pXW06 were gifts from Dr. Yi Tang
at the University of California, Los Angeles. pXW55 carries the ampicillin-resistance gene
and URA3 as the selection markers, and was used to express M1-M2 linker-containing or
-lacking M23 of BbBEAS and BbBSLS. pXW06 carries the ampicillin-resistance gene and
TRP1 as the selection markers, and was used to express M1-M2 linker-containing or lacking M1 of BbBEAS and BbBSLS.
Beauveria bassiana ATCC 7159 was obtained from the American Type Culture
Collection and was grown in potato dextrose broth at 250 rpm and 28 ℃. The genomic
DNA was extracted from the mycelia of the fungus and used as the template to amplify the
bbBeas and bbBsls gene fragments.
5.3.2 DNA manipulations
Isolation of plasmid DNA from E. coli was conducted with a GeneJET™ Plasmid
Miniprep Kit (Fermentas) by following the manufacturer’s instructions. Gene ligations
were performed with T4 DNA ligase (New England Biolabs).
5.3.3 Gene amplification and plasmid construction
The gene fragments bbBeasM1 with M1-M2 linker, bbBeas-M23 with M1-M2 linker,
bbBeas-M1 without M1-M2 linker, bbBeasM23 without M1-M2 linker, bbBeasM1 with
partial M1-M2 linker, and bbBeasM23a with partial M1-M2 linker were amplified by PCR
from the genomic DNA of B. bassiana ATCC 7159 with Phusion® High-Fidelity DNA
Polymerase (New England Biolabs) with specific primers (Table D1). Similarly, bbBslsM1
with M1-M2 linker, bbBslsM23 with M1-M2 linker, bbBslsM1 without M1-M2 linker,
bbBslsM23 without M1-M2 linker, bbBslsM1 with partial M1-M2 linker and bbBslsM23a
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with partial M1-M2 linker were amplified from the template. These gene fragments were
ligated into the cloning vector pJET1.2 (Fermentas) to yield twelve plasmids including
pDY38, pDY39, pDY60, pDY61, pDY62, pDY66, pDY69, pDY72, pDY90, pDY91,
pDY94 and pDY95. These plasmids were confirmed by digestion checks and gene
sequencing.
The bbBeasM1 with M1-M2 linker and bbBeasM1 without M1-M2 linker inserts were
excised from pDY39 and pDY94 with NdeI and PmeI and ligated into pXW06 between the
same sites to generate pDY45 and pDY99, respectively. The bbBeasM23 with M1-M2
linker and bbBeas-M23 without M1-M2 linker inserts were excised from pDY38 and
pDY91 with SpeI and PmlI and ligated into pXW55 between the same sites to yield pDY58
and pDY98. The bbBslsM1 with M1-M2 linker and bbBslsM1 without M1-M2 linker inserts
were excised from pDY69 and pDY95 with NdeI and PmeI and ligated into pXW06
between the same sites to generate pDY73 and pDY102. The bbBslsM23 with M1-M2
linker and bbBslsM23 without M1-M2 linker inserts were excised from pDY72 and pDY90
with SpeI and PmlI and ligated into pXW55 between the same sites to generate pDY78 and
pDY97.
The bbBslsM23a with partial M1-M2 linker insert was excised from pDY62 with
SpeI and ligated into pDY60 at the same site to generate pDY68. Then the bbBeasM1bbBslsM23a insert was excised from pDY68 with NdeI and ligated into the pDY42
(harboring the entire bbBsls gene) vector treated with NdeI to replace a fragment to afford
pDY70. The bbBeasM23a with partial M1-M2 linker insert was excised from pDY66 with
SpeI and ligated into pDY61 at the NheI site to generate pDY67. The bbBslsM1bbBeasM23a insert was then excised from pDY67 with NdeI and ligated into the pDY37
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(harboring the entire bbBeas gene) vector treated with NdeI to replace a fragment to
generate pDY71. The plasmids constructed in this work are shown in Table D2.
5.3.4 Transformation of S. cerevisiae and Fermentation of the engineered strains
Plasmids were introduced into S. cerevisiae BJ5464-NpgA using the lithium acetate
method. Correct transformants were selected by appropriate autotrophy. The engineered S.
cerevisiae strain carrying pDY37, pDY42, pDY70 or pDY71 was fermented in a SC-Ura
dropout medium (6.7 g/l yeast nitrogen base; 20 g/l glucose; 0.77 g/l -Ura DO supplement)
at 30 °C with shaking at 250 rpm. When the OD600 reached 0.6, equal volume of YP
medium (10 g/l yeast extract; 20 g/l peptone) was added. The cultures were maintained
under the same conditions for an additional 72 h to produce the cyclooligomer
depsipeptides (CODs). Strains carrying a pXW55 derived plasmid and a pXW06 derived
plasmid were fermented in a Sc-Ura-Trp dropout medium (6.7 g/l yeast nitrogen base; 20 g
/l glucose; 0.72 g/l -Trp/-Ura DO supplement) at 30 °C with shaking at 250 rpm until the
OD600 reached 0.6, and then equal volume of YP medium was added. The fermentation
broths were cultured under the same conditions for an additional 72 h to produce the
corresponding CODs.
5.3.5 Extraction and analysis of the products in the engineered S. cerevisiae strains
A typical procedure used to analyze the products in the engineered S. cerevisiae
BJ5464-NpgA strains is given below. 100 mL of fermentation broth was centrifuged at
2,737 ×g for 5 min to separate the supernatant and the cells. The supernatant was extracted
three times with 100 mL of ethyl acetate, and the cells were extracted twice with 50 mL of
methanol. The extracts were then combined and evaporated in vacuo to dryness. The
residue was re-dissolved in 500 μL of methanol and analyzed on an Agilent 6130 Single
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Quad LC-MS (C18, 5 μm, 4.6 mm × 250 mm column). A linear gradient of acetonitrilewater (containing 0.1% formic acid) was programmed from 80% to 100% over 20 min at
a flow rate of 1 mL min-1 and the metabolites were monitored at 210 nm. Standard curves
based on the linear relationship between the amounts and the peak areas were established
for beauvericin, beauvericin A, beauvericin B, beauvericin C and bassianolide for
quantitative measurement of their production in different engineered strains.

Figure 17. Dissection and reconstitution of BbBEAS and BbBSLS in S. cerevisiae
BJ5464-NpgA. BbBEAS and BbBSLS were dissected into two fragments, M1 and M23,
with or without the linker. The fragments were co-expressed in S. cerevisiae BJ5464-NpgA
and the production of beauvericins and bassianolide was analyzed by LC-MS.
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5.4 Results
5.4.1 Dissection and reconstitution of BbBEAS and BbBSLS in S. cerevisiae
The boundary of BbBEAS and BbBSLS between M1 and M2 was analyzed by
multiple sequence alignment of nonribosomal peptide synthetases (NRPSs) (Fig. D1 and
D2) and using a web-based software tool [8]. The intermodular linker between M1 and M2
(M1–M2 linker, abbreviated as ‘‘linker’’ hereafter) is shown in Fig. 1B and C. We used
two Escherichia coli/S. cerevisiae shuttle vectors, pXW55 and pXW06, to express the
dissected enzymes in S. cerevisiae BJ5464-NpgA [9]. The primers used and plasmids
constructed in this study are shown in Tables D1 and D2, respectively. The first two
expression plasmids used for the dissection of BbBEAS were pDY45 and pDY58, which
harbor the linker-containing BbBEAS fragments bbBeasM1– and bbBeasM23–,
respectively (Fig. 17). Expression of either of these plasmids in the yeast yielded no
products. Co-expression of these two plasmids in S. cerevisiae BJ5464-NpgA led to the
production of beauvericins, including beauvericin and beauvericins A–C (ESI-MS spectra
are shown in Fig. D3), at 10.67 1.44 mg L1 (Fig. 17). Although the titer is lower than that
of the intact enzyme (33.82±1.41 mg/l), this result for the first time demonstrated that
BbBEAS can be dissected into modules and functionally reconstituted in the yeast. To
examine whether the intermodular linker influences the interaction and function of the
modules, we also cloned the linker-lacking bbBeasM1 and bbBeasM23 to constructtwo
additional expression plasmids pDY99 and pDY98. Co-expression of these two plasmids
in the yeast yielded no products (Fig. 17), suggesting that the linker is essential for the
reconstitution of beauvericin biosynthesis by the dissected fragments. We further coexpressed pDY45 with pDY98 and pDY58 with pDY99. Interestingly, the former did not
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yield any products, while the latter generated beauvericins in a much lower titer (Fig. 17).
These results suggested that the N-terminal linker of BbBEASM23 is required for either
the stability of the fragment of modules 2 and 3 (M23) or the interaction between M1
andM23. Inclusion of the same linker in the C-terminus of BbBEASM1 significantly
improved the collaborative work of M1 and M23, as reflected by the increased titer of
beauvericins.
5.4.2 Product profiles of the original and hybrid CODSs in the intact form
Using a similar approach, we dissected BbBSLS into M1 and M23 (with or without
the linker) by constructing four plasmids pDY73, pDY78, pDY97 and pDY102 (Table D2).
Co-expression of pDY73 and pDY78, which harbor BbBSLSM1– and BbBSLSM23–,
respectively, reconstituted the production of bassianolide (the ESI-MS spectrum is shown
in Fig. D3) in the yeast at 8.87±0.53 mg/l (Fig. 17). Unexpectedly, beauvericin and trace
amounts of beauvericins A–C were also produced by this strain. To find out whether the
production of beauvericins was due to the dissection of BbBSLS, which may have
influenced the overall structure of the modular enzyme, we re-examined the product profile
of S. cerevisiae BJ5464-NpgA/pDY42. LC-MS analysis revealed that the intact BbBSLS
also produced beauvericins (Fig. 18) in addition to bassianolide. In contrast, the yeast strain
expressing the intact BbBEAS only produced beauvericins (Fig. 18). This indicated that
BbBSLS is a flexible CODS which can incorporate either L-Phe or L-Leu and catalyze
trimerization or tetramerization of the monomers. We also searched for the potential hybrid
products containing both N-methyl-L-Leu and N-methyl-L-Phe by extracting the target ion
peaks from the ESI-MS spectra. However, no hybrid CODs were found. We propose that
bassianolide as the major product perfectly fits the active site of BbBSLS. The trimeric
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beauvericins containing N-methyl-L-Phe which is larger than N-methyl-L-Leu may occupy
similar space as the tetramer bassianolide does. The possible hybrid products may not fit
the active site well and thus cannot be synthesized efficiently enough to be detected. In
addition, the condensation of the monomers in COD biosynthesis is not well understood,
and it is also likely that missing of the hybrid CODs is due to insufficient capacity of the
domains involved in the oligomerization to incorporate monomers containing different
amino acid precursors into the products. When pDY102 and pDY97, which, respectively,
harbor the linker-lacking M1 and M23 of BbBSLS, were co-expressed in the yeast, no
products were detected. This is consistent with the result for BbBEAS. Co-expression of
pDY73 with pDY97 and pDY102 with pDY78 yielded similar results to those for BbBEAS
as well (Fig. 17).

Figure 18. Product profiles of the original and hybrid CODSs in the intact form. Both wild
type CODSs (pDY37: BbBEAS; pDY42: BbBSLS) and hybrid enzymes (pDY71:
BbBSLSM1–BbBEASM23; pDY70: BbBEASM1–BbBSLSM23) were expressed in S.
cerevisiae BJ5464-NpgA and the production of CODs was analyzed by LC-MS.
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5.4.3 Module swapping between BbBEAS and BbBSLS
Functional dissection of BbBEAS and BbBSLS provides a useful tool for further
investigation of these giant enzymes. Expression of truncated fragments of the enniatin
synthetase from Fusarium scirpi has been previously attempted in E. coli [9]. However, the
proteins were mainly produced as inclusion bodies and required renaturation for testing
their adenylation activity. No CODs have ever been synthesized using these fragments. In
this work, we dissected two CODSs into functional modules and reconstituted the
production of the corresponding products by co-expression of the modules with the
important intermodular linker. This opens a new opportunity to investigate and engineer
the functional modules instead of the giant enzymes for combinatorial biosynthesis of new
bioactive molecules.
The primary function of BbBEASM1 and BbBSLSM1 is supposedly to activate and
load D-Hiv onto the CODSs, although we have recently found that BbBEASM1 can also
utilize D-Hmv to synthesize beauvericins A–C[7]. We hypothesize that M1 from BbBEAS
and BbBSLS can be exchanged because of a similar function. To test this hypothesis, we
made eight co-transformations using the eight expression plasmids constructed above. As
shown in Fig. 19, when BbBSLSM1– and BbBEASM23– were co-expressed in the yeast,
beauvericins were synthesized. Similarly, co-expression of BbBEASM1– and
BbBSLSM23– led to the production of bassianolide and beauvericins. These results clearly
indicated that M1 of BbBEAS and BbBSLS can be exchanged without influencing the
product profiles. The final products are determined by M23, which controls the selection
of the L-amino acid, forms the corresponding dipeptidol, and catalyzes the subsequent
cyclooligomerization. Additional module swapping experiments that contained different
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combinations of heterologous M1 andM23, with or without the linker, were conducted to
further test the role of the M1–M2 linker in the collaborative work between heterologous
modules.

Figure 19. Module swapping between BbBEAS and BbBSLS. Heterologous modules from
BbBEAS and BbBSLS were co-expressed in S. cerevisiae BJ5464-NpgA and the products
were analyzed by LC-MS.
As shown in Fig. 19, co-transformants containing the linker-lacking BbBEASM23 or
BbBSLSM23 yielded no products. Combinations of a linker-lacking M1 with a
heterologous linker-containing M23 afforded products corresponding to M23 (Fig. 19) in
relatively low titers. These results indicated that the N-terminal linker of M23 of BbBEAS
and BbBSLS is required for the collaborative work of heterologous M1 and M23. It has
been previously reported that short communication mediating (COM) domains play a
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decisive role in protein–protein recognition in bacterial modular NRPSs such as those
involved in tyrocidine biosynthesis [10, 11]. Similarly, intermodular linkers in polyketide
synthases are involved in the assembly of functional modules and the intermodular
polyketide chain transfer [12]. Our results revealed a similar role of the intermodular linker
in fungal CODSs. We propose that the C2 domain has specific binding sites for the donor
and acceptor that will allow these two thiolated precursors, which are, respectively, linked
to T1 and T2, to recognize and bind to C2, as seen in other NRPSs such as the gramicidin
synthetase [13].
In addition to testing module swapping of CODSs using dissected enzymes, we also
made two hybrid enzymes BbBEASM1–BbBSLSM23 and BbBSLSM1–BbBEASM23.
The linkers between the heterologous M1 and M23 were made up of the C-terminal portion
of the linker of M1 and the N-terminal portion of the linker of M23 in the original enzymes.
As shown in Fig. 18, LC-MS analysis revealed the biosynthesis of beauvericins in S.
cerevisiae BJ5464-NpgA/pDY71 and the production of bassianolide and beauvericins in S.
cerevisiae BJ5464-NpgA/pDY70. These results were consistent with those from the coexpression of the separate modules. The same results from both intact enzymes and coexpressed dissected enzymes further confirmed that BbBEASM1 and BbBSLSM1 can be
swapped.
Although module/domain swapping represents an attractive tool to create new
molecules, it is often hampered by the heavily impaired biosynthetic capacity of the
chimeric NRPSs [14]. Successful construction of hybrid CODSs in the intact form
indicated that these fungal enzymes are friendly to genetic manipulations. There were
several reports on the construction of bacterial hybrid NRPSs. For example, hybrid NRPSs
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were made by fusions of modules from TycA, TycB and TycC involved in tyrocidine
biosynthesis [15]. Another paper has reported the construction of a new bi-modular NRPS
by replacing an activation domain with the one with N-methylation activity using the
actinomycin NRPS [16]. While these enzymes were made of modules from the same
biosynthetic systems, other studies on intermodular linkers/COM domains have allowed
the crosstalk between modules from different NRPSs. However, no module-swapping
work on fungal NRPSs has been reported. This work thus represents the first example of
construction of functional hybrid fungal CODSs, which provides a comprehensive
platform for future engineering of fungal CODSs in both intact and dissected forms for
novel ‘‘unnatural’’ natural products.
5.5

Conclusion
This work revealed that modular CODSs from fungi can be functionally dissected

into modules and expressed in S. cerevisiae. Co-expression of the dissected M1 and M23
of these CODSs reconstituted the production of their products. The linker between M1 and
M2 plays a pivotal role in the reconstitution of the dissected CODSs. BbBEASM1 and
BbBSLSM1 are exchangeable and the final products are determined by M23. BbBSLS is
a flexible CODS that synthesizes both bassianolide and beauvericins.
5.6
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CHAPTER 6
DECODING AND REPROGRAMMING FUNGAL ITERATIVE NONRIBOSOMAL
PEPTIDE SYNTHETASES **
6.1 Abstract
Nonribosomal peptide synthetases (NRPSs) assemble a large group of structurally and
functionally diverse natural products. While the iterative catalytic mechanism of bacterial
NRPSs is known, it remains unclear how fungal NRPSs create products of desired length.
Here we show that fungal iterative NRPSs adopt an alternate incorporation strategy.
Beauvericin and bassianolide synthetases have the same C1-A1-T1-C2-A2-MT-T2a-T2b-C3
domain organization. During catalysis, C3 and C2 take turns to incorporate the two
biosynthetic precursors into the growing depsipeptide chain that swings between T1 and
T2a/T2b with C3 cyclizing the chain when it reaches the full length. We reconstruct the total
biosynthesis of beauvericin in vitro by reacting C2 and C3 with two SNAC-linked
precursors and present a domain swapping approach to reprogramming these enzymes for
peptides with altered lengths. These findings highlight the difference between bacterial and
fungal NRPS mechanisms and provide a framework for the enzymatic synthesis of nonnatural nonribosomal peptides.
6.2 Introduction
Nonribosomal peptides (NRPs) represent an important family of bioactive natural
products, such as daptomycin, penicillin and vancomycin. They are assembled by

This chapter has been published as Yu, D.,# Xu, F.,# Zhang, S., Zhan, J.* (2017): Decoding and
reprogramming fungal iterative nonribosomal peptide synthetases. Nature Communications 8, 15349. (# cofirst author)
**
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nonribosomal peptide synthetases (NRPSs) that consist of a series of catalytic domains [1].
Adenylation (A), thiolation (T) and condensation (C) are essential domains for the
formation and elongation of the peptide chain. Other tailoring domains, such as
methyltransferase (MT), oxidation (Ox) and epimerization (E), contribute to the large
structural diversity in natural NRPs [2]. Iterative NRPSs generate NRP products with
repeated moieties/monomers [3], such as bacterial metabolites enterobactin, echinomycin
and gramicidin, as well as fungal natural products beauvericin (1), beauvericins A–C (2–
4), bassianolide (5), enniatins A–C (6–8) and verticilide (9) (Fig. 20a). These molecules
possess a wide range of biological activities, including antimicrobial, insecticidal,
anthelmintic, herbicidal, anti-haptotactic, anti-cholesterol and anticancer activities [3–8].
1–9 are cyclic oligomers of monomer synthesized from a hydroxycarboxylic acid and an
N-methylated amino acid. For instance, 1 is a cyclic trimer of a dipeptidol monomer
synthesized from N-methyl-Lphenylalanine (N-Me-L-Phe) and D-hydroxyisovaleric acid
(D-Hiv), and 5 is an octadepsipeptide containing four units of D-Hiv-N-Me-L-Leu (leucine:
Leu). However, how fungal iterative NRPSs are programmed to assemble these compounds
is not well understood.
Previous studies on bacterial iterative NRPSs, such as those involved in the
biosynthesis of tyrocidine and gramicidin S, revealed that these enzymes use an
oligomerization approach for chain elongation and length control through the C-terminal
thioesterase (TE) domain. They oligomerize a monomer intermediate formed by upstream
condensation domains and catalyse the subsequent head-to-tail cyclization for product
release [12,13]. However, TE or a homologous domain is absent in fungal iterative NRPSs
such as BbBEAS and BbBSLS. Based on the conserved signature regions, it was generally
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proposed that A1 of BbBEAS and BbBSLS activates D-Hiv, while A2 recognizes L-Phe
and L-Leu, respectively. The activated D-Hiv is transferred to T1, and MT methylates the
A2-activated amino acid4. However, the roles of several key domains in these fungal
NRPSs remain unknown, including the twin T2 domains and three C domains. More
importantly, the product assembly process by fungal NRPSs is poorly understood.

Figure 20. Fungal iterative NRPSs and their products. (a) Representative NRPs (1–9)
synthesized by fungal iterative NRPSs. The monomer unit is green shaded. (b) Domain
organization of BbBEAS and BbBSLS. Both modular enzymes have the same architecture
of C1-A1-T1-C2-A2-MT-T2a-T2b-C3. To differentiate these two enzymes, BbBEAS is shown
in blue and BbBSLS in red. (c) HPLC analysis of the in vitro reaction of BbBEAS and
BbBSLS with ATP, SAM, D-Hiv and L-amino acid (L-Phe for BbBEAS and L-Leu for
BbBSLS).
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In this work, we report that BbBEAS and BbBSLS adopt an alternate incorporation
strategy to assemble the products. The two precursors, D-Hiv and N-Me-L-Phe/N-Me-LLeu, are alternately incorporated into the extending depsipeptide chain by C2 and C3. The
C3 domain controls the product length and cyclizes the full-length depsipeptide chain to
form the final products. Products with altered chain lengths are obtained by swapping the
C3 domain, providing a domain swapping approach to reprogramming these enzymes for
new molecules.
6.3 Methods
6.3.1 Analysis and purification of compounds
Compounds were analysed at 210 nm using an Agilent Ecilpse XDB-C18 column (5
mm, 4.6mm×250mm) on an Agilent 1200 HPLC coupled with an Agilent 6130 single
quadrupole mass spectrometer. High-resolution mass spectrum of FX1 was collected on an
Agilent 6210 LCMS. Four HPLC programmes were used. Programme 1 (for Figs 20c and
22c,d and Figs 23b,d,f and 25): 5–90% acetonitrile–water with 0.1% formic acid from 0 to
30 min, 90–100% acetonitrile–water with 0.1% formic acid from 30 to 35 min and 100%
acetonitrile–water with 0.1% formic acid from 35 to 50 min at 1 ml/min. Programme 2 (for
Figs 21b–d and 22e and Figs 23a,c,e and 24a,c): 80–100% acetonitrile–water with 0.1%
formic acid over 20 min at a flow rate of 1ml/min. Programme 3 (for Fig. 24d): 50–100%
acetonitrile–water with 0.1% formic acid over 30 min at 1 ml/min. Programme 4 (for Fig.
22b): 5–70% acetonitrile–water with 0.1% formic acid over 40 min at 1 ml/min. Compound
purification was performed on the same HPLC.
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6.3.2 Strains and plasmids
E. coli XL1-Blue (Agilent Technologies) was used for routine cloning and pJET1.2
(Fermentas) was used as the cloning vector. E. coli cells were grown in Luria-Bertani (LB)
medium at 37 ℃. When necessary, 50 μg/ml ampicillin was added. E. coli BL21(DE3)
(Agilent Technologies) cells were used for expression of C1(BbBEAS), C2(BbBEAS), C3(BbBEAS),
C3(BbBEAS-H2901A), C3(BbBSLS) and MT(BbBEAS). S. cerevisiae BJ5464-NpgA (MATa ura3-52
his3-D200 leu2- D1 trp1 pep4::HIS3 prb1 D1.6R can1 GAL) was obtained from Dr. Nancy
Da Silva at the University of California, Irvine. The strain was maintained on YPD (10
mg/l yeast extract; 20 mg/l peptone; 20 mg/l dextrose) agar plates at 30 ℃ and used for
expression of BbBEAS, BbBSLS, their mutants or truncated variants, and co-expression
of the dissected fragments. The E. coli/S. cerevisiae shuttle vectors YEpADH2p-URA3
and YEpADH2p-TRP1 were gifts from Dr. Yi Tang at the University of California, Los
Angeles.
6.3.3 Gene amplification and plasmid construction
The gene fragments C3(bbBeas), bbBeas-ΔC3, C1(bbBeas), C1(bbBsls), T2aT2bC3(bbBeas),
T2bC3(bbBeas), C3(bbBsls), C1A1T1C2A2MT(bbBeas), bbBeas-ΔC1, C1A1T1C2A2MTT2a(bbBeas),
bbBsls-ΔC3,

bbBsls-ΔC1,

C1A1T1C2A2MT(bbBsls),

T2aT2bC3(bbBsls),

T2bC3(bbBsls)

and

C1A1T1C2A2MTT2a(bbBsls) were amplified by PCR from pDY37 or pDY42 [14] using
Phusion High-Fidelity DNA Polymerase (New England Biolabs) with specific primers
(Table E2). These PCR products were ligated into the cloning vector pJET1.2 to yield 16
plasmids including pDY83, pDY85, pDY92, pDY93, pDY104, pDY105, pDY106,
pDY108, pDY109, pDY111, pDY112, pDY113, pDY135, pDY136, pDY137 and pDY138.
These plasmids were confirmed by digestion checks and gene sequencing.
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The C3(bbBeas), T2aT2bC3(bbBeas) and T2bC3(bbBeas) inserts were excised from pDY83,
pDY104 and pDY105 with NheI and PmlI and ligated into YEpADH2p- URA3 between
the same sites to generate pDY87, pDY114 and pDY115, respectively. The bbBeas-ΔC1,
bbBsls-ΔC3, bbBsls-ΔC1, bbBsls-ΔT2aT2bC3 and bbBsls-ΔT2bC3 inserts were excised from
pDY109, pDY112, pDY113, pDY135 and pDY138 with SpeI and PmlI and ligated into
YEpADH2p-URA3 between the same sites to generate pDY117, pDY119, pDY121,
pDY150 and pDY141. The bbBeas-ΔC3, bbBsls-C3, bbBeas-ΔT2aT2bC3, bbBeas-ΔT2bC3,
T2aT2bC3(bbBsls) and T2bC3(bbBsls) inserts were excised from pDY85, pDY92, pDY93,
pDY106, pDY108, pDY111, pDY136 and pDY137 with NdeI and PmeI and ligated into
YEpADH2p-TRP1 between the same sites to yield pDY88, pDY100, pDY101, pDY116,
pDY122, pDY118, pDY140 and pDY139, respectively.
Site-directed mutagenesis in pDY37 and pDY42 that harbour the original bbBeas and
bbBsls genes was carried out to construct the mutant plasmids. The PCR conditions were
as follows: initial activation of the Phusion High-Fidelity DNA Polymerase for 5min at
95 ℃, followed by 36 cycles of 40 s denaturation at 95 ℃, annealing for 40 s at 63 ℃ and
extension for 15.5 min at 65 ℃. PCR products were treated with DpnI (New England
Biolabs) for 24 h at 37 ℃ to remove the templates, ligated and introduced into E. coli XL1Blue. Colonies were subjected to digestion checks and sequencing to confirm the correct
mutation. pDY145 (bbBeas-H2901A), pDY149 (bbBeas-D179A), pDY158 (bbBeasS2591A) and pDY162 (bbBeas-S2688A) were made from pDY37, while pDY151 (bbBslsH170A), pDY152 (bbBsls-H2861A) and pDY161 (bbBsls-D174A) were made from
pDY42. For double mutations, pDY183 (bbBeas-S2591A) was made from pDY162.
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Based on the AscI site in bbBeas, the gene fragments (AscI)bbBeasΔT2a,
(AscI)bbBeas with T2aT2bC3(bbBsls), (AscI)bbBeas with T2bC3(bbBsls) and (AscI)bbBeas with
C3(bbBsls) were amplified by splicing by overlap extension PCR using pDY37 and pDY42
as the templates. Similarly, (BsrGI)bbBsls with T2aT2bC3(bbBeas), (BsrGI)bbBsls with
T2bC3(bbBeas) and (BsrGI)bbBsls with C3(bbBeas) were amplified. These gene fragments were
ligated into the cloning vector pJET1.2 to yield seven plasmids including pDY165,
pDY188, pDY189, pDY190, pDY191, pDY192 and pDY222. They were confirmed by
digestion checks and gene sequencing. The (AscI)bbBeas-ΔT2a, (AscI)bbBeas with
T2aT2bC3(bbBsls), (AscI)bbBeas with T2bC3(bbBsls) and (AscI)bbBeas with C3(bbBsls) inserts were
excised with AscI and PmlI from the corresponding pJET1.2-derived plasmids and ligated
into pDY37 between the same sites to generate pDY173, pDY201, pDY204 and pDY203,
respectively. The (BsrGI)bbBsls with T2aT2bC3(bbBeas), (BsrGI)bbBsls with T2bC3(bbBeas) and
(BsrGI)bbBsls with C3(bbBeas) inserts were excised with BsrGI and PmlI from the
corresponding pJET1.2-derived plasmids and ligated into pDY42 between the same sites
to generate pDY215, pDY205 and pDY224, respectively.
The gene fragments C1(bbBeas), C2(bbBeas), C3(bbBeas), C3(bbBsls) and MT(bbBeas) were
amplified by PCR from the genomic DNA of B. bassiana ATCC 7,159 with Phusion HighFidelity DNA Polymerase with specific primers (Table E2). These gene fragments were
ligated into the cloning vector pJET1.2 to yield five plasmids including pFC1, pFC62,
pFC2, pFC9 and pZJ134. The gene fragment C3(bbBeas-H2901A) was amplified from pDY145
and ligated into pJET1.2 to yield pFC44. These plasmids were confirmed by digestion
checks and gene sequencing. The C1(bbBeas), C3(bbBsls) and MT(bbBeas) inserts were excised
from pFC1, pFC9 and pZJ134 with NdeI and BamHI and ligated into pET28a between the
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same sites to generate pFC3, pFC11 and pJCZ21, respectively. The C2(bbBeas) insert was
excised from pFC62 with NdeI and HindIII and ligated into pET28a between the same sites
to generate pFC63. The C3(bbBeas) and C3(BbBEAS-H2901A) inserts were excised from pFC2 and
pFC44 with NheI and BamHI and ligated into pET28a between the same sites to generate
pFC4 and pFC46, respectively. The plasmids constructed in this work are shown in Table
E3.
6.3.4 Analysis of the products of the engineered yeast strains.
The NRPSs were expressed in S. cerevisiae BJ5464-NpgA. The correct transformants
were selected by autotrophy of uracil and/or tryptophan. Yeast strains harbouring one
plasmid were cultured in 50 ml of SC-Ura (or -Trp) dropout medium (6.7 mg/l yeast
nitrogen base; 20 mg/l glucose; 0.77 mg /l -Ura or 0.74 mg/l -Trp dropout supplement) at
30 ℃ with shaking at 250 rpm. For co-expression experiments, -Trp/-Ura dropout was used.
After the OD600 value reached 0.6, an equal volume of YP medium (10 mg/l yeast extract;
20 mg/l peptone) was added, and the cultures were maintained under the same conditions
for an additional 3 days. The cultures were then extracted three times with 100 ml of ethyl
acetate and subjected to analysis on an Agilent 1200 HPLC (at 210 nm) coupled with an
Agilent 6130 single quadrupole mass spectrometer. The product titres were calculated from
three independent experiments based on the standard curves of purified compounds.
6.3.5 Protein expression and purification
C-terminal His6-tagged BbBEAS, BbBSLS and their mutants and truncated variants
were expressed in S. cerevisiae BJ5464-NpgA for protein purification. For 1 l of yeast
culture, the cells were grown at 25 ℃ in modified YPD medium (with appropriate dropout
supplement) that contains 1% dextrose for 72 h. The cells were collected by centrifugation
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(4,000 rpm for 20 min), resuspended in 20 ml of lysis buffer (50 mM NaH2PO4, pH 8.0,
0.15 M NaCl, 10 mM imidazole) and lysed with sonication on ice. Cell debris was removed
by centrifugation (35,000×g for 1 h at 4 ℃). Two mililitres of Ni-NTA agarose resin was
incubated with the supernatant at 4 ℃ for 7 h. The mixture was loaded into a gravity flow
column. Buffer A (50 mM Tris-HCl, pH 7.9, 2 mM EDTA, 2 mM DTT) with increasing
concentrations of imidazole was used as washing buffers. Purified proteins were
concentrated and exchanged into the reaction buffer (50 mM Tris- HCl, pH 8.0). The yields
of these modular enzymes were 20.8 mg/l. N-terminal His6-tagged C1(BbBEAS) (22.5 mg/l),
C2(BbBEAS) (35.1 mg/l), C3(BbBEAS) (29.2 mg/l), C3(BbBEAS-H2901A) (22.1 mg/l), C3(BbBSLS) (23.6
mg/l) and MT(BbBEAS) (23.0 mg/l) were expressed with the induction of 200 μM IPTG and
purified from E. coli BL21(DE3) strains harbouring pFC3, pFC63, pFC4, pFC46, pFC11
and pJCZ21, respectively, using a similar Ni-NTA chromatography method.
6.3.6 Purification and structural characterization of 8 and 15
To isolate the two products from reprogrammed BbBEAS and BbBSLS, the
corresponding cultures were scaled up to 2 l and grown at 30 ℃ with shaking at 250 rpm
for 72 h. The ethyl acetate extracts were dried under reduced pressure and subjected to
MCI column chromatography, successively eluted with a gradient of methanol-water
(0:100, 20:80, 50:50 and 100:0, v/v). The fractions containing the target compounds were
further separated by HPLC, eluted with a gradient of acetonitrile–water (80–100% over 20
min) at a flow rate of 1ml/min, to yield 8 (10.1 mg) and 15 (2.5 mg). The purified
compounds were identified based on the spectral data.
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6.3.7 Chemical preparation of substrates and intermediate products
Beauvericins (1–4) and bassianolide (5) were extracted with ethyl acetate from 5 l of
fermentation broths of S. cerevisiae BJ5464-NpgA/pDY37 and S. cerevisiae BJ5464NpgA/ pDY42, respectively. After evaporation of the solvent, the crude extracts were
hydrolysed in 20 ml of acetonitrile–water (1:1) containing 0.1N NaOH for 48 h at 40 ℃
with stirring. The resultant hydrolytic products were extracted by ethyl acetate, loaded on
a silica gel 60 open column, and eluted with a gradient of acetone-hexanes (50, 70 and
100%, v/v) and methanol. The monomer (11 or 12)- containing fractions were purified by
HPLC, washed with 40% acetonitrile–water at a flow rate of 1ml/min to yield 71.2 mg of
11 and 51.6 mg of 12. A mixture of 1-ethyl-3-(3-dimethyllaminopropyl) carbodiimide
hydrochloride (0.1 mmol) and hydroxybenzotriazole (0.1 mmol) was added into 15 ml of
tetrahydrofuran containing 0.1 mmol 11 or 12. After stirring the resulting mixture for 1 h
at 40 ℃, K2CO3 (0.05 mmol) was added, and the reaction was stirred for overnight at 40 ℃.
The reaction was then stopped and concentrated by rotary evaporation. The resultant
cyclized products 10 and 13 were purified by HPLC. A gradient of acetonitrile–water (5–
60% over 30 min) was programmed at a flow rate of 1ml、min and 17.6 mg of 10 and 12.2
mg of 13 were purified from the respective reactions.
To prepare D-Hiv-N-Me-L-Phe-SNAC (S3), 11 (0.1 mmol) and SNAC (0.12 mmol)
were added to 1ml of dimethylformamide in a 10- ml round flask and cooled down to 0 ℃.
The solution was then treated with diphenylphosphorylazide (0.15 mmol) and
triethylamine (0.2 mmol). The reaction mixture was stirred for 3 h before the reaction was
stopped and concentrated by rotary evaporation. The resultant monomer-SNAC was
purified by HPLC. A gradient of acetonitrile–water (5–90% over 30 min) was programmed
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at a flow rate of 1ml/min to yield 7.7 mg of S3. D-Hiv was purchased from Sigma-Aldrich
(St Louis, USA), and (D-Hiv-N-Me-L-Phe)2 and (D-Hiv-N-Me-L-Phe)3 were purchased
from the Chinese Peptide Company (Hangzhou, China), which were used to synthesize DHiv-SNAC (S1), (D-Hiv-N-Me-L-Phe)2-SNAC (S4) and (D-Hiv-N-Me-L-Phe)3-SNAC
(S6) using the same method for S3.
To prepare N-Methyl-L-Phe-SNAC (S2), L-Phe-SNAC was synthesized first. tButyloxy carbonyl (Boc)-L-Phe (1 mmol), N,N-dicyclohexylcarbodiimide (1 mmol) and
1-hydroxybenzotriazole (1 mmol) were dissolved in 15 ml of tetrahydrofuran (THF),
followed by adding N-acetylcysteamine (1 mmol). After stirring the resulting solution for
45 min at 25 ℃, K2CO3 (0.5 mmol) was added and the reaction mixture was stirred for an
additional 3 h at 25 ℃. After filtration, the solvent was removed in vacuo. The resulting
residue was dissolved in ethyl acetate and washed once with an equal volume of 10%
aqueous NaHCO3. The organic layer was dried by MgSO4, filtered and concentrated in
vacuo. The crude product was subjected to silica gel column chromatography, eluted with
4% (v/v) MeOH-CHCl3, to afford Boc-L-Phe-SNACs. Boc group was removed by
dissolving Boc-L-Phe-SNAC in 50% TFA/CH2Cl2 and stirring at 25 ℃ for 1 h. After
removing solvent, the residue was taken up in a minimal volume of CH2Cl2 and precipitated
with ether. The resulting solid was washed twice with ether and dried to afford L-PheSNAC.
A typical methylation reaction of L-Phe-SNAC (100 ml) consisted of 6.4 mM
MT(BbBEAS), 0.8 mM L-Phe-SNAC and 2.4 mM SAM in 100 mM Tris-HCl buffer (pH 7.5).
The reaction mixtures were incubated at 25 ℃ for 30 min and then quenched with MeOH
(50 ml). The mixtures were briefly vortexed and centrifuged at 15,000 rpm for 5min to
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remove the precipitated protein before the samples were injected into LC–MS for analysis.
The supernatants were analysed by HPLC under 235 nm, eluted with an increasing gradient
of acetonitrile (10–15%) in H2O containing 0.1% TFA with a flow rate of 1ml/min.
Purification of S2 was carried out using the same HPLC method.
6.3.8 In vitro enzymatic studies
For a typical in vitro NRPS activity assay, a 400-µl reaction contained 50 mM TrisHCl buffer (pH 8.0), 2 mM NRPS (or dissected fragments), 5mM ATP, 25mM MgCl2, 7.5
mM L-Leu or L-Phe, 2.25 mM D-Hiv and 3 mM SAM. After 3 h incubation at 25 ℃, the
reactions were quenched with methanol for LC–MS analysis.
To test the condensation activity of C2, S1 (0.3 mM) and S2 (0.3 mM) or S4 (84 mM)
were incubated with 30 mM C2 domain in 1 ml of 50 mM Tris-HCl buffer (pH 7.8) at 25 ℃
for 12 h.
To test the condensation activity of C1, S1 (0.3 mM) and S2 (0.3 mM) or S4 (84 mM)
were incubated with 30 mM C1 domain in 1 ml of 50 mM Tris-HCl buffer (pH 7.8) at 25 ℃
for 12 h.
To test the condensation activity of C3, S4 (84 mM), S1 (0.3mM) and S2 (0.3 mM,
when needed) were incubated with 30 mM C3 domain in 1ml of 50 mM Tris-HCl buffer
(pH 7.8) at 25 ℃ for 12 h.
To test the macrocyclization activity of C1 and C3, the SNAC substrates S3, S4 or S6
(75 mM) were, respectively, incubated with 30 mM C1 or C3 domain or their mutants in
100 ml of 50mM Tris-HCl buffer (pH 7.8) at 25 ℃ for 4 h.
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For in vitro total biosynthesis, S1 (1 mM) and S2 (1 mM) were incubated with C2
domain (50 mM) and C3 domain (50 mM) in 2ml of 50 mM Tris-HCl buffer (pH 7.8) at
25 ℃ for 12 h.
6.4

Result

6.4.1 Purification and reconstitution of BbBEAS and BbBSLS
We have recently expressed BbBEAS and BbBSLS and achieved highyield
production of 1–5 (33.8 mg/l for 1–4 and 21.7 mg/l for 5) in Saccharomyces cerevisiae
BJ5464-NpgA [14]. To decode the functions of the catalytic domains in BbBEAS (352
kDa) and BbBSLS (348 kDa), we first expressed and purified these giant enzymes from S.
cerevisiae BJ5464-NpgA. As shown in Fig. E1, both enzymes were expressed in the yeast
and obtained in pure form (0.8 mg/l for both BbBEAS and BbBSLS). Reaction of C-His6tagged BbBEAS with adenosine triphosphate (ATP), S-adenosylmethionine (SAM), L-Phe
and D-Hiv yielded 1 (trace i, Fig. 20c), which was confirmed by electrospray ionisation
mass spectrometry (ESI-MS) (Fig. E2), high-resolution electrospray ionization mass
spectrometry (HR-ESI-MS) (Fig. E3) and a comparison with the authentic sample prepared
and fully characterized in our previous work (trace ii, Fig. 20c) [14]. Similarly, BbBSLS
was found to synthesize 5 (traces iii and iv, Fig. 20c, Fig. E2 and Fig. E4) from L-Leu and
D-Hiv [14]. Formation of 1 and 5 allowed direct functional characterization of BbBEAS
and BbBSLS. These results indicated that both BbBEAS and BbBSLS were functionally
expressed in S. cerevisiae and their catalytic activity can be reconstituted in vitro, providing
a great platform to further study the catalytic domains in these modular NRPSs.
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6.4.2 Roles of the twin T2 domains and the biosynthetic model
Two possible biosynthetic models were proposed for BbBEAS and other similar
NRPSs: linear (alternate incorporation of the precursors) and parallel (oligomerization of
a monomer synthesized from the precursors) (Fig. 21a) [4]. In the linear model, T1 and
T2a/T2b are alternately used for tethering the growing depsipeptide chain for addition of the
D-hydroxycarboxylic acid and N-Me-L-amino acid units. T2a and T2b have the same
function and only one of them is required. In contrast, in the parallel model, one of the twin
T2 domains is proposed to hold the synthesized dipeptidol monomer after it is synthesized
at the other T2 domain [4]. Additional monomers are added to the T2b- or T2a-linked
monomer through oligomerization to form the dimer and subsequently the trimer (1) or
tetramer (5). In this parallel model, both twin T2 domains are required. Bacterial iterative
NRPSs adopt a product assembly process that is more like the parallel model in Fig. 23a,
except that the growing product chain is linked to the TE instead of a T domain. To
understand what model is used by fungal iterative NRPSs, it is necessary to reveal the roles
of the twin T2 domains in BbBEAS and BbBSLS.
Sequence analysis revealed that the twin T2 domains in both BbBEAS and BbBSLS
contain the conserved motif (I/L)GG(D/H)SL, in which the key serine (Ser or S) residue
serves as the phosphopantetheine attachment site (Fig. E5). We first examined how
inactivation of T2a and/or T2b affects the biosynthesis. Mutation of S2591 in T2a to alanine
(A) did not abolish the production of beauvericins (trace i, Fig. 21b), but the titre (0.7±0.1
mg/l) calculated from three replicates was significantly lower than that (33.8±1.4 mg/l) by
wild-type BbBEAS. In contrast, the T2b mutant BbBEAS-S2688A produced beauvericins
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(trace ii, Fig. 21b) with a titre of 23.0±1.0 mg/l. When both key Ser residues were mutated,
no products were synthesized by BbBEAS-S2591A/S2688A (trace iii, Fig. 21b).

Figure 21. Roles of the twin T2 domains in BbBEAS and BbBSLS. (a) Two possible
models for the assembly process of 1: linear model (top, with filled arrows) and parallel
model (bottom, with unfilled arrows). The two precursors and the growing depsipeptide
chain are tethered to the T domains through phosphopantetheinyl prosthetic groups. In
the linear model, T2a and T2b have the same function of holding the growing
depsipeptide chain. (b) HPLC analysis of the products of mutant enzymes BbBEAS-
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S2591A, BbBEAS-S2688A and BbBEAS-S2591A/S2688A in S. cerevisiae BJ5464NpgA. (c) HPLC analysis of the effect of removal of T2a and/or T2b on beauvericin
biosynthesis. (d) HPLC analysis of the effect of removal of T2a and/or T2b on
bassianolide biosynthesis.

We next tested how removal of the twin T2 domains from BbBEAS affects
beauvericin biosynthesis using a dissection and co-expression approach. BbBEAS was
dissected at different positions and the fragments were functionally expressed in S.
cerevisiae BJ5464-NpgA (traces i–iv, Fig. 21c). Using this system, we removed T2a from
BbBEAS by co-expressing C1-A1-T1-C2-A2-MT and T2b-C3 in the yeast. Liquid
chromatography–mass spectrometry (LC–MS) analysis revealed that beauvericins were
produced at 5.0±1.2 mg/l (trace v, Fig. 21c) in the absence of T2a. This was validated by
the construction of an intact enzyme BbBEAS-ΔT2a, which produced beauvericins at
0.5±0.1 mg/l (trace vi, Fig. 21c), confirming that the dissection and co-expression approach
is effective and reliable. To remove T2b, C1-A1-T1-C2-A2-MT-T2a and standalone C3 were
co-expressed in the yeast, yielding 1–4 at 13.0±3.9 mg/l (trace vii, Fig. 21c). When both
T2 domains were removed, no products were detected (trace viii, Fig. 21c). These results
were consistent with those from Ser mutations, which confirmed that only one of the twin
T2 domains is required for beauvericin biosynthesis.
Similarly, we also dissected BbBSLS before and after T2a, and confirmed that the
fragments can be co-expressed in the yeast to reconstitute bassianolide biosynthesis (traces
i and ii, Fig. 21d). Removal of T2a (trace iii, Fig. 21d) or T2b (trace iv, Fig. 21d) did not
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abolish the production of 5, although the titre by the former was much lower (2.9 mg/l
versus 10.6 mg/l). This further confirmed that T2a plays a major role in the biosynthetic
process as inactivation or removal of this domain significantly lowered the efficiency of
the product assembly line. By contrast, T2b is less important in the biosynthetic process and
may serve as an auxiliary T domain to contribute to the overall efficiency. Because the
presence of both twin T2 domains is not necessary for the biosynthesis, the possibility of
oligomerization (parallel model) in chain elongation can be ruled out. Thus, it is concluded
that 1–5 are assembled through an alternate incorporation approach (linear model, Fig. 21a)
by the fungal NRPSs.
6.4.3 The condensation activity of the C1 and C2 domains
Another mystery of BbBEAS and BbBSLS is the unknown roles of the three C
domains in the biosynthetic process. We analysed the C domains in four reported fungal
iterative NRPSs. As shown in Fig. 22a, the C2 domains of these fungal NRPSs have the
conserved HHxxxDG motif [15]. It was generally believed that the second histidine (H) in
this motif serves as a general base for the condensation in most NRPSs, while aspartic acid
(D) plays an important role in the structure of C domains [16,17]. The first H residue in
this motif is not highly conserved, as some C domains such as the C3 domains shown in
Fig. 22a have an S at this position. The exact function of the G residue in this motif is not
clear. Compared to C2 and C3, the C1 domains of these fungal NRPSs are more divergent
and C1(BbBEAS) does not have the essential H residue. As the C-terminal condensation
domain, C3 is likely involved in the final cyclization and concomitant release of the peptide
chain from the end of the NRPS assembly lines. The remaining two condensation domains,
C1 and C2, are possibly responsible for forming the ester and amide bonds in the product
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assembly line, respectively. We first tested the condensation activity of C2. C2(BbBEAS) was
overexpressed and purified from E. coli BL21(DE3) (Fig. E6), andreacted with D-HivSNAC (S1) (SNAC: N-acetylcysteamine) [18] and N-Me-L-Phe-SNAC (S2). As shown in
Fig. 22b, D-Hiv-N-Me-L-Phe-SNAC (S3) was synthesized by C2(BbBEAS), and then
spontaneously cyclized to form cyclo-D-Hiv-N-Me-L-Phe (10, Fig. 22b). In contrast, this
domain could not form an ester bond as the reaction of S1 and (D-Hiv-N-Me-L-Phe)2SNAC (S4) with C2(BbBEAS) did not yield any products (Fig. E7). Consequently, the role of
C2 was determined to be forming the amide bond in the assembly process of NRPs.

Figure 22. Investigation of the condensation activity of C1 and C2. (a) Comparison of the
conserved HHxxxDG region in the C domains of four reported fungal iterative NRPSs. The
active site H residues are highlighted. (b) HPLC analysis of the in vitro reaction of
C2(BbBEAS) with D-Hiv-SNAC (S1) and N-Me-L-Phe-SNAC (S2). (c) HPLC analysis of the in
vitro reaction of C1(BbBEAS) with S1 and S2. (d) HPLC analysis of the in vitro reaction of
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C1(BbBEAS) with S1 and S4. (e) HPLC analysis of the products of C1-mutated BbBEAS and
BbBSLS in S. cerevisiae BJ5464-NpgA.

We next attempted to understand whether C1 forms the ester bond. C1(BbBEAS) was
overexpressed and purified from E. coli BL21(DE3) (Fig. E6). Incubation of C1(BbBEAS)
with S1+S2 or S1+S4 did not yield any products (Figs. 22c and d). Because C1(BbBEAS) lacks
the active site H, we mutated D179 to A and expressed this mutant enzyme BbBEASD179A in S. cerevisiae BJ5464-NpgA. LC–MS analysis revealed the synthesis of
beauvericins by BbBEAS-D179A (trace i, Fig. 22e) at 24.2±1.0 mg/l, indicating that the
mutation did not affect the biosynthetic process. Similarly, mutation of H170 and D174 in
the conserved motif of C1 of BbBSLS did not interfere with bassianolide biosynthesis
(traces ii and iii, Fig. 22e), indicating that mutation of these functionally or structurally
important residues does not influence the biosynthesis of 5. These results clearly indicate
that C1 has no condensation activity. To further probe the role of C1 in beauvericin
biosynthesis, we constructed a truncated version of BbBEAS by removing C1. No
beauvericins were produced by BbBEAS-ΔC1. Addition of standalone C1(BbBEAS) into the
yeast did not recover beauvericin biosynthesis. SDS–PAGE analysis revealed that
BbBEAS-ΔC1 (308 kDa) was not expressed and the attempt to purify His6-tagged
BbBEASDC1 using Ni-NTA chromatography from the yeast host failed. Similarly,
BbBSLS-ΔC1 could not be expressed in the yeast either. Thus, removal of C1 resulted in
unsuccessful expression of the truncated enzymes, suggesting that the presence of C1 is
critical for the expression of BbBEAS and BbBSLS.
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6.4.4 The condensation activity of the C3 domain
To understand how the ester bond is formed, we next investigated the condensation
activity of C3. We first removed this domain to yield a truncated variant of BbBEAS.
Expression of BbBEAS-ΔC3 yielded no products (trace i, Fig. 23a). In trans addition of
standalone C3(BbBEAS) into S. cerevisiae BJ5464-NpgA reconstituted the synthesis of
beauvericins (26.5±1.3mg/l, trace ii, Fig. 23a). This suggests that C3 plays an essential role
in beauvericin biosynthesis. We next examined the effect of mutation of the conserved H
on beauvericin biosynthesis. BbBEAS-H2901A failed to produce beauvericins (traces iii,
Fig. 23a), indicating that the condensation activity of C3 is required for the biosynthetic
process.
To gain more insight into the role of C3, C-His6-tagged BbBEAS-ΔC3 was purified
from S. cerevisiae BJ5464-NpgA and reacted with ATP, SAM, D-Hiv and L-Phe. No
beauvericins were detected by LC–MS. Instead, small amounts of 10 and 11 (trace i, Fig.
23b) were produced, which were respectively identified as the cyclic and linear D-Hiv-NMe-L-Phe based on the ESI-MS (Fig. E2) and NMR (Table E1) as well as a comparison
with the chemically prepared standards (traces ii and iii, Fig. 23b). 10 can be hydrolysed
in 0.1N NaOH to yield 11. Production of 10 and 11 indicated that the biosynthetic process
stopped after the formation of the monomer. The same products were observed from the
reaction of purified C-His6-tagged BbBEAS-H2901A (trace iv, Fig. 23b), confirming that
mutation of H2901 did cause the loss of the condensation ability of C3.
We also overexpressed and purified C3(BbBEAS) from E. coli BL21(DE3) (Fig. E6).
Co-reaction of C3(BbBEAS) and BbBEAS-ΔC3 with necessary components yielded 1 (trace i,
Fig. 23c). (D-Hiv-N-Me-L-Phe)2-D-Hiv-SNAC (S5) was synthesized from S1 and S4 by
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standalone C3(BbBEAS), then spontaneously hydrolysed to form (D-Hiv-N-Me-L-Phe)2-DHiv (14, Fig. 23d) thathas a molecular mass of 640 (Fig. E2). Addition of S2 into the
reaction system did not produce any extra products including 1 (Fig. E8). Thus, C3 is
responsible for the formation of the ester bond between T1-linked D-Hiv and the monomer
D-Hiv-N-Me-L-Phe or the dimer (D-Hiv-N-Me-L-Phe)2 that is tethered to T2a or T2b.

Figure 23. Investigation of the ether bond-forming activity of C3. (a) HPLC analysis of
the in vivo products of C3-less or C3-mutated BbBEAS in S. cerevisiae BJ5464-NpgA.
(b) HPLC analysis of the in vitro reactions of C3-less or C3-mutated BbBEAS with ATP,
SAM, D-Hiv and L-Phe. (c) HPLC analysis of the in vitroreconstitution of the
biosynthesis of 1 and 5 by the co-reactions of C3-less NRPS and standalone C3 with
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ATP, SAM, D-Hiv and L-amino acid (L-Phe for BbBEAS and L-Leu for BbBSLS). (d)
HPLC analysis of the in vitro reaction of C3(BbBEAS) with D-Hiv-SNAC (S1) and (D-HivN-Me-L-Phe)2-SNAC (S4). (e) HPLC analysis of the in vivo products of C3-less or C3mutated BbBSLS in S. cerevisiae BJ5464-NpgA. (f) HPLC analysis of the in
vitro reactions of C3-less or C3-mutated BbBSLS with ATP, SAM, D-Hiv and L-Leu.

The same experiments were applied to BbBSLS. BbBSLS-DC3 and BbBSLSH2861A failed to synthesize 5 (traces i and iii, Fig. 23e). In trans addition of standalone
C3(BbBSLS) recovered bassianolide biosynthesis (traces ii and iv, Fig. 23e). In vitro reactions
of ATP, SAM, D-Hiv and L-Leu with purified BbBSLSΔC3 (trace i, Fig. 23f) or BbBSLSH2861A (trace ii, Fig. 23f) did not yield 5, but the linear (12) and cyclic D-Hiv-N-Me-LLeu (13) (traces i–iv, Fig. 23f), respectively. Addition of C3(BbBSLS) into the reaction system
reconstituted bassianolide biosynthesis (trace ii, Fig. 23c). These results further confirmed
that C3 plays an essential role in forming the ester bond during the biosynthesis of 1–5.
Removal or inactivation of C3 did not affect the functions of the upstream domains, but
stopped the biosynthetic process at the monomer stage.
6.4.5 Identification and reprogramming of chain length control
With the understanding of the roles of the twin T2 and three condensation domains,
we next attempted to identify the product-length-controlling domain(s) by constructing a
series of chimeric enzymes. Since module 1 of BbBEAS and BbBSLS are exchangeable
without affecting the product profiles [19], we tested the effects of swapping the C-terminal
domains on the product formation. We first constructed an enzyme C1-A1-T1-C2-A2-
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MT(BbBEAS)T2a-T2b-C3(BbBSLS). Unlike wild-type BbBEAS (trace i, Fig. 24a), C1-A1-T1-C2A2-MT(BbBEAS)T2a-T2b-C3(BbBSLS) did not synthesize beauvericins, but a new product FX1
(15) (trace ii Fig. 24a) with a molecular mass of 1,044 (Fig. E2) at 3.2±0.6 mg/l. The
molecular formula of 15 was determined to be C60H76N4O12 by HR-ESI-MS (Fig. E9). The
structure was established as a cyclic tetramer (Fig. 24b) based on the one-dimensional
(Table E1) and two-dimensional NMR data (Fig. E10). This was further confirmed by
chemical hydrolysis of 15 in 0.1N NaOH, which yielded the monomer 11 (Fig. E11). We
then made C1-A1-T1-C2-A2-MT-T2a(BbBEAS)-T2b-C3(BbBSLS) and C1-A1-T1-C2-A2-MT-T2aT2b(BbBEAS)-C3(BbBSLS). Both enzymes produced 15 as the sole product (traces iii and iv, Fig.
24a). These results revealed that replacement of C3(BbBEAS) with C3(BbBSLS) is sufficient to
reprogramme chain length control in BbBEAS. The same results were obtained for
BbBSLS (traces i–iv, Fig. 24c). C1-A1-T1-C2-A2-MT-T2a-T2b(BbBSLS)-C3(BbBEAS) generated 8
(Fig. E12) as the only product. Therefore, C3 was unambiguously identified as the chainlength-controlling domain.
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Figure 24. Identification and reprogramming of chain length control. (a) HPLC analysis
of the products of wild-type BbBEAS and its engineered versions in S.
cerevisiae BJ5464-NpgA. (b) Structure of the new tetrameric product FX1 (15)
generated by reprogramming BbBEAS. (c) HPLC analysis of the products of wild-type
BbBSLS and its engineered versions in S. cerevisiae BJ5464-NpgA. (d) HPLC analysis
of the in vitro reactions of depsipeptidyl-SNACs with C3(BbBEAS). Three SNAC
derivatives including D-Hiv-N-Me-L-Phe-SNAC (S3), (D-Hiv-N-Me-L-Phe)2-SNAC
(S4) and (D-Hiv-N-Me-L-Phe)3-SNAC (S6) were used to mimic the intermediates in
beauvericin biosynthesis.
C-terminal TE, R, Cy or C is often involved in the cyclization and concomitant
release of the peptide chain from the end of the NRPS assembly lines [20]. Since no TE,
Cy or R domains are present in BbBEAS and BbBSLS, we considered that C1 and C3 might
be involved in the macrocyclization. To probe the cyclization activity and specificity of C3,
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three depsipeptidyl-SNACs that mimic the linear monomer, dimer and trimer intermediates
tethered to T2a or T2b were reacted with C3(BbBEAS). S3 is unstable and can undergo quick
spontaneous cyclization to yield 10 in the reaction buffer (traces i and ii, Fig. 24d). Addition
of C3(BbBEAS) into the system did not cause observable changes in the formation rate of 10
(trace iii, Fig. 24d). The dimer substrate S4 is stable in the buffer (trace iv, Fig. 24d), but
was not cyclized by C3(BbBEAS) to yield 16 (trace v, Fig. 24d). The trimer substrate (D-HivN-Me-L-Phe)3-SNAC (S6) mimics the full-length intermediate. This substrate is stable in
the reaction buffer (trace vi, Fig. 24d). Incubation of S6 with C3(BbBEAS) yielded 1 (trace vii,
Fig. 24d), while C3(BbBEAS-H2901A) failed to cyclize it (trace viii, Fig. 24d). The same
reactions were applied to C1(BbBEAS) but no cyclization products 16 and 1 were detected.
These in vitro reactions further confirmed that C3 catalysed the macrocyclization in
beauvericin biosynthesis. Mutation of the active site residue H in C3(BbBEAS) to A abolished
its macrocyclization activity, indicating that this domain uses the same active site for the
condensation and macrocyclization, both leading to the formation of an ester bond
(intermolecular or intramolecular) between the carboxyl of L-Phe and hydroxyl of D-Hiv.
Moreover, C3 only cyclizes the mature depsipeptide intermediate. This property is critical
for chain length control, which also explains why 10 and 16 are not produced by the
beauvericin-producing strain B. bassiana and the yeast strain that expresses BbBEAS.
6.4.6 In vitro total biosynthesis of 1 using the C2 and C3 domains
Our results revealed that C2 and C3 work collaboratively to generate a linear fulllength intermediate that is subsequently cyclized and released by C3. We next attempted to
use these two domains for in vitro total biosynthesis of 1 from the beginning precursors.
To this end, we reacted C2(BbBEAS) and C3(BbBEAS) with the two mimicking substrates S1 and
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S2, while the control contains the same components except the two domains were
inactivated. The reactions were subjected to LC–MS analysis. As shown in Fig. 25a, there
is a small product peak at 25.8 min that had a [M+H]+ peak at m/z 642 (Fig. E2). Extraction
of the ion chromatogram at m/z 642 (i, Fig. 25a) from the negative control (left panel) and
the reaction (right panel) revealed that this product was only formed in the reaction, which
has the same molecular mass and retention time (Fig. 25d) as S4. The extracted ion
chromatogram (EIC) at m/z 784 clearly showed the synthesis of 1 (ii, Fig. 25a). Similarly,
EICs at m/z 262, 641 and 903 indicated the formation of 10 (iii), 14 (iv) and S6 (v) in the
reaction mixture. We further enlarged the high-performance liquid chromatography (HPLC)
traces of the negative control (i, Fig. 25b), the reaction (ii, Fig. 25b) and the standard of 1
(iii, Fig. 25b), which clearly revealed that 1 was synthesized from the two beginning
precursors S1 and S2 by the two isolated domains. Furthermore, the peak of S6 was also
observed, which showed the same retention time as the extracted ion peak shown in trace
v of Fig. 25a. These results indicated the success of in vitro total biosynthesis of 1 by C2
and C3 and showed a series of biosynthetic intermediates or their hydrolysed products.
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Figure 25. In vitro total biosynthesis of 1 using C2 and C3 domains. (a) LC–MS analysis
of the in vitro reaction of C2(BbBEAS) and C3(BbBEAS) with S1 and S2. The left panel is the
negative control with inactivated C2 and C3, while the right is the actual reaction. The
HPLC traces are shown on the top, followed by the EICs of the intermediates and final
product. (i)–(v) are EICs at m/z 642 (i), 784 (ii), 262 (iii), 641 (iv) and 903 (v),
respectively. (b) Enlarged view of the region of 30.1–34.4 min of the HPLC traces of
the negative control (i), reaction (ii) and the standard of 1 (iii).
6.5 Discussion
Fungal NRPs represent an important group of bioactive natural products. BbBEAS
and BbBSLS are two fungal iterative NRPSs that are involved in the biosynthesis of the
anticancer NRPs 1–5. However, the assembly process of these cyclooligomer
depsipeptides is unclear, largely due to the poorly understood domains including T2a, T2b,
C1, C2 and C3 in these modular enzymes. We used a combination of enzyme dissection,
domain swapping, site-directed mutagenesis and in vitro enzymatic reactions to study
BbBEAS and BbBSLS. This work elucidates fungal NRPSs’ chain elongation and length
control strategy. Highly consistent results were obtained from both BbBEAS and BbBSLS,
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suggesting that this family of fungal iterative NRPSs follows a general biosynthetic
mechanism, which is different from the approach used by bacterial iterative NRPSs.
A typical NRPS module contains a C domain, an A domain and a T domain for chain
elongation. Co-existence of two T domains in module 2 of fungal iterative NRPSs not only
represents an interesting structural feature, but also raises questions about the roles of these
T domains in fungal NRP biosynthesis. There are several examples of twin carrier proteins
in a megasynthase. For example, it was previously reported that module 6 of the leinamycin
polyketide synthase from Streptomyces atroolivaceus S-140 contains twin acyl carrier
protein (ACP) domains that are separated by a MT domain. Either is sufficient for the
biosynthesis, and ACP6–2 is preferred [21]. In our work, we found that T2a plays a major
role in the formation of the NRPs. Two possible biosynthetic models have been previously
proposed to explain the biosynthetic process of fungal NRPs based on how the depsipeptide
chain is elongated and how the twin T2 domains are involved in the assembly process. We
specifically mutated the key Ser residue in these T domains that is required for the 40phosphopantetheinylation. Inactivation of either T2 domain did not abolish the formation
of the corresponding NRPs, but affected the yield to different extents. Similar results were
observed when one of the T2 domains was removed, providing solid evidence against the
parallel model (Fig. 21a), which requires the functions of both T2a and T2b. Thus, it is
hypothesized that the biosynthesis of 1–5 proceeds through the linear model (Fig. 21a).
This was confirmed by the in vitro reactions of C2(BbBEAS) and C3(BbBEAS), which
demonstrated that C2 forms the amide bond and C3 catalyses the synthesis of the ester bond.
Co-reactions of C2(BbBEAS) and C3(BbBEAS) with D-Hiv-SNAC and N-Me-L-Phe- SNAC
reconstituted the in vitro biosynthesis of 1 with only two condensation domains.
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Furthermore, some of the intermediates or hydrolysis products were observed, including
cyclo-D-Hiv-N-Me-LPhe, (D-Hiv-N-Me-L-Phe)2-SNAC, (D-Hiv-N-Me-L-Phe)2-D-Hiv
(hydrolysis product) and (D-Hiv-N-Me-L-Phe)3-SNAC, which provides direct evidence for
the alternate incorporation approach described in the linear biosynthetic model (Fig. 23a).
C3 is a crucial domain that integrates three functions, including condensation, chain
length control and macrocyclization. While it acts like normal condensation domains to
form the ester bond in the depsipeptide chain, this domain is actively involved in chain
elongation and catalyses the macrocyclization of the mature intermediate for product
release. It is different from CT domains in fungal noniterative NRPSs that only perform
cyclization [22] and Cy domains that form oxazoline or thiazoline rings using the D
residues in the conserved motif DXXXXD [23,24]. Bacterial iterative NRPSs typically use
a C-terminal TE domain to cyclize and release the final products. The enterobactin
synthetase is such an enzyme whose TE plays a key role in the oligomerization [25]. The
monomer intermediate is transferred from the T domain of EntF (C-A-T-TE) to the active
site
Ser residue of the TE, which allows the T domain to be used for the formation of the
next monomer. The TE catalyses the oligomerization and holds the growing peptide chain
until it reaches the full length for macrocyclization. A similar TE was observed in the
tyrocidine [12] and gramicidin NRPSs [13]. It was also reported that cyclooligomerization
can be catalysed through ATP-dependent condensation reactions by NRPS-independent
siderophore synthetases, such as DesD26, PubC27 and BibC28 that participate in the
biosynthesis of desferrioxamine, putrebactin and bisucaberin, respectively.
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Here we show that fungal iterative NRPSs use a different strategy for chain
elongation and product length control. Bacterial NRPSs use an oligomerization approach
through their C-terminal TE for product chain elongation. The cyclooligomerization by
bacterial iterative NRPSs involves acylation and deacylation of the active site serine
residue of the C-terminal TE. The monomer intermediate is formed by upstream domains
and transferred from a T domain to the Ser of TE. Additional units of the monomer are
then added to the monomer-O-TE intermediate to elongate the peptide chain to the full
length for product cyclization and release. Therefore, bacterial iterative NRPSs
oligomerize a monomer unit that is synthesized from the precursors for chain elongation,
and the growing oligomer intermediate is formed at and always tethered to the TE. In
contrast, fungal iterative NRPSs use an alternate incorporation approach to extend the
peptide chain. The growing depsipeptide chain in the biosynthesis of 1–5 swings between
T1 and the twin T2 domains. The monomer is not used as a unit for chain elongation at all.
C3 needs to work with the other condensation domain (C2) to alternately incorporate the
two precursors (D-Hiv and N-Me-L-Phe or N-Me-L-Leu). Therefore, bacterial iterative
NRPSs adopt a product assembly process that is more like the parallel model in Fig. 23a,
while fungal iterative NRPSs use a linear biosynthetic route.
In the linear model (Fig. 21a), C3(BbBEAS) forms an ester bond between T1-tethered DHiv and T2a- or T2b-tethered D-Hiv-NMe-L-Phe and (D-Hiv-N-Me-L-Phe)2 in beauvericin
biosynthesis, while C2 catalyses the formation of an amide bond between T2a- or T2btethered N-Me-L-Phe and T1-tethered D-Hiv, D-Hiv-N-Me-L-Phe-D-Hiv and (D-Hiv-NMe-L-Phe)2-D-Hiv. C3(BbBSLS) has the same function except that N-Me-L-Leu is used. Both
C2 and C3 work collaboratively to elongate the depsipeptide chain. Once C2 catalyses the
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last condensation step to yield the full-length depsipeptide chain, C3 acts as a decision
maker to determine and inform the biosynthetic machinery of whether further elongation
is required. For instance, when a hexadepsipeptide intermediate is synthesized, C3(BbBEAS)
will shut down the elongation line and perform the macrocyclization. Instead, C3(BbBSLS)
will continue the elongation to get an octadepsipeptide intermediate and then conduct the
macrocyclization and product release. When C3(BbBEAS) was substituted for the C3 in
BbBSLS, it continued to condense D-Hiv and the hexadepsipeptide intermediate (D-HivN-Me-L-Phe)3, and C2(BbBEAS) will continue to form an additional amide bond to get an
octadepsipeptide. Cyclization of this intermediate yielded the new product 15. Similarly,
substitution of C3(BbBSLS) with its counterpart in BbBEAS switched BbBSLS from an
octadepsipeptide synthetase to a hexadepsipeptide synthetase and yielded 8. Thus, C2 is
flexible and can catalyse extra or fewer condensations according to the ‘command’ of C3.
While C3 is strict with the number of condensation, it is flexible enough to condense
‘unnatural’ precursors. Consequently, reprogramming of BbBEAS and BbBSLS can be
conveniently and readily achieved by swapping the C3 domain. Our work thus provides an
unprecedented tool for engineering fungal iterative NRPSs to yield ‘unnatural’
cyclooligomer depsipeptides with varied chain lengths. This work also presents in vitro
total biosynthesis of a fungal NRP using only two condensation domains.
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CHAPTER VII
SUMMARY AND ENGINEERING VALUE
7.1

Summary of my dissertation research
This dissertation is focused on understanding and engineering of bacterial/fungal

nonribosomal peptide biosynthetic systems. In Chapter II, the indigoidine biosynthetic
gene cluster was found in Streptomyces chromofuscus ATCC 49982. Through
heterologous expression, the function of Sc-indC has been identified as an indigoidine
synthetase and the Sc-indB plays a role of helper in indigoidine biosynthesis. Indigoidine
shows a bright blue color and is more stable at low temperature during the production. The
titer of indigoidine in E. coli BAP1 reached 2.78 g/l under the optimized conditions. With
the help of Sc-indB, the titer was dramatically increased by 41.4% (3.93 g/l). To further
improve the yield of the blue pigment, a glutamine synthetase gene was introduced into the
expression system to enhance the indigoidine synthetic pathway by increasing the
availability of the precursor, L-glutamine. Because a nitrogen source is required for amino
acid biosynthesis, the titer reached the highest (7.08±0.11 g/l) when 2.5 mM (NH4)2HPO4
was added to the fermentation broth of E. coli BAP1/Sc-IndC+Sc-IndB+GlnA.
Chapter III to Chapter VI describes the work on reconstitution of two fungal NRPSs
(BbBEAS and BbBSLS) in Saccharomyces cerevisiae BJ5464-NpgA and investigation of
the catalytic mechanism of fungal iterative NRPSs. BbBEAS and BbBSLS were
successfully expressed in S. cerevisiae, leading to the production of their corresponding
products, beauvericin (1) and bassianolide (5), respectively. The titers of these two peptides
in the engineered strain were comparable to those in the native producer B. bassiana. A
kivr gene was co-expressed with bbBEAS gene in the engineered strain to supply more D-
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HIV for the biosynthesis of both 1 and 5 [1]. The co-expression of KIVR and BbBEAS
enabled the production of beauvericins at an unprecedented high level of 105.8±2.1 mg/l.
BbBEAS and BbBSLS have the same domain organization and share 66% identity
and 79% similarity. We then conducted a series of experiments on functional dissection
and reconstitution of these modular enzymes in S. cerevisiae including module swapping
between BbBEAS and BbBSLS, and construction of hybrid CODSs. The linker between
M1 and M2 plays a pivotal role in the reconstitution of the dissected CODSs. M1(BbBEAS)
and M1(BbBSLS) are exchangeable and the final products are determined by M23. To further
understand and reprogram these fungal iterative NRPSs, we further investigated the
functions of T2a, T2b, C2 and C3, as well as the chain length control mechansim. Our results
revealed that T2a plays a major role in the formation of the NRPs and the C3 is a crucial
domain that integrates three functions, including condensation, chain length control and
macrocyclization. The fungal iterative NRPSs use an “alternate incorporation” approach
for chain elongation, which is different from the oligomerization strategy adopted by
bacterial iterative NRPSs.
7.2

Engineering value

7.2.1 Engineered production of indigoidine in E.coli BAP1
The water-insoluble blue pigment indigoidine is synthesized through condensation
of two units of L-glutamine by NRPSs. Because of the presence in its structure of carbon–
carbon double bonds conjugated with a carbonyl group, indigoidine is a powerful radical
scavenger that enables phytopathogens to tolerate oxidative stress, organic peroxides, and
superoxides during the plant defense response. Its bright blue color resembles the industrial
dye indigo, thus representing a new natural blue dye that may find uses in industry. The
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chemical synthesis of indigo requires harsh conditions for it involves heating N-(2carboxyphenyl)-glycine to 200 °C (392 °F) in an inert atmosphere with sodium hydroxide
but our biosynthesis methods of indigoidine through engineered E. coli is more
environment-friendly. Under the optimized conditions, the titer of indigoidine reached 7.08
g/L, which enables the production of this blue dye in the industry scale. The waterinsoluble pigment precipitates during the fermentation. Based on this characteristic, we
developed an economical and efficient extraction process. Pure indigoidine can be easily
harvested through this method.
7.2.2 Engineered production of beauvericins and bassianolide in S. cerevisiae
Fungal cyclooligomer depsipeptides (CODs) have displayed a wild variety of
bioactivites, including antibiotic, insecticidal, anthelminthic, herbicidal, antiretroviral,
cytotoxic, anti-haptotactic, anti-cholesterol, and chemosensitizer properties, as well as
repression of amyloid plaque formation in Alzheimer's disease [2]. Beauvericins have
displayed potent anticancer activity against various cell lines and can also inhibit migration
of the metastatic prostate cancer (PC-3M) and breast cancer (MDA-MB-231) cells [3, 4].
In our work, we successfully examined the heterologous reconsititution of BbBEAS and
BbBSLS in S. cerevisiae and production of the corresponding products, beauvericins and
bassianolide. The co-expression of BbBEAS and KIVR in S. cerevisiae with
supplementation of 10 mM L-Val led to a nearly 200% increase in the total titer of
beauvericins (from 33.8 to 105.8 mg/l). With this efficient expression system, we also
functionally characterized a NRPS from F. venenatum NRRL 26139 as a new beauvericin
synthetase, which was named as FvBEAS. Our module/domain swapping works represents
the first example of construction of functional hybrid fungal CODSs, which provides a
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comprehensive platform for future engineering of NRPSs. We successfully reconstructed
the total biosynthesis of beauvericin in vitro by reacting C2 and C3 with two SNAC-linked
precursors and present a domain swapping approach to reprogramming these enzymes for
peptides with altered lengths. Thus, this work provides an efficient production process for
the anticancer natural products beauvericina and bassianolide, and offers an unprecedented
tool for engineering fungal iterative NRPSs to yield ‘unnatural’ NRPs with varied chain
lengths.
7.3 Future Research
7.3.1 Indigoidine fermentation without the use of any inducer and antibiotics
The titer of indigoidine from engineered E. coli BAP1 reached 7.08 g/l, which is
appropriate for industrial production. But the fermentation of indigoidine still requires
IPTG for induction and antibiotics for keeping plasmids stable, which will increase the
production costs. To avoid adding antibiotics during the fermentation, another strategy is
needed. The outer membrane (OM) of most Gram-negative bacteria contains
lipopolysaccharide (LPS) in the outer leaflet. The essential E. coli protein, LptB, has been
implicated in LPS transport to the OM [5]. The lptB gene can be amplified by polymerase
chain reaction (PCR) from the genome of E. coli BAP1 with Phusion DNA polymerse
using a pair of primers, 5'-aaCATATGGCAACATTAACTGCAAAGAA-3' and 5'aaCTCGAGTCAGAGTCTGAAGTCTTCC-3'. These primers are designed based on the
sequence of lptB and will be synthesized by Sigma-Aldrich. I will amplify the lptB gene
and ligate it into the cloning vector pJET1.2. The lptB insert will be excised with NdeI and
XhoI and ligated into pACYCDuet-1 between the same sites. I will use a simple and highly
efficient method to disrupt the chromosomal lptB gene in E. coli BAP1. In this procedure,
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pACYCDuet-1-lptB will be used as a helper plasmid to keep the cells alive during the
chromosomal lptB gene disruption [6].
I will also excise the lptB gene with an additional T7 promoter insert from
pACYCDuet-1-lptB with HindIII and XhoI and ligate it into pJV6 between the same sites
to generate pJV6-lptB. This plasmid will contain both Sc-indC and lptB. Once the
chromosomal lptB gene of E. coli BAP1 is successfully knocked out by homologous
recombination, pJV6-lptB will be introduced into E. coli BAP1/∆lptB for the production
of indigoidine. During the fermentation of the engineered E. coli strain, no antibiotics are
required.
We will next eliminate the need for IPTG induction. The expression of sc-indC in
pJV6 needs IPTG for induction. Lac operator which is located in the downstream of T7
promoter could be bound by repressors, which interferes with binding of RNAP to the
promoter. The lacI gene coding for the repressor lies nearby the lac operon and is always
expressed. Once the lacO gene has been removed, the gene located under T7 promoter will
be continuously expressed. SOE PCR will be performed to remove lacO from pJV6-lptB.
Introduction of this plasmid into E. coli BAP1/∆lptB will allow indigoidine production
without any inducer and antibiotics.
7.3.2 Identification of key amino acids in chain length control in C3 domain
The C3 domain controls the chain elongation and is strict with the number of
condensation. Beauvericin is produced by BbBEAS and has three monomer units, and
bassianolide produced by BbBSLS has four units. The C-terminal C3 domain was found to
play a critical role in determining the number of condensation during the assembly process.
The protein sequence alignment of C3(BbBEAS) and C3(BbBSLS) shows about 80% similarity.
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We will construct a hybrid C3 domain with partial BbBEAS-C3 and BbBSLS-C3 by the
SOE PCR method. The new C3 domain will be co-expressed with BbBEAS-∆C3 gene or
BbBSLS-∆C3 gene. The products will be analyzed by HPLC. The resulting peaks of
compound FX1 or enniatin C will indicate which part is essential for the chain elongation
and numbers of unit control. By constructing a series of hybrid C3 domains, the key amino
acids or active sites that control the chain elongation may be identified.
7.4
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Fig. B1. PCR amplification of Sc-indA, Sc-indB and Sc-indC. M: DNA ladder; 1: Sc-indA;
2: Sc-indB; 3: Sc-indC.
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APPENDIX C
NMR data for compounds 1-5:
Beauvericin (1): 1H NMR (CDCl3, 300 MHz): δ 7.24~7.32 (15H, m, aromatic CH of LPhe), 5.54 (3H, dd, J = 11.3, 3.6 Hz, α-CH of L-Phe), 4.94 (3H, d, J = 8.0 Hz, α-CH of DHiv), 3.42 (3H, dd, J = 14.6, 4.7 Hz, β-CH2 of L-Phe), 3.03 (9H, s, N-CH3), 3.00 (3H, dd,
J = 14.9, 11.8 Hz, β-CH2 of L-Phe), 1.98 (3H, m, β-CH of D-Hiv), 0.82 (9H, d, J = 6.6 Hz,
γ1-CH3 of D-Hiv), 0.48 (9H, d, J = 6.6 Hz, γ2-CH3 of D-Hiv); 13C NMR (CDCl3, 75 MHz):
δ 170.5, 170.3, 136.6, 128.9, 128.8, 127.1, 75.9, 57.4, 34.7, 32.2, 29.9, 18.3, 17.7; ESI-MS
(+): m/z 784.4 [M+H]+, 801.4 [M+NH4]+, 806.3 [M+Na]+, 822.3 [M+K]+.
Bassianolide (2): 1H NMR (CDCl3, 300 MHz): δ 5.65 (1H, dd, J = 11.3, 4.7 Hz, α-CH of
L-Leu), 5.62 (1H, dd, J = 11.8, 4.7 Hz, α-CH of L-Leu), 5.51 (1H, brs, α-CH of D-Hiv),
5.44 (1H, dd, J = 11.8, 4.4 Hz, α-CH of L-Leu), 5.44 (1H, d, J = 7.4 Hz, α-CH of D-Hiv),
5.28 (1H, d, J = 6.9 Hz, α-CH of D-Hiv), 5.00 (1H, d, J = 2.5 Hz, α-CH of D-Hiv), 4.43
(1H, dd, J = 11.3, 4.1 Hz, α-CH of L-Leu), 3.25 (3H, s, N-CH3), 3.05 (3H, s, N-CH3), 3.01
(3H, s, N-CH3), 2.89 (3H, s, N-CH3), 2.08~2.32 (4H, m, β-CH of D-Hiv), 1.72~1.88 (8H,
m, β-CH2 of L-Leu), 1.60 (2H, m, γ-CH of L-Leu), 1.43 (2H, m, γ-CH of L-Leu), 0.86~1.04
(42H, m, δ-CH3 of L-Leu, γ-CH3 of D-Hiv), 0.67 (3H, d, J = 6.6 Hz, δ-CH3 of L-Leu), 0.55
(3H, d, J = 6.9 Hz, δ-CH3 of L-Leu); 13C NMR (CDCl3, 75 MHz): δ 171.7, 171.6, 171.2,
170.7, 170.5, 170.4, 169.7, 168.9, 76.1, 75.4, 74.5, 74.4, 57.7, 54.5, 54.4, 53.5, 38.7, 38.1,
37.8, 37.0, 31.8, 31.2, 31.1, 30.7, 30.4, 29.9, 29.5, 28.4, 25.6, 25.4, 25.1, 24.9, 24.0, 23.9,
23.8, 23.7, 21.4, 21.2, 21.1, 21.0, 20.8, 20.4, 18.9, 18.7, 18.4, 18.3, 15.9, 14.9; ESI-MS (+):
m/z 909.6 [M+H]+, 931.6 [M+Na]+, 947.5 [M+K]+.
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Beauvericin A (3): 1H NMR (CDCl3, 300 MHz): δ 7.25~7.30 (15H, m, aromatic CH of LPhe), 5.59 (3H, m, α-CH of L-Phe), 5.04 (1H, d, J = 6.0 Hz, α-CH of D-Hmv), 4.91 (2H,
m, α-CH of D-Hiv), 3.46 (3H, dd, J = 14.8, 4.1 Hz, β-CH2 of L-Phe), 3.04 (6H, s, N-CH3),
3.02 (3H, m, β-CH2 of L-Phe), 3.00 (3H, s, N-CH3), 1.90 (2H, m, β-CH of D-Hiv), 1.60
(1H, m, β-CH of D-Hmv), 0.69~0.91 (14H, m, γ2-CH3 of D-Hmv, δ-CH3 of D-Hmv, γ1CH3 of D-Hiv, γ1-CH2 of D-Hmv), 0.49 (6H, d, J = 6.0 Hz, γ2-CH3 of D-Hiv); ESI-MS
(+): m/z 798.4 [M+H]+, 815.4 [M+NH4]+, 820.3 [M+Na]+, 836.4 [M+K]+.
Beauvericin B (4): 1H NMR (CDCl3, 300 MHz): δ 7.25~7.35 ( 15H, m, aromatic CH of LPhe), 5.62 (3H, m, α-CH of L-Phe), 5.07 (2H, m, α-CH of D-Hmv), 4.93 (1H, d, J = 5.8
Hz, α-CH of D-Hiv), 3.52 (3H, m, β-CH2 of L-Phe), 3.03 (3H, s, N-CH3), 3.00 (6H, s, NCH3), 2.98 (3H, m, β-CH2 of L-Phe), 1.80 (1H, m, β-CH of D-Hiv), 1.48 (2H, m, β-CH of
D-Hmv), 0.71~0.93 (19H, m, δ-CH3 and γ2-CH3 of D-Hmv, γ1-CH2 of D-Hmv, γ1-CH3 of
D-Hiv), 0.56 (3H, d, J = 6.3 Hz, γ2-CH3 of D-Hiv); ESI-MS (+): m/z 812.4 [M+H]+, 829.4
[M+NH4]+, 834.4 [M+Na]+, 850.3 [M+K]+.
Beauvericin C (5): 1H NMR (CDCl3, 300 MHz): δ 7.22~7.34 (15H, m, aromatic CH of LPhe), 5.60 (3H, dd, J = 12.1, 3.9 Hz, α-CH of L-Phe), 5.07 (3H, d, J = 4.7 Hz, α-CH of DHmv), 3.46 (3H, dd, J = 15.7, 4.4 Hz, β-CH2 of L-Phe), 2.97 (9H, s, N-CH3), 2.96 (3H,
m, β-CH2 of L-Phe), 1.43 (3H, m, β-CH of D-Hmv), 0.88 (6H, m, γ1-CH2 of D-Hmv),
0.70~0.75 (18H, m, γ2-CH3 of D-Hmv and δ-CH3 of D-Hmv); ESI-MS (+): m/z 826.4
[M+H]+, 843.4 [M+NH4]+, 848.3 [M+Na]+, 864.4 [M+K]+.
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Fig. C1. Construction of the expression plasmid for BbBEAS.
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Fig. C2. Construction of the expression plasmid for KIVR.
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Fig. C3. ESI-MS spectra of beauvericin (a), bassianolide (b), beauvericin A (c),
beauvericin B (d), and beauvericin C (e) from Beauveria bassiana ATCC 7159.
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Fig. C4. HPLC traces of the purified products 1-5 from the engineered yeast strains at 210
nm.

175

Fig. C5. 1H NMR spectrum of beauvericin in CDCl3.
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Fig. C6. 13C NMR spectrum of beauvericin in CDCl3.
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Fig. C7. HPLC analysis of the biosynthesis of beauvericins in S. cerevisiae BJ5464NpgA/pDY37 (i) and S. cerevisiae BJ5464-NpgA/pDY37+pDY48 (ii).

Fig. C8. HPLC analysis of the biosynthesis of beauvericins in S. cerevisiae BJ5464NpgA/pDY37+pDY48 when 30 mM L-Val (i) and 10 mM L-Ile (ii) were supplemented.
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Fig. C9. HPLC analysis of beauvericin biosynthesis in F. venenatum NRRL 26139 (i) and
S. cerevisiae BJ5464-NpgA/pDY59 (ii).
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APPENDIX D
Table D1. Primers used in this work. The restriction sites are in bold.
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Table D2. Plasmids constructed in this work.
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Fig. D1 Amino acid sequence alignment of five fungal CODSs. BbBEAS: GenBank
accession number ACI30655; BbBSLS: GenBank accession number ACR78148; XsBSLS:
GenBank accession number ABR28366; FvESYN: GenBank accession number Q00869;
FvBEAS: GenBank accession number AGC31490. The intermodular M1-M2 linker is
boxed.
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Fig. D2 Amino acid sequence alignment of BbBEAS, BbBSLS and a stand-alone NRPS
condensation domain VibH (GenBank accession number AAD48879). The intermodular
M1-M2 linker is boxed.
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APPENDIX E

Fig. E1. SDS-PAGE analysis of the expression and purification of BbBEAS from S.
cerevisiae BJ5465-NpgA/pDY37 (left) and BbBSLS from S. cerevisiae BJ5465NpgA/pDY42 (right). M: Protein ladder, 1: Soluble fraction of the lysate, 2: Insoluble
fraction of the lysate, 3: Flow through, 4-6: Eluents by buffer A with 10, 100 and 250 mM
imidazole, respectively.

188

189

190

Fig. E2. ESI-MS (+) spectra of compounds synthesized (S1 and S2) or biosynthesized (15, 8, 10-15, S3, S4 and S6) in this work and the authentic samples of beauvericin and
bassianolide.
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Fig. E3. High resolution ESI-MS of 1 generated in the in vitro reaction of BbBEAS.

192

Fig. E4. High resolution ESI-MS of 5 generated in the in vitro reaction of BbBSLS.

Fig. E5. Amino acid sequence alignment of the twin T2 domains of BbBEAS and BbBSLS
with TycC-T3 and GrsB-T3. TycC-T3 is a T domain from TycC (tyrocidine synthetase 3,
GenBank accession number AAC45930) and GrsB-T3 is from GrsB (gramicidin S
synthetase 2, GenBank accession number BAA06146). The conserved motif
(I/L)GG(D/H)SL is highlighted and the key Ser residue is boxed.
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Fig. E6. SDS-PAGE analysis of the purified C1, C2, C3 and MT domains from E. coli
BL21(DE3). M: Protein ladder, 1: C1(BbBEAS), 2: C3(BbBEAS), 3: C3(BbBEAS-H2901A), 4:
MT(BbBEAS), 5: C3(BbBSLS), 6: C2(BbBEAS).

Fig. E7. HPLC analysis of the reaction of C2(BbBEAS) with S1 and S4. (i) S1+S4+inactivated
C2(BbBEAS); (ii) S1+S4+C2(BbBEAS).
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Fig. E8. HPLC analysis of the reaction of C3(BbBEAS) with S1, S2 and S4. (i)
S1+S2+S4+inactivated C3(BbBEAS); (ii) S1+S2+S4+C3(BbBEAS).
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Fig. E9. High resolution ESI-MS of FX1 (15).
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Fig. E10. Selected HMBC and 1H-1H COSY correlations for FX1 (15).
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Fig. E11. High resolution ESI-MS of D-Hiv-N-Me-L-Phe (11) obtained by hydrolysis of
15 with 0.1 N NaOH.

198

Fig. E12. High resolution ESI-MS of enniatin C (8) generated by C1-A1-T1-C2-A2-MT-T2aT2b(BbBSLS)-C3(BbBEAS) in the yeast.
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Table E1. NMR data for 8, 10, 11 and 15.
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Table E2. Primers used in this study.
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